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ABSTRACT 
Gastric cancer (GC) is an important cause of morbidity and mortality worldwide. GC is 
thought to result from the combined effects of three major players: environmental factors, 
susceptibility genetic variants, and deregulated signalling pathways associated with functionally 
relevant molecular aberrations. Over time, the combined effects of those players will alter the 
normal patterns of epithelial cell proliferation, apoptosis and differentiation programs, driving 
the gastric carcinogenesis process. 
The most well-known association between environmental factors and genetic 
susceptibility in increasing the risk towards GC is found in the life-long infection with 
Helicobacter pylori and host chronic inflammatory response. In this scenario, individuals that 
due to their genetic makeup produce a more intense inflammatory response are at increased 
risk of GC. However, it remains unclear how inflammation drives gastric carcinogenesis. 
It is thought that inflammatory mediators must be able to disrupt gastric homeostasis 
through the modulation of critical signalling pathways. At the cellular level, inflammatory stimuli 
induce the activation of signalling cascades that culminate in the activation and/or expression 
of transcription factors that will execute the biological functions triggered by those stimulatory 
signals. Furthermore, inflammation-activated transcription factors are also found to play 
relevant biological roles in malignancies. This observation is highly suggestive of a tight relation 
between inflammation and cancer, in which critical molecular effectors play crucial functions in 
the inflammatory and carcinogenic processes.  
Based on the exposed, the main goal of this work was to get a deeper understanding of 
the signalling events and associated molecular mechanisms underlying inflammation-driven 
GC development. To accomplish our major goal, we focused on two specific aims: I) to 
determine the expression patterns of inflammation-associated molecular effectors on normal 
gastric mucosa, preneoplastic and GC lesions; II) to determine the inflammation-modulated 
signalling cascades responsible for the expression/activation status of molecular effectors and 
the underlying biological meaning through in vitro and in vivo approaches. 
The results generated in this work indicate C/EBPα as a transcription factor specific of 
differentiated gastric foveolar epithelial cells. Additionally, C/EBPα was found downregulated 
in 30% of GC cases studied, and was found to act as a potent anti-proliferative effector on GC 
cells. Moreover, C/EBPα expression was found to be negatively regulated by p38 and ERK1/2 
signalling, two critical MAPK branches previously reported as activated in gastric inflammation 
and GC. On the other hand, C/EBPβ which is frequently overexpressed in preneoplastic lesions 
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and GC, promotes in vitro and in vivo cell proliferation. Also, C/EBPβ expression was found to 
be necessary for the full tumorigenic ability of GC cells. Exploring the association between 
inflammatory mediators and C/EBPβ expression, we demonstrate that interleukin-1 beta (IL1B) 
is able to induce the expression of C/EBPβ through the activation of MAPK signalling cascades. 
Thus, our results suggest that these two members of the C/EBP-family of transcription factors 
play specific and non-overlapping functions in the maintenance of gastric homeostasis, and the 
deregulation of their normal pattern of expression can be an important step in gastric 
carcinogenesis. Based on other cell models, we observed CREB-dependent transcriptional 
activity as a mechanism underlying C/EBPβ expression in GC cells lines. We also demonstrate 
that in normal gastric mucosa C/EBPβ and CREB are expressed in a compartmentalized 
glandular region within which gastric progenitor cells are located, while in GC samples both 
proteins are associated and overexpressed in the majority of cases studied. Moreover, we 
demonstrate that CREB acts as a crucial effector in both basal and IL1B-induced GC cell 
proliferation and in in vivo tumorigenic ability of GC cells. 
Our results provide further support to the hypothesis that the effect of chronic 
inflammation on gastric carcinogenesis, as seen in the context of genetically susceptible 
individuals infected with H. pylori, includes modulation of signalling pathways that regulate 
important biological mechanisms in epithelial cells. Furthermore, our results may help inform 
new strategies for prevention and treatment of GC, including the control of chronic inflammation 
and the identification of new therapy targets. 
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RESUMO 
 O cancro gástrico (CG) constitui uma das principais causas de morte por cancro em 
todo o mundo. Ao longo dos anos, vários estudos foram realizados com a finalidade de 
compreender os fatores subjacentes ao desenvolvimento desta neoplasia. Várias evidências 
sugerem que a combinação de fatores ambientais, suscetibilidade genética e ocorrência de 
mutações resulte na alteração dos padrões normais de proliferação e diferenciação celulares, 
desencadeando o processo de carcinogénese gástrica. 
A mais relevante associação entre ambiente e suscetibilidade genética como fatores de 
risco para desenvolvimento de CG é encontrada na infeção por Helicobacter pylori e a resposta 
inflamatória crónica do hospedeiro. De facto, hospedeiros que devido à sua constituição 
genética desencadeiam uma resposta inflamatória mais intensa à infeção, estão em risco de 
desenvolver CG. No entanto, os mecanismos moleculares subjacentes à carcinogénese 
gástrica induzida pela inflamação são ainda pouco conhecidos. 
Alguns estudos sugerem que os mediadores inflamatórios devem ser capazes de 
perturbar a homeostasia do epitélio gástrico através da modulação de importantes vias de 
sinalização. A nível celular, os estímulos inflamatórios são capazes de induzir a expressão e 
ativação de importantes fatores de transcrição que tomarão parte na execução das funções 
biológicas despoletadas por esses sinais. Além disso, os fatores de transcrição ativados por 
mediadores inflamatórios também atuam como importantes executores de funções biológicas 
nas células tumorais. Desta forma, tem sido sugerido a existência de uma interconexão entre 
inflamação e cancro, em que importantes fatores de transcrição desempenham funções 
cruciais em ambos os processos inflamatório e tumoral.  
Com base no exposto, este trabalho teve como objetivo principal a obtenção de uma 
compreensão mais profunda dos eventos de sinalização e mecanismos moleculares 
subjacentes, despoletados pela inflamação, no desenvolvimento de CG. De forma a atingir 
este objetivo, focámos o trabalho em dois objetivos específicos: I) determinar os padrões de 
expressão de fatores de transcrição associados a inflamação em estômago normal, lesões 
pré-neoplásicas e GC; II) determinar os eventos de sinalização celular responsáveis pela 
modulação da expressão dos fatores de transcrição, assim como determinar o significado 
biológico destes fatores através de ensaios in vitro e in vivo. 
 Neste trabalho observámos que o C/EBPα, além de ser um marcador de diferenciação 
do epitélio gástrico, é também um possível supressor tumoral gástrico, dada a perda de 
expressão em 30% dos casos de CG estudados e o papel anti-proliferativo que desempenha 
a nível celular. Em oposição, o C/EBPβ, justificando a sobre-expressão em lesões pre-
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neoplásicas e CG, desempenha um papel crucial na proliferação in vivo do epitélio gástrico 
normal e no potencial tumorigénico de linhas celulares de CG. Estes resultados sugerem que 
estes dois membros da família C/EBP desempenham funções específicas e não sobreponíveis 
na manutenção da homeostasia gástrica, e que a desregulação da expressão normal de cada 
um deles pode desempenhar um papel relevante na carcinogénese gástrica. 
Mecanisticamente relevante, e dado a inflamação e a ativação oncogénica culminarem na 
expressão/ativação de fatores de transcrição, os nossos resultados demonstram que o 
mediador pro-inflamatório IL1B induz a expressão de C/EBPβ, possivelmente através da ação 
transcricional do CREB, que se mostrou ser fundamental para a transcrição e manutenção dos 
níveis celulares basais de C/EBPβ. Para além da regulação do gene CEBPB, e da sobre-
expressão na maioria dos casos de CG analisados, o CREB revelou desempenhar um 
importante papel na proliferação celular induzida pela IL1B. Adicionalmente, foi possível 
demonstrar que o CREB desempenha um papel tumorigénico nas células de CG. Os 
resultados obtidos fornecem suporte à hipótese de que os efeitos da inflamação crónica na 
carcinogénese gástrica, como observado em indivíduos geneticamente suscetíveis infetados 
com H. pylori, incluiu a modulação de vias de sinalização que regulam importantes 
mecanismos biológicos nas células epiteliais gástricas. Além disso, os resultados obtidos 
neste trabalho poderão ser utilizados no desenvolvimento de novas estratégias para 
prevenção e tratamento de CG, incluindo o controlo da inflamação crónica e a identificação de 
novos alvos terapêuticos. 
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1 – Gastric cancer 
Gastric cancer (GC) is a worldwide health burden that, for the majority of cases, is 
thought to result from the combined effects of three major players: environmental factors, 
susceptibility genetic variants, and the accumulation of specific (epi)genetic alterations. The 
long-term effects caused by these players will alter the epithelial cell proliferative, apoptotic, 
and differentiation programs, culminating in the initiation and progression of the gastric 
carcinogenesis process. 
 
 
1.1 – Epidemiological data 
 GC incidence and mortality decreased significantly over the past 70 years [1, 2]. 
However, a global cancer statistics analysis places GC as one of the most prevalent and deadly 
forms of cancer worldwide [3, 4]. By gender, GC is the fourth most common cause of cancer in 
men and the fifth in women, and incidence rates are about twice in males as in females. The 
predominance of GC in males may be related to hormonal factors, namely the lack of a 
protective effect induced by oestrogens, as suggested by some studies [5, 6]. 
 The worldwide distribution of GC is marked by geographical variations, with the highest 
incidence rates detected in Eastern Asia, Eastern Europe, and South America [4]. Because GC 
incidence in Japan is one of the highest in the world [7], the implementation of population-
applied mass screening programs for early GC detection is responsible for the significant 
decline in mortality [8]. Outside Japan, where no such mass screening is implemented, only a 
minor percentage of GCs are discovered at an early stage, ending in a 5-year survival rate of 
less than 20% in United States and 10 - 20% in European countries [9]. In Portugal, GC is the 
fourth most common cancer type and the second cause of cancer death in men and the third 
in women. Moreover, Portugal exhibits the highest GC incidence in Western Europe [10]. 
  Due to the different histopathological characteristics of GC, there was an urgent need 
to organize GC in different categories or types. The Laurén classification is the most commonly 
used and describes two main histological types with different clinical and pathological 
characteristics: the diffuse and intestinal [11]. Diffuse GC is marked by the presence of isolated 
poorly cohesive clusters of cells dispersed through the stroma, it can be multifocal [12], can 
have a hereditary basis, and occurs more commonly in young patients [13]. Furthermore, no 
preceding steps have been identified for diffuse type other than chronic gastritis [6, 12]. The 
3
 
 
intestinal type is the most common form of GC, it is constituted by well-differentiated cells that 
form glandular structures with an intestinal-like pattern, and is more frequently observed at 
older ages [12]. The pathological evolution of normal gastric mucosa into intestinal type GC 
has been characterized as a progressive multistep process. The process begins with chronic 
gastritis, which progresses to atrophic gastritis followed by intestinal metaplasia, dysplasia, and 
at last cancer with subsequent metastatic dissemination [14] 
 
 
1.2 – Environmental risk factors 
 A large amount of data suggests that environmental and lifestyle factors are pivotal 
contributors to GC aetiology [3, 4]. An argument that strengthens the association between 
environmental factors and GC incidence comes from the observation that migrant populations 
from high risk areas exhibit a marked reduction in risk when they move to low-incidence areas 
[15]. Furthermore, subsequent generations acquire risk levels similar to the background risk of 
the host country [7]. 
 
1.2.1 – Diet and lifestyle 
 A relevant factor in the aetiology of GC is diet, especially for development of the 
intestinal histological type. Consumption of adequate amounts of fruit and vegetables seems 
to lower the risk of GC, with antioxidants proposed as having protective effects by reducing the 
cellular damage caused by free radicals [6, 16, 17]. The high intake of salt and salt-preserved 
foods was found to be significantly associated with increased risk to develop GC [1, 17, 18]. 
Indeed, not only the ingestion of salt induced gastritis in animal models but also enhanced the 
effects of gastric carcinogens [19, 20]. It has been suggested that the worldwide decrease in 
GC incidence during the last decades can be attributed to the introduction of refrigeration, which 
led to a reduction in consumption of salt preserved foods and allowed the increase intake of 
fresh vegetables and fruits [1]. 
 A lifestyle factor causally associated with the development of GC is tobacco smoking 
[21]. The results obtained in independent studies enrolling populations from distinct 
geographical origins and distinct genetic backgrounds strongly suggested the positive 
association between smoking and GC [22, 23]. 
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1.2.2 – Helicobacter pylori infection and gastric pathogenesis 
Helicobacter pylori (H. pylori) is a Gram-negative, urease-positive bacterium that 
specifically colonizes the human stomach, and is responsible for one of the most common 
chronic bacterial infections worldwide [24]. This bacterium is normally found in the superficial 
gastric mucus layer, with only a small percentage found adherent to gastric epithelial cells. The 
infection is mainly acquired during early childhood, predominantly by the gastric-oral route. 
However, other modes of transmission such as the faecal–oral or the oral–oral route together 
with indirect transmission through contaminated food or water may also be possible [25]. Until 
2002, the overall estimate of the prevalence of H. pylori infection in middle-aged adults was 
calculated as 74% in developing countries and 58% in developed countries [26]. 
Even before the discovery of H. pylori it was well recognized that gastric inflammation 
and decreased production of gastric acid (hypochlorhydria) were conditions strongly associated 
with GC. Long-term follow-up studies in high-risk populations demonstrated the slow 
development of atrophic gastritis over years and identified the importance of gastric atrophy 
and intestinal metaplasia as risk factors for GC [27]. Correa et al. (1992) proposed the 
hypothesis that GC development, namely intestinal type GC, was a slow and complex multistep 
process, in which H. pylori-induced gastritis was the initial trigger [14]. Since then, the link 
between H. pylori infection and the risk for GC became well established [28]. Noteworthy, in a 
long-term study enrolling more than 1500 participants, GC developed in 2.9% of H. pylori 
infected individuals but in none of the uninfected subjects, strengthening the association 
between H. pylori and GC [29]. Therefore, due to the long-term effects of the bacteria over 
gastric epithelial cells, H. pylori was recognized as a type 1 carcinogen for GC by the 
International Agency for Research on Cancer (IARC) [30]. 
H. pylori as a species is quite heterogeneous, being composed by various strains. The 
strains differ in terms of genetic background and, as a direct consequence, the corresponding 
bacterial proteins produced. Some of the proteins synthesized are virulence factors that have 
profound damaging effects on gastric epithelial cells. The two best characterized virulence 
factors are the cytotoxin VacA and the cag pathogenicity island and its effector CagA [31]. 
Although H. pylori infection is the initial cause of gastric inflammation, only a small 
percentage of infected individuals will ultimately progress to cancer. The pathological basis for 
this phenomenon resides in the interaction of H. pylori virulence factors with the underlying 
inflammatory response of the host towards the infection [32]. Support for the importance of host 
response was observed in early animal experiments when different mouse strains were 
infected with H. pylori. The ability of H. pylori to colonize the gastric mucosa and to induce 
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histological lesions, such as gastritis and glandular atrophy, was strongly dependent on the 
mouse strain [33, 34]. Those results revealed the critical importance of the host genetic 
background for the development of gastric lesions. 
 
 
1.3 – Host genetic susceptibility 
Gastric colonization by H. pylori is followed by a mucosa infiltration of different immune 
cells such as lymphocytes, polymorphonuclear leukocytes (PMNs), and 
monocytes/macrophages [35], which are responsible for the increased mucosal expression of 
many inflammatory mediators, including several interleukins (such as IL1B, IL6, and IL8), 
tumour necrosis factor alpha (TNFα), and interferon-c (IFNc) [36-38]. Genetic polymorphisms 
in inflammation-related genes influence inter-individual variation in the magnitude of 
inflammatory response, and this contributes to the individual ultimate clinical outcome [6, 39]. 
One of the most biologically relevant pro-inflammatory cytokines in the context of H. 
pylori infection is interleukin-1beta (IL1B), due to two main reasons: the protein levels are 
strongly up-regulated in response to infection and this cytokine is the most powerful known 
gastric acid inhibitor – contributing to the development of gastric atrophy and hypochlorhydria 
[36, 38]. In an associative study using a Caucasian population, El-Omar et al. (2000) 
demonstrated that polymorphisms in the pro-inflammatory IL1 gene cluster (IL1B encoding 
IL1B and IL1RN encoding the endogenous receptor antagonist IL1RA) increased the risk of 
developing neoplastic gastric changes in response to H. pylori infection [40]. Specifically, the 
individuals that carry the IL1B-31C or -511T and IL1RN*2/*2 genotypes were significantly 
associated with risk of developing neoplastic gastric lesions. Functionally relevant, the 
aforementioned alleles were positively associated with increased production of IL1B [41-43]. 
Further, the carriers for the combination of IL1B-511T and IL1RN*2 alleles exhibited the highest 
levels of IL1B in a context of H. pylori infection [44]. Validating the first associative studies, the 
correlation for IL1 gene cluster polymorphisms and GC were also observed in independent 
studies using patient samples from different geographical areas and ethnic groups [45-47]. 
Additionally, supporting the association between H. pylori and host response, Figueiredo et al. 
(2003), reported that the combination of high-risk bacterial virulence factors and host genotype 
conferred the greatest risk of developing gastric malignancy [32]. 
The existence of polymorphisms in other inflammation-related genes, such as TNFA 
and IL10 were also reported as independent additional risk factors for development of GC [48]. 
The cytokine TNFα has a powerful pro-inflammatory effect, and is produced in the gastric 
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mucosa in response to H. pylori infection [49]. Machado et al. (2003) reported the TNFA-308 
G>A polymorphism as an independent factor for increased risk of GC [50]. On the other hand, 
IL10 functions as a potent anti-inflammatory cytokine that is able to downregulate IL1B and 
TNFα protein levels. In this manner, decreased levels or deficiency of IL10 may result in a 
hyper-inflammatory response to H. pylori. In this scenario, individuals homozygous for the IL10 
ATA haplotype (based on three promoter polymorphisms at positions -592, -819, and -1082) 
were identified at increased risk GC. Some studies suggested that the presence of at least one 
of the three risk alleles was directly associated with the risk of GC, but only among Asians [51-
53]. Noteworthy, the risk towards GC increased progressively with the number of risk alleles in 
inflammation-associated genes (IL1B-511T, IL1RN*2/2, TNFA-308*A, and IL10 ATA) [48]. 
Also, a promoter polymorphism on IL8 (-251 T>A), for which the A allele was described as 
being associated with increased production of the interleukin-8 in H. pylori-infected gastric 
mucosa, was described to Increase the risk of developing premalignant gastric lesions [54]. 
Functionally, IL8 is a cytokine that functions as a potent chemo-attractant factor for immune 
cells, and in the induction of pro-inflammatory cytokines, and by this way acts as an important 
pro-inflammatory signal. Taken together, those results clearly demonstrate that inflammation is 
biologically a functional driver force in the process of gastric carcinogenesis. 
In summary, individuals that possess a particular inflammation-related genetic makeup 
react naturally against H. pylori with a more intense inflammatory response. The cumulative 
stress caused by the feedback between bacteria, the genetic constitution of the host, and 
environmental factors will eventually drive preneoplastic transformation from an atrophic 
gastritis to a full-developed GC (Figure 1). 
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Figure 1. Effects of bacterial, host genetics, and environmental factors on the pathogenesis of H. pylori-induced 
gastric cancer. The combination of risk factors induces chronic inflammation, hypochlorhydria, and sustained 
genotoxic stress. Gastric cancer arises as the long-term end product of the combinatorial effects of those factors 
over the gastric epithelium (adapted from Amieva & El-Omar, 2008 [31]). 
 
 
1.4 – Gastric epithelial progenitor cells – putative target cells for neoplastic 
transformation 
It is generally accepted that cancer arises from a single cell in which a series of 
molecular aberrations are responsible for continued clonal evolution and heterogeneity [55, 56]. 
In this respect, cancer onset is dependent on two fundamental processes: the ongoing 
acquisition of heritable (epi)genetic aberrations by individual cells, and the selection acting on 
the resultant phenotypic diversity. By the combined action of mutational occurrence and 
selection, foci of cells with an altered pattern of proliferation versus differentiation will give rise 
to neoplastic lesions [57]. 
 The multistep tumourigenesis theory focuses mainly on the nature and number of 
mutations, leaving behind the intrinsic properties of the cell in which those mutations occur. 
Nonetheless, the identification of the cell types that, by the effect of mutations, are able to 
initiate and sustain growth of the cancer clone is a major issue in cancer research [56]. All cells 
in a tissue are derived from tissue-specific progenitor/stem cells able to undergo self-renewal 
as well as to give rise to all cells that will differentiate into the mature cells that compose each 
tissue. Progenitor cells live longer than their derived differentiated cells and, for that particular 
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reason, may be exposed to mutagenic agents for a longer time, ending in the accumulation of 
an advantageous set of aberrations that will drive carcinogenesis [58]. 
 
1.4.1 – Gastric gland unit 
 The gastrointestinal (GI) tract plays crucial roles in the processes of digestion and 
nutrient absorption, and also creates a functional physical and chemical barrier against 
pathogens. In addition, GI epithelia exhibits the highest cellular turnover [59]. Histologically, the 
endoderm-derived gastric mucosa is classically divided into four regions: cardia (most 
proximal), fundus, corpus (intermediate, encompassing the majority of gastric area), and 
antrum or pylorum (most distal region). The gastric mucosa is formed by glandular units 
composed by a pit or foveolar zone and a long tubular structure further subdivided into the 
isthmus, neck, and base zones. In the corpus region, the gastric gland is composed of four 
types of terminally differentiated cells that are replaced at different rates: parietal cells, 
zymogenic chief cells, surface mucous foveolar cells, and hormone-secreting enterorendocrine 
cells. The gastric antrum has fewer parietal cells but possesses a unique population of mucus-
producing cells located near the base of the gland units that resemble corpus mucous neck 
cells [60]. Interestingly, mucous neck cells can perform two functions: secreting mucins and 
small peptides, and also give rise to chief cells (Figure 2) [60, 61]. 
 
Figure 2. Anatomy and histology of a mammalian stomach. The gastric prominent regions in most mammals are a 
proximal corpus and a distal antrum or pylorus. The corpus epithelium is organized into repeating gastric units that 
are invaginations from the surface and contain multiple cell lineages in four distinct zones. Acid-secreting parietal 
cells are represented in blue, digestive enzyme secreting zymogenic chief cells in red, mucous neck cells in green, 
and the mucus-secreting pit cells nearest the surface in purple. In the antrum, the gastric units are simpler, with few 
parietal or zymogenic cells. Antral units contain two distinct types of mucous cells: the ones lining the surface (in 
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purple) are similar to the surface cells of the corpus, and those nearer to the base have properties intermediate 
between zymogenic cells and mucous neck cells of the corpus (in red-yellow) (adapted from Mills & Shivdasani, 
2011 [60]). 
 
 
The common origin of all gastric epithelial cells is well established, although stem cell 
properties seem to differ between corpus and antrum [62]. Knowing that gastric progenitor/stem 
cells originate all the resident gastric-specific cell types and that aberrant differentiation of the 
gastric epithelium occurs during tumourigenesis, understanding normal and abnormal gastric 
epithelial stem cell biology may be of the outmost relevance to uncover the origins of GC. 
 In the late 1940s Leblond et al. (1948), using nucleotides marked with radioisotopes, 
identified in the gastric epithelium the cells that incorporated marked nucleotides into their 
nucleus – an obvious indication of DNA replication [63]. A narrowing region in the gastric gland 
(isthmus) where the resident cells incorporated marked nucleotides, was identified. 
Furthermore, those authors also observed one or only a few cells in the isthmus constantly 
regenerating cells that migrate bi-directionally, differentiating along the migration into the 
mature cell types that constitute the gastric glands [63]. 
 In 1974, Cheng et al. proposed the Unitarian Theory stating that all mature 
gastrointestinal epithelial cells derive from a common progenitor/stem cell [64]. Nevertheless, 
in a series of in vivo chemical mutagenesis experiments, Bjerknes and Cheng (2002) observed 
that while most glands arose from a single stem cell, some gastric glands carried mutant cells 
of only a single lineage, suggesting new cells had arisen continually along that lineage [65]. 
This observation suggested that some gastric units might keep progenitor cells that are 
committed to replenishing cells of only a single lineage.  
 
1.4.2 – Response of gastric epithelial progenitor cells to injury 
 According to Mills et al. (2011), gastric mucosal injury can be grouped into two 
categories: focal (characterized by repairable damage that does not change the cell 
differentiation pattern) and diffuse (characterized by chronic damage that change cellular 
differentiation) [60]. The focal damage, caused by e.g. toxin ingestion, is rapidly repaired by 
restitution from expansion of surface epithelial cells and by increased cell proliferation in 
neighbouring gastric units [66]. The diffuse category of injury results in abnormal cell 
differentiation (metaplasia), most usually caused from chronic inflammation in response to 
infection with the bacterium H. pylori [14] or by autoimmune gastritis [67]. Metaplasia is normally 
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associated with cancer risk development and seem to reflect a permanent alteration in the 
biological conduct of the progenitor cells [60].  
Regarding H. pylori infection, it is well known that the permanent colonization of gastric 
mucosa and associated inflammation leads to the expansion of the proliferative cell zone and 
development of the preneoplastic lesion spasmolytic polypeptide-expressing metaplasia 
(SPEM), caused by the chronic inflammatory response of the host (Figure 3). The parietal cells 
are lost, and the zymogenic cell lineage is reprogrammed so that genes expressed exclusively 
in mucous neck cells, such as trefoil factor 2 (TFF2), are expressed in cells at the base of the 
gland [68]. Furthermore, the increased number of proliferating cells observed in gastric 
metaplasia can enhance the probability of occurrence of tumour-driver mutational events. 
 
 
Figure 3. H. pylori induces development of SPEM. Chronic inflammation of the corpus leads to changes in epithelial 
differentiation within the gastric unit. Gastric atrophy arises, and the zymogenic chief cell lineage is reprogrammed 
so that genes that are normally expressed only in mucous neck cells, such as TFF2 (represented in green), are 
expressed at high levels in cells at the base of the gland. Proliferation is increased and occurs more basally in the 
unit (adapted from Mills & Shivdasani, 2011 [60]). 
 
 
1.5 – Molecular biology of gastric cancer 
The combinatorial effects of long-term gastric bacteria colonization and associated 
chronic inflammation create the proper conditions for the occurrence and fixation of molecular 
alterations. Genetic aberrations in a panel of genes have been described in GC [39, 69]. 
However, the mutational landscape of GC remains largely unknown because the described 
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mutations are found at low frequencies and, except some cases, there is a general lack of 
knowledge about their biological role in the process of gastric carcinogenesis. 
 
1.5.1 – The CDH1 gene 
 Germline mutations in CDH1 (encoding cell adhesion E-cadherin) are found in 30–40% 
of all hereditary diffuse gastric cancer (HDGC) families [70], with the remaining 60–70% of 
cases lacking a known genetic culprit. Additionally, CDH1 mutations have also been found in 
sporadic diffuse type GC with a frequency of 50–70%, but not in intestinal type GC [71]. 
Nonetheless, the gastric mucosa in CDH1 mutation carriers is normal until a second “hit” 
inactivates the normal CDH1 allele, which occurs frequently by promoter hypermethylation [6]. 
 
1.5.2 – Microsatellite instability  
 The emergence of microsatellite instability (MSI) is dependent on the deficiency or 
inactivation of one of the DNA mismatch repair (MMR) proteins – MLH1, MSH2, MSH6, or 
PMS2 – that render cells unable to repair DNA replication errors in short DNA sequence 
repeats, leading to the appearance of new alleles not present in the adjacent normal cells [104]. 
Noteworthy, the deficiency or inactivation of MMR proteins does not reside on a genetic basis 
since mutations are a rare event [72]. Promoter hypermethylation is frequently observed. 
Genetic instability at the level of microsatellites has been found in approximately 10% of 
sporadic GC [73], more commonly in the intestinal type [74]. 
 
1.5.3 – Selected acquired somatic alterations 
Loss of expression of trefoil peptide 1 (TFF1) has been described in preneoplastic 
lesions and in approximately 50% of intestinal type GC [75]. However, loss of TFF1 expression 
does not stand on gene mutations, deriving instead from loss of heterozygosity (LOH) and 
promoter hypermethylation [76]. The biological significance of TFF1 loss was demonstrated in 
a TFF1 knockout mouse model, in which mice displayed gastric hyperplastic lesions, and 30% 
of them developed multifocal intra-mucosal tumours [77]. These results strongly suggest TFF1 
as a gastric tumour suppressor. 
 The MET encodes a transmembrane protein that acts as the receptor for hepatocyte 
growth factor (HGF), and has been found amplified in GC, more frequently in the diffuse than 
in intestinal type (39 % in diffuse versus 19% in intestinal type) [69, 78]. Another gene that has 
been reported to be amplified in GC is HER2. The human epidermal growth factor receptor 2 
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(HER2) is a tyrosine kinase with no known ligands but able to signal by establishing dimers 
with other receptor proteins. In addition to gene amplification, HER2 has also been shown to 
be overexpressed at the protein level in up to 20% of intestinal type GC, but only rarely in 
diffuse type [39, 69, 79]. 
 The TP53 gene encodes a nuclear protein that plays crucial roles in cell cycle control, 
DNA repair, and apoptosis [80]. TP53 has consistently been found altered in GC, by LOH and 
mutations. In fact, TP53 is the most frequently mutated gene in GC with a mutational frequency 
of up to 60%, regardless of histological type [12]. Interestingly, and possibly suggesting to play 
an initial role in gastric carcinogenesis is the detection of TP53 mutations in preneoplastic 
lesions such as adenomas [81] and intestinal metaplasia [82]. Thus, TP53 mutation seems not 
to be a GC specific event but instead an initial transformation-driver event. Also mutated in GC, 
one can find KRAS. In fact, the KRAS gene is frequently mutated in different cancers, and GC 
is no exception with approximately 5% of the intestinal type cases exhibiting KRAS mutations 
[83]. Curiously, and in clear contrast to colorectal cancer (CRC), KRAS mutations in GC are 
more frequently observed in MSI positive cases instead of MSS cases [84, 85]. 
 The phosphatase and tensin homolog (PTEN) gene is one of the most frequently 
mutated or lost genes in cancer [86]. Due to promoter hypermethylation, PTEN expression is 
lost in up to 20% of GC cases, with no histological association [87]. Additionally, LOH has been 
referred as an underlying cause of PTEN loss of expression in GC [88]. 
 RUNX3 is a member of the runt domain-containing family of transcription factors which 
regulates the SMAD gene family transcription and TGFβ signalling. RUNX3 is frequently 
inactivated in GC by protein mislocalization and promoter hypermethylation [89]. Further, 
RUNX3 knockout mice (RUNX3-/-) showed elongated gastric glands with increased epithelial 
cell proliferation (hyperplasia) [90]. Additionally, RUNX3-/- mice showed loss of chief cells and 
development of SPEM, displaying also a higher susceptibility to GC following treatment with 
the chemical carcinogen N-methyl-N-nitrosourea (MNU). Those results gave functional support 
to the hypothesized role of RUNX3 as a gastric tumour suppressor [91]. 
 
 
2 – Inflammation and cancer 
There is a tight connection between inflammation and cancer. However, the mechanistic 
of this complex relationship remains largely unknown. In this chapter, aspects of the relation 
between signalling mediators and cellular effectors involved in inflammation and cancer will be 
focused. 
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2.1 – Mechanisms of inflammation-driven cancer development 
Inflammation is the natural response of an individual to relieve infection or tissue insult, 
in order to promote healing and tissue regeneration. However, in cases in which acute 
inflammation progresses into a condition of chronic persistence, one of the possible long-term 
consequences is cancer. The relation between cancer and inflammation was initially detected 
in the nineteenth century, when Rudolf Virchow observed the presence of inflammatory cells in 
tumour tissues and that tumours often arise at sites of chronic inflammation [92]. Nowadays, 
with the implementation of new and highly sensible detection techniques, it became evident 
that virtually every tumour contains inflammatory cells [93]. 
The inflammatory response is coordinated by several mediators, which are produced 
and secreted from inflammatory, epithelial, and mesenchymal cells. Of all the mediators 
released, cytokines are central players in the inflammatory process [94]. The secreted 
cytokines interact with receptors present on the cytoplasmic membrane of epithelial cells, 
modulate associated intracellular signalling cascades and culminate in the activation of 
transcription factors – such as nuclear factor-κB (NF-κB). The activation of NF-κB is responsible 
for the production of growth factors, the synthesis of cyclooxygenase (COX)-2, and increased 
amounts of reactive oxygen species (ROS) [95, 96]. In this scenario, the NF-κB-target gene 
COX2 will act as an inducer of cell growth and angiogenesis [97], whereas ROS have the ability 
to directly alter the normal function of different biomolecules [98]. 
In order to become a cancer, a normal cell has to undergo a series of irreversible, 
functionally relevant, and heritable molecular aberrations. Thus, inflammation must have the 
ability to induce DNA damage, leading to permanent alterations within the cell genome. [96]. In 
an almost ingenious manner, inflammation can enhance tumour formation by inducing the 
production of growth factors and cytokines that stimulate tissue-specific stem cell expansion. 
Acting in this manner, inflammation expands the pool of the ideal target cells for mutagenesis 
– undifferentiated, long-lived entities with the intrinsic ability to propagate their genome to the 
next generation [96]. 
It has been reported that ROS and reactive nitrogen intermediates (RNI) released by 
inflammatory cells are two major players in promoting DNA damage of epithelial cells. 
Additionally, Inflammatory cells may employ cytokines, such as IL1B or TNFα, to promote ROS 
formation in the surrounding epithelial cells [95, 96]. Independently of the mechanism behind, 
inactivating mutations in the tumour suppressor gene TP53, presumably caused by oxidative 
insults trough ROS, were detected in cancer cells and in inflamed, non-dysplastic colitis-
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associated epithelial cells. This observation highly suggests that chronic inflammation is a 
precocious condition, able to induce genetic mutations [95, 99]. The same phenomenon was 
found in different chronic inflamed tissues, such as Barrett’s oesophagus (BO) [100], and 
hepatitis C virus (HCV)-associated chronic hepatitis [101]. 
Inflammatory mediators are also able to inactivate or repress DNA repair pathways, e.g. 
the mismatch repair (MMR) system. Mutations or epigenetic silencing of MMR response genes 
are associated with the MSI phenotype, characterized by increased rates of DNA replication 
errors scattered throughout the genome [102]. Noteworthy, MSI can be detected in epithelial 
cells of inflamed non-dysplastic intestinal mucosa of patients with chronic ulcerative colitis 
(CUC), suggesting that inactivation of the MMR system is an early event in colon 
carcinogenesis [102, 103]. 
The connection between inflammation and cancer cannot be viewed as a one-way road, 
since there is evidence that DNA mutations in epithelial cells can lead to inflammation and 
thereby promote carcinogenesis. This interrelationship was uncovered following attempts to 
understand the reason why inflammatory cells and mediators are present in the 
microenvironment of virtually all cancers – even present in cancer types for which there is no 
evident underlying inflammatory condition [96, 104]. In a study using two transgenic mouse 
models in which mutated KRAS was expressed under the promoter of putative gastric stem cell 
markers (DCAMKL1 and K19), Okumura et al. demonstrated that mutated KRAS induced the 
expression of inflammatory mediators, such as IL1B and IL6. The authors also described that 
those mice developed preneoplastic lesions, starting from gastric atrophy, metaplasia, 
hyperplasia, and culminating in high-grade dysplasia [105]. Consequently, Mantovani et al. 
(2008) reported that the connection between inflammation and cancer can be described as 
consisting of two pathways: an extrinsic pathway, promoted by inflammatory conditions that 
increase cancer risk (e.g. H. pylori induced gastritis); and an intrinsic pathway, promoted by 
genetic mutations that stimulate the synthesis of inflammatory mediators that will nurture 
tumourigenesis (Figure 4) [104]. 
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Intracellularly, the two pathways converge, resulting in the activation of transcription 
factors that coordinate the production of inflammatory mediators, such as cytokines. 
Accordingly, transcription factors are considered the “masters and commanders” of the whole 
cancer-associated inflammatory process. The cytokines produced and released by cancer cells 
Figure 4. Inflammation and cancer associated pathways. Cancer and inflammation are connected by the intrinsic 
and the extrinsic pathways. The intrinsic pathway is originated by genetic aberrations that cause neoplasia. 
Transformed cells induce the production of inflammatory mediators, generating a tumor-inflammatory 
microenvironment for which there is no underlying inflammation. In the extrinsic pathway, inflammatory or infectious 
conditions increase the risk towards cancer. The two pathways converge into one point: the activation of transcription 
factors, which coordinate the production of inflammatory mediators. The inflammatory mediators recruit and activate 
more inflammatory cells, generating a cancer-related inflammatory microenvironment (adapted from Mantovani et 
al., 2008 [142]). 
16
 
 
activate the same transcription factors in inflammatory cells, stromal cells, and other tumour 
cells, ending with more inflammatory mediators being produced, generating a cancer-
promoting inflammatory microenvironment [104]. 
Of the outmost importance, signalling pathways and transcription factors that are 
involved in progenitor/stem cell maintenance and renewal (e.g. STAT3) are targets of 
inflammation-induced expression [106], and are also frequently found up-regulated in cancer 
[107]. This observation is highly suggestive of a tight relation between inflammation and cancer, 
in which critical molecular effectors may play crucial functions in the inflammatory and 
carcinogenic processes. 
 
 
2.2 – IL1B and cancer-related inflammation 
IL1B is a potent pro-inflammatory cytokine that is not present in tissues under normal 
homeostatic conditions, but it is produced and secreted upon inflammatory signals [108]. When 
secreted at low doses, IL1B induces limited inflammatory responses, while at high quantities, 
it induces a strong and extensive inflammation that is followed by damage of the normal tissue 
architecture [109]. Remarkably, inflammatory responses are severely attenuated in IL1B 
knockout (IL1B-/-) mice, confirming the crucial role of this cytokine in inflammation [110]. In 
addition to the destructive effects over tissue architecture, IL1B may be involved in the 
carcinogenesis process through the activation of infiltrating inflammatory cells or the target cells 
for transformation to produce ROS and RNI that can ultimately cause genetic aberrations [95].  
The functional evidences about the relevance of IL1B on tumour formation were 
obtained from IL1B-/- mice. In one study, wild type (wt) and IL1B-/- mice were treated with the 
carcinogenic 3-methylcholantrene (3-MCA). After 110 days of treatment, 60–70% of wt mice 
developed fibrosarcomas, against only 5% of tumours in IL1B-/- mice [108]. Furthermore, IL1B 
was found to be involved in cancer cell invasiveness and metastization. Using an IL1B-/- mouse 
model as a cell recipient, Voronov et al. (2003) demonstrated that the local growth and invasion 
of inoculated B16 melanoma cells was inhibited in IL1B-/- mouse but not in wt animals [111]. 
Moreover, and contrarily to control mice that promptly developed lung metastases, IL1B-/- mice 
lacked the ability to form lung metastases after being inoculated with B16 melanoma cells [111].  
IL1B is considered a pro-tumorigenic cytokine in different cancer models, conferring an 
aggressive phenotype to cancer cells. IL1B is expressed in 90% of invasive breast cancers, 
while in ductal in situ carcinomas (DISC) it is rarely expressed [112]. Moreover, elevated IL1B 
tumour content has been shown to be significantly associated with established aggressive 
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parameters (oestrogen receptor negativity and high tumour grade) [112, 113]. In the GI tract, 
IL1B is highly expressed in colorectal cancer (CRC) in comparison with normal colonic mucosa 
[114]. In vitro experiments performed on CRC cell lines indicate IL1B as a growth factor able 
to induce cell proliferation [115], inhibit chemically-associated apoptosis [116], and promote 
stemness and invasive properties [117]. 
Development of oesophageal adenocarcinoma (OAC) has been linked to chronic 
inflammation of the oesophagus [118]. The main risk factor for OAC is Barrett’s oesophagus 
(BO), involving a progression into low-grade/high-grade dysplasia [119]. Using a transgenic 
mouse model with IL1B overexpression restricted to oesophagus, Quante et al. (2012) 
demonstrated that increased expression of this cytokine alone is sufficient for the stepwise 
formation of Barrett-like metaplasia, dysplasia and intra-mucosal OAC [120]. Noteworthy, the 
lesions observed in the transgenic IL1B mouse oesophagus share high degree of similarity at 
the histological and molecular levels with human BO and OAC [120]. 
 
 
2.2.1 – IL1B role on gastric cancer development 
A robust amount of evidences supports the association between IL1B and GC 
development. The first evidences came from the observation that IL1B levels are strongly up-
regulated in the gastric milieu of individuals infected with H. pylori [36, 38]. Additionally, IL1B 
was shown to be a potent repressor of the expression of the gastric tumour suppressor TFF1 
[121]. In one of the first studies to evaluate the biological roles of IL1B on gastric epithelial cells, 
Beales et al. (2002), reported that this cytokine exerts a significant pro-mitogenic effect [49]. In 
fact, the increase in cell proliferation was dependent on the activation of the extracellular signal-
regulated kinase (ERK1/2) branch of the mitogen-activated protein kinase (MAPK) pathway 
[49]. Noteworthy, activation of the ERK1/2 signalling pathway was found to be increased in H. 
pylori-infected individuals [122] and in GC samples when compared with paired adjacent 
normal gastric mucosa [123-125]. To explore the in vivo impact of IL1B on H. pylori-mediated 
gastric epithelium behaviour, Shigematsu et al. (2013) infected IL1B-/- mice (BALB/C 
background) with the bacterium [126]. The authors observed a decrease in the proliferation 
rate and an increase in apoptosis levels of IL1B-/- gastric epithelium when compared with control 
wt gastric mucosa [126]. These results validated the previously described pro-mitogenic role of 
IL1B over the gastric epithelium [49]. 
 A seminal work that supported and validated the role of IL1B in H. pylori induced gastric 
carcinogenesis came from a transgenic mouse model in which IL1B overproduction was 
18
 
 
specifically targeted to the gastric epithelium [127]. With IL1B overexpression confined to the 
gastric mucosa, these transgenic mice developed, in a stepwise fashion that mimicked human 
gastric carcinogenesis, inflammation and hyperplasia, gastric atrophy, metaplasia, dysplasia, 
and GC. Relevantly, the formation of gastric lesions occurred even in the absence of H. pylori 
infection, which when introduced led to a reduction in time to lesions formation. Additionally, 
the pathological changes, including the progression towards GC, were refrained by 
administration of interleukin-1 receptor antagonist (IL1RA), proving beyond doubt that IL1B is 
the responsible for the pathological effects observed on the gastric epithelium [127]. 
 
 
2.3 – TGFβ and gastric cancer: from genetics to inflammation  
Transforming growth factor (TGF)-β is a multifunctional cytokine with critical functions 
in many cellular responses such as cell growth, apoptosis, and differentiation [128]. In non-
transformed epithelial cells, TGFβ inhibits proliferation through the activation of the cyclin-
dependent kinase (CDK) inhibitors p15, p21, and p27 [129], and by repressing the expression 
of cell proliferation inducer c-Myc [130]. Studies on the TGFβ receptor complex and its 
downstream signalling mediators (SMADs) revealed TGFβ as an important tumour suppressor 
pathway [128] [131]. In fact, decreased or even loss of expression of TGFBRI or TGBFRII is 
observed in some GC cases [132]. Also, frameshift mutations in TGFBRII are a frequent event 
in gastric and colorectal cancers with MSI [133], and SMAD4 inactivation by promoter 
methylation and loss of heterozygosity (LOH) was also detected in GC cases [134]. 
TGFβ is also a powerful immunosuppressive and anti-inflammatory mediator [135]. The 
evidence about TGFβ regulation of the tumour microenvironment emerged from the analysis 
of primary tumours and also from transgenic mouse models. Target deletion of Smad4 from 
head and neck epithelia (HN-Smad4-/-) promoted spontaneous formation of tumours in mice, 
characterized by increased inflammation and genomic instability [136]. Noteworthy, the levels 
of inflammatory mediators, such as IL1B, were found to be significantly increased in tumours 
derived from those HN-Smad4-/- transgenic mice [137]. In humans, the majority of 
gastrointestinal MSI cancers have inactivating mutations in TGFBRII [131] and are 
characterized by the presence of a strong lymphocytic infiltration [138]. The histological 
observation of inflammatory infiltrate in MSI tumours with mutated TGFBRII strengthens the 
anti-inflammatory role of TGFβ signalling pathway. 
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3 – Transcription factors as crucial effectors in normal and pathological conditions 
The critical change in gene expression that follows processes such as cell proliferation, 
differentiation, expression of cell-specific genes, and response to inflammatory mediators is 
controlled mainly at the transcriptional level. Also in cancer, transcription factors are the final 
effectors of oncogenic signalling pathways [139]. In this chapter will be addressed the biological 
functions of CREB and C/EBP families of transcription factors in normal and pathological 
contexts. 
 
 
3.1 – CREB transcription factor family 
 Extracellular stimuli elicit changes in gene expression in target cells through the 
activation of intracellular signalling kinase cascades that culminate in the phosphorylation and 
activation of critical transcription factors. The cyclic AMP (cAMP) responsive element-binding 
protein (CREB), with a molecular weight of approximately 43KDa [140], is one of the best 
characterized stimulus-induced transcription factors [141]. Originally, CREB was described to 
be activated in response to the second messenger cAMP [142]. Later, CREB was identified as 
a direct effector of other signalling pathways, activated by a diverse array of stimuli [143-145]. 
At the functional point of view, CREB mediates gene transcription by binding as a dimer to a 
conserved cAMP-responsive element (CRE) binding motif present on the promoter of target 
genes [146].  
 Phosphorylation of CREB at Ser133 plays a crucial role on the activation of CREB, 
inducing the transactivation of different target genes by promoting the recruitment and complex 
formation with the transcriptional co-activator CREB-binding protein (CBP) and its paralogue 
p300 [147, 148]. However, CREB-mediated transcription via a phosphorylation-independent 
mechanism also occurs, although in this case CREB co-activators are not CBP/p300 but are 
transducers of regulated CREB activity (TORCs) [149].  
 Shortly after the characterization of CREB, other two highly related gene products were 
described: activating transcription factor 1 (ATF1) [150] and cAMP-response element 
modulator (CREM) [151]. While CREB and ATF1 proteins are expressed in different cell types, 
CREM is expressed more specifically in neuroendocrine tissues. The primary protein structure 
of CREB family members uncovers a centrally positioned kinase-inducible domain (KID), inside 
of which the Serine 133 is located – and several potential phosphorylation sites [144, 152]. The 
KID region is flanked by hydrophobic glutamine-rich domains, Q1 and Q2, which function as 
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constitutive activators [153]. A basic leucine zipper (bZIP) dimerization domain and a nuclear 
localization signal are located in the protein carboxyl terminal (Figure 5) [144, 154]. 
 
Figure 5. Functional domains of CREB protein. The scheme depicts the major domains of the protein. Numbers on 
top indicate the position of amino acid residues, (+) marks refer to the positively charged basic domain, and L refers 
to the leucine zipper domain. The position of the nuclear localization signal (NLS) is also shown as well as kinase-
inducible domain (KID), and Q1/Q2 activation domains (adapted from Shaywitz & Greenberg, 1999 [154]). 
 
 The CREM gene can give rise to different transcripts by alternative splicing, encoding 
proteins with distinct activator or repressor properties [155]. Noteworthy, a truncated CREM 
isoform, known as inducible cAMP response element repressor (ICER), consistent with the lack 
of an activation domain, acts as a potent repressor of transcription mediated by CREB family 
members [156]. ICER avidly dimerizes with CREB or other family members and through a 
dominant negative inhibition mode of action, inhibits CREB-dependent transcriptional activity. 
 
 
3.2 – CREB knockout and transgenic models 
 CREB null mice (CREB-/- mice) die immediately after birth from respiratory distress [157] 
due to a defective maturation of alveolar epithelium [158]. Furthermore, CREB-/- mice have an 
impaired T cell development, and a strong reduction in the corpus callosum [157]. Functionally 
relevant, CREM protein levels are up-regulated in CREB-/- mice possibly as a compensatory 
mechanism to re-establish the transcription of CREB-dependent target genes; however not 
sufficient to rescue the abnormal development of CREB-/- mice [158] On the other hand, CREM 
and ATF1 null mice do not exhibit any discernible phenotypic alterations, surviving to adulthood 
[159, 160]; however CREM males are sterile owing to enhanced apoptosis of post-meiotic germ 
cells. 
 Due to the absence of a CREB-specific phenotype in knockout mice due to a partial 
compensatory functional mechanism by other members of the CREB family [158, 161], a 
different approach to address CREB biology was achieved through the development of 
transgenic mouse models expressing dominant-negative forms of CREB. The development of 
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transgenic models, granted the identification of CREB has a crucial player in the control of 
survival and proliferation of different cell types [144]. As an example, expression of a dominant-
negative transgene – described as A-CREB – in chondrocytes resulted in dwarfism due to a 
strong reduction in the cellular proliferation potential [161]. Further studies revealed that CREB 
is positively involved in the transcription of several cell-cycle mediators, such cyclin D1, cyclin 
A, and proliferating cell nuclear antigen (PCNA) [144, 162, 163]. A function for CREB in growth 
factor-dependent survival has been demonstrated in different cell models, in which the 
overexpression of a dominant-negative CREB protein induces cell death [164, 165]. Other 
arguments that point CREB as a pro-survival effector emerged from in vitro assays in which 
the expression of ICER – the endogenous antagonist of CREB – promoted apoptosis through 
inhibition of CREB-dependent transactivation of the anti-apoptotic gene BCL2 [166, 167].  
 
 
3.3 – CREB target genes 
 The differential transcriptional regulation of target genes by CREB is probably achieved 
by varying the sequence composition and spatial placement of the CRE-binding motif on gene 
promoters. Firstly described as an eight-base-pair palindrome, 5’-TGACGTCA-3’ [146], the 
CRE-binding motif also occurs as a half-size motif (5’-CGTCA-3’ or 5’-TGACG-3’) [168, 169]. 
Furthermore, the occupancy of the CRE-binding motif by CREB seems to be possibly regulated 
by DNA methylation: the full-length CRE (5’-TGACGTCA-3’) contains a central CpG 
dinucleotide, and methylation of the cytosine of this site inhibits, at least in vitro, CREB binding 
and subsequent gene transcription [170]. 
In the first approach to define the pool of CREB target genes, Mayr et al. (2001), 
compiled and described a total of 105 genes directly regulated by CREB [144]. However, 
because the predicted number of CRE-binding sites in the human genome largely exceeded 
that report, two genome-wide analyses to identify CREB target genes were performed [171, 
172]. In one study, CREB was found to interact with more than 6300 promoter loci [171], and 
in the other CREB was found to occupy approximately 4000 promoters [172]. However, and 
despite the large number of CREB target genes described, Zhang et al. (2005) observed and 
reported that CREB activity may be targeted only to certain genes at the level of promoter 
occupancy, Ser133 phosphorylation, or recruitment of the transcriptional apparatus [172]. In 
fact, Cha-Molstad et al. (2004) observed that promoter occupancy by CREB is a dynamic 
process and varies from one cell type to another, thus showing that the ability of CREB to bind 
a particular CRE-binding motif represents a crucial component of gene regulation [173]. 
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Niehof et al. (1997) reported that one hepatocyte specific CREB-target gene is the 
transcription factor CCAAT/enhancer-binding protein (C/EBP)-β [174]. Beyond hepatocytes, 
CREB acts as a critical activator of C/EBPβ expression also in preadipocytes [175]. In this cell 
model, when CREB is silenced, the other members of the family – ATF1 and CREM – are 
overexpressed, substituting CREB in the transactivation of CEBPB [176]. 
 
 
3.4 – CREB in inflammation 
 CREB was found to be an important player in the inflammatory process. For example in 
leukemia cell lines, CREB acts as a direct transcriptional regulator of IL1Β. In the leukemic cell 
model, IL1B operates as an autocrine growth factor, where through a positive feedback 
mechanism that cytokine induces the transcription of it is own gene through the action of CREB 
[177]. In a different cellular context, in aminon-derived cells, CREB and C/EBPβ were found to 
be the transcriptional effectors necessary for IL1B expression [178]. Nevertheless, CREB acts 
not only as a direct transcriptional activator of inflammatory mediators but is also primed by 
inflammatory signals to regulate the expression of a specific set of inflammation-associated 
genes in different cellular contexts. In this regard, the increase in expression of MUC8 and 
MUC5AC – whose up-regulation is virtually always observed in airway inflammatory conditions 
[179] – in respiratory epithelial cells in response to inflammatory stimuli is mediated by the 
transcriptional activity of CREB [180, 181]. 
Kudo et al. (2007) reported the pattern and timing of expression and activation of 
different transcription factors in the gastric epithelium of Mongolian gerbils associated with H. 
pylori infection. CREB was found to be one of the up-regulated transcription factors in response 
to H. pylori infection, and was strongly correlated with gastric mucosa inflammation and 
ulceration [182]. Furthermore, H. pylori-induced gastritis was found to be significantly 
associated with COX2 expression [183]. This enzyme seems to contribute to the gastric 
carcinogenesis process, because it is frequently found overexpressed in preneoplastic lesions 
and GC, where it leads to the increase in the levels of ROS and RNI [184, 185]. Jüttner et al. 
(2003) provided a molecular pathway underlying H. pylori-dependent COX2 expression, in 
which CREB, after being activated by MAPK signalling, is responsible for COX2 expression 
[186]. 
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3.5 – CREB in cancer 
One aspect generally accepted in the cancer research field is that unrelated tumours 
can activate the same oncogenic pathway/s using alternative strategies to that particular end. 
This is true for CREB-dependent signalling because its activation, by direct or indirect 
mechanisms, is frequently observed in various tumour types [187]. 
 The first evidence about CREB involvement in cancer emerged with the identification of 
the chromosomal translocation t(12;22) in clear cell sarcomas (CCS) that creates the fusion 
protein EWS-ATF1 [188]. More recently, the EWS-CREB fusion protein was also found in a 
gastrointestinal CCS [189]. Both in EWS-ATF1 and EWS-CREB fusion proteins, the KID 
domain of ATF1/CREB is substituted by the EWS activation domain, originating a new fusion-
transcription factor that has a functional CRE-binding recognition domain and acts 
independently of phosphorylation events [190]. Remarkably, the presence of the CRE-binding 
domain has been shown to be mandatory for the cellular transformation and tumour cell survival 
[191]. 
  
3.5.1 - Leukemogenesis 
 The role of CREB in leukemogenesis has been supported by various studies in leukemia 
patients and leukemia-derived cell cultures [192-195]. Increased protein levels of CREB and 
phosphorylated CREB (pCREB) were found in bone marrow cells from patients with acute 
lymphoid leukemia (ALL) or with acute myeloid leukemia (AML) in comparison with control 
individuals [194, 195]. Furthermore, leukemia patients with increased CREB levels have a poor 
prognosis, characterized by a decrease in the time to relapse and a decrease in event-free 
survival [192, 193]. In vitro enforced overexpression and gene silencing assays in leukemia cell 
lines allowed to observe that CREB confers increased growth and survival advantages [193]. 
Furthermore, the in vivo silencing of CREB in an aggressive model of BCR/ABL-driven 
leukemia resulted in a significant increase in animal survival [196]. Taken together, these 
results indicate CREB as an important proto-oncogene in leukemogenesis. 
Transplantation of bone marrow cells silenced for CREB expression in irradiated mice 
resulted in a smaller number of committed progenitor cells compared with control non-silenced 
cells. However, long-term engraftment revealed no major effects on mice, suggesting that 
CREB insufficiency is not essential for hematopoietic stem cell (HSC) activity [196]. Thereby, 
CREB seems to be a critical factor for the maintenance of leukemia cell biology but not essential 
for the normal function of HSCs. This aspect revealed the dependence of leukemia cells on 
CREB-dependent signalling, which can be used in future cancer-targeted therapies. 
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3.5.2 – Epithelial cancers 
Similarly to leukemias, CREB expression has been reported as deregulated in cancers 
with an epithelial origin. Prostate cancer (PC) is the most frequent cancer type in men in 
developed countries [4]. At early disease stages, PC is responsive to androgenic regulation, 
but eventually progresses to a stage that is resistant to androgen deprivation and poorly 
responsive to the present available therapies [197]. Progression of PC to androgen resistance 
is associated with up-regulation of insulin-like growth factor-1 receptor (IGF1R) [198] and 
Genua et al. (2009) disclosed that CREB is responsible for IGF1R increased expression in PC 
[199]. Furthermore, the immunohistochemical analysis on normal prostate gland showed no 
detectable levels of pCREB, whereas positive pCREB staining was observed in all PC of the 
poorly-differentiated type and also associated bone metastasis [200]. This positive association 
between pCREB and metastasis suggests that this CREB-dependent signalling is involved in 
PC tumour progression and metastization [200]. 
In breast, CREB transcript level was significantly up-regulated in tumours compared with 
adjacent normal tissue [201]. Patients with higher transcript levels of CREB had a significantly 
shorter disease-free survival compared with patients with low levels of CREB mRNA [201]. 
Moreover, highly metastatic breast cancer cell lines express higher levels of CREB compared 
to non-metastatic cell lines. In highly metastatic cell lines, CREB expression is necessary for 
the transcriptional expression of genes PTHrP, MMPs, and OPG, which are closely involved in 
cancer metastasis and bone destruction [202]. Recently, a positive link between HER2-positive 
breast tumours and CREB expression was described, in which HER2 increases pCREB levels 
[203]. Based on in vitro and in vivo evidences, increased pCREB levels in HER2-positive breast 
tumours were found necessary for cell proliferation, survival and migration, as well as for 
tumour formation ability [203]. 
 In never smoking patients with non-small-cell-lung cancer (NSCLC) CREB and pCREB 
were found significantly up-regulated in tumour tissue compared with adjacent normal tissues 
[204]. Moreover, in those NSCLC cases the authors reported an inverse association between 
the expression level of CREB and pCREB and disease free-survival [204]. 
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3.6 – C/EBP transcription factor members 
 The first CCAAT/enhancer binding protein (C/EBP) member identified was reported to 
be able to interact with the CCAAT box motif present in the promoter of several genes [205]. 
Thereafter, the optimal C/EBP binding motif was identified as being RTTGCGYAAY, where R 
is A or G, and Y is C or T, though some additional variations are tolerated [206]. Additionally, 
five C/EBP members were identified, all characterized by possessing a conserved basic-
leucine zipper (bZIP) type of DNA-binding and dimerization domain located at the protein C-
terminus [207, 208]. To prevent possible nomenclature mistakes, Cao et al. (1991) proposed 
that each C/EBP member should be named with a Greek letter according to the chronological 
order of their discovery (C/EBPα – C/EBPζ) [209]. Four C/EBP-family members are intronless 
(C/EBPα, -β, -δ, and -γ), whereas C/EBPε and -ζ possess two and four exons, respectively 
(Figure 6) [208]. 
 
Figure 6. Representation of C/EBP family members. The leucine zipper is shown in yellow, with black vertical lines 
indicating the leucine residues; the basic region is in red. The position of the activation domains (AD) and negative 
regulatory domains (RD) are shown in green and blue respectively. ? indicates the N-terminus activation domain of 
C/EBPζ (adapted from Ramji & Foka, 2002 [208]). 
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 In analogy to other transcription factors, C/EBP protein dimerization is mandatory for 
DNA binding [207, 210], and due to the highly conserved bZIP domain between all family 
members, C/EBP proteins are able to form heterodimers with different binding and 
transcriptional activities [208, 209, 211]. In opposition to the bZIP C-terminal portion of C/EBPs, 
the N-terminal part is quite divergent between members, with the exception of the activation 
domains that are important for the interaction with elements of the basal transcriptional 
apparatus [208, 212]. 
 Notwithstanding the existence of six C/EBP members, the number of C/EBP proteins in 
a specific cell at a certain moment can be higher. The reason for this resides first, in the fact 
that C/EBPε can give rise to different peptides by alternative use of promoters and exon-
alternative splicing [213], and second because C/EBPα and –β mRNA molecules can give rise 
to different peptides by a leaky ribosome scanning mechanism [214]. Through this mechanism, 
C/EBPα transcript can give rise to a full-length 42KDa and a truncated 30KDa isoforms, while 
C/EBPβ mRNA can originate three isoforms, 38KDa (LAP*), 35KDa (LAP), and 21KDa (LIP) 
[208, 214]. 
 All C/EBP members exhibit a specific cell/tissue expression profile: C/EBPα and 
C/EBPβ are expressed in a wide range of cell types; C/EBPδ is expressed in adipose tissue, 
intestine, and lung [209, 211]; C/EBPγ and C/EBPζ are ubiquitously expressed [208, 215], and 
C/EBPε expression is largely confined to granulocytic cells [213]. 
 Of the six C/EBP members, C/EBPα and C/EBPβ have been the most thoroughly 
studied in human and animal models, while research focusing the other members is still very 
scarce. Thus, from now on, in next sub-chapters it will be described the up-to-date data about 
the biological processes in which C/EBPα and C/EBPβ are involved. 
 
3.6.1 – C/EBPs in cellular proliferation and differentiation 
From the first observations about C/EBPα expression, reporting the strong protein levels 
in terminally differentiated cells that an anti-proliferative role was suggested for this 
transcription factor [216]. In fact, when C/EBPα expression is induced in in vitro assays it is 
able to efficiently inhibit cell proliferation [216, 217]. Mechanistically, the inhibition of cell 
proliferation triggered by C/EBPα can occur by the action of this protein on: a) the regulation, 
and activation of the CDK inhibitor p21 [218]; b) the inhibition of CDKs activity [219]; c) the 
repression of E2F-mediated transcriptional activity [220]; and interaction with the SWI/SNF 
complex [221, 222]. 
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Mice silenced for C/EBPα (C/EBPα-/-) die shortly after birth due to a limited production 
of liver enzymes necessary for glucose metabolism [223]. Nevertheless, cultured hepatocytes 
from C/EBPα-/- new-born mice display increased proliferative activity, with increased transcript 
levels of the proliferation activators Jun and MYC [224, 225]. Also, terminal differentiation of 
neutrophils [226] and the respiratory epithelium [227] are profoundly imbalanced in the absence 
of C/EBPα. During adipogenesis, C/EBPα expression is observed in the late stages of the 
process, when it is responsible for the transcription of genes specific of differentiated mature 
adipocytes [228]. Those observations supported the notion that a single transcription factor is 
able to regulate two essential features of differentiated cells: promote cell-specific gene 
expression and proliferation arrest. 
 In opposition to C/EBPα, C/EBPβ is able to play anti-proliferative or proliferative 
functions, depending on the cell type context. In keratinocytes, C/EBPβ seems to have anti-
proliferative functions because enforced expression of C/EBPβ in mouse keratinocytes 
inhibited cell growth and induced phenotypical changes associated with a differentiated 
phenotype. Moreover, analysis of the epidermis of C/EBPβ-/- mice revealed epidermal 
hyperplasia and decreased expression of the differentiation markers keratin 1 (K1) and keratin 
10 (K10) [229]. On the other hand, several reports indicate C/EBPβ as a promoter of cellular 
proliferation. As an example, C/EBPβ expression is promptly induced in hepatocytes after 
partial hepatectomy, where it is necessary for promoting liver regeneration [230]. Also, the 
mammary epithelial cells (MECs) from C/EBPβ-/- mice showed a decrease in the proliferative 
rate, ending in abnormal lobulo-alveolar morphogenesis [231, 232]. Enforced expression of 
C/EBPβ in human MEC resulted in hyper-proliferation that was accompanied by the acquisition 
of a partially transformed phenotype, characterized by an increase in the invasive ability [233]. 
Moreover, C/EBPβ was described as a critical transcription factor in mammary stem cells 
(MaSC), promoting the cellular outgrowth potential [234]. 
The preadipocyte differentiation model revealed the functional link between C/EBPβ and 
C/EBPα expressions. In this model, the differentiation from preadipocytes into adipocytes 
occurs through the serial induction of these two transcription factors. The expression of C/EBPβ 
(and also C/EBPδ) is rapidly induced in preadipocytes after the differentiation stimulus, 
diminishing its protein levels during the terminal phases of differentiation. In these last phases 
of adipocyte differentiation, C/EBPα expression is strongly induced, standing as the most highly 
expressed member of C/EBP-family. In fact, C/EBPα regulates the terminal adipocyte 
differentiation, turning on the battery of adipocyte-specific genes required for the full-
functionality of mature adipocytes [235, 236] (Figure 7). 
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Figure 7. Temporal pattern of C/EBPs expression during preadipocyte differentiation. Abbreviations: NI, non-
induced; TD, terminal differentiation. Arrow point to the approximate time when proliferation ends (adapted from 
Calkhoven & Ab, 1996 [236]) 
 
 
3.6.2 – C/EBPs and inflammation 
Soon after the identification of C/EBPs that a functional link with inflammation was 
established based on the ability of inflammatory mediators to promote the activity or expression 
of members of this family of transcription factors. For example, C/EBPβ was first identified as 
an inducible protein in response to activation of IL6 signalling pathway [237]. In fact, IL6 
stimulation was not only able to induce the expression of C/EBPβ but also was shown to 
decrease C/EBPα expression [208, 237, 238]. Additionally, subsequent studies allowed the 
identification of a broad range of inflammation-related genes activated by C/EBPs such as 
cytokines and their receptors, and elements of signal transduction pathways [208]. 
Work performed with mouse models allowed to discriminate relevant roles of C/EBPs in 
the inflammatory cells. Functionally relevant, C/EBPα and C/EBPβ are expressed in cells from 
the myeloid lineage [208, 209, 211]. C/EBPα-/- mice lack mature neutrophils due to defects in 
myeloid differentiation beyond the myeloblast stage, and C/EBPβ-/- mice lack mature or 
functional macrophages [208, 209, 211], [239]. In fact, macrophages from C/EBPβ-/- mice 
exhibit impaired expression of inflammatory mediators, such as TNFα [237, 238]. Additionally, 
C/EBPβ is also involved in epithelial cell response to inflammatory insults. In this regard, mice 
with an airway and alveolar epithelial-specific disruption of C/EBPβ (CebpbΔLE) displayed a 
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dramatic impairment of neutrophils and pro-inflammatory mediators to the lungs when 
compared with control mice [240]. 
 TGFβ is a powerful immunosuppressive and anti-inflammatory cytokine [135] that is able 
to block the biological functions of IL6 [241]. The causative impairment in IL6 signalling 
activation occurs at the transcriptional level, where the SMADs complex operate as inhibitors 
of C/EBPβ-dependent transcription of acute-phase genes, such as haptoglobin (HP). The 
inhibitory effect of TGFβ over C/EBPβ was previously reported in rat intestinal epithelial cells, 
where TGFβ caused the attenuation of an inflammatory-dependent increase in expression of 
C/EBPβ and also the loss of binding of this transcription factor to HP promoter [242]. 
 In the gastric epithelium it is known that H. pylori infection promotes COX2 expression 
through activation of toll-like receptors (TLR) [243]. Searching for a regulator of COX2 
expression in GC, Regalo et al. (2006) identified C/EBPβ as promoter-activating transactivator 
of COX2 in GC cell lines [185].  
 
 
3.6.3 – C/EBPs in cancer 
 From what has been exposed above, it is evident that C/EBPs play important roles in 
normal cell biology and in inflammation-associated processes. Nonetheless, C/EBPs were also 
found to play complex and important roles in cancer. Thus, in this sub-chapter, it will be 
described the involvement of C/EBPs in the carcinogenesis process. 
 
3.6.3.1 – C/EBPα behaves as a tumour suppressor 
 The first evidences that suggested C/EBPα as a tumour suppressor were found in AML. 
In this blood cancer type, inactivating somatic mutations were found in approximately 10% of 
leukemic patients [244, 245]. Two-thirds of CEBPA mutations are bi-allelic: the combination of 
N- and C-terminal CEBPA mutations accelerates disease development and explains the clinical 
occurrence of this mutational configuration [246]. In addition to mutations, C/EBPα protein is 
also frequently found downregulated in AML as a direct consequence of CEBPA promoter 
hypermethylation [247]. Nevertheless, CEBPA mutations are not a common event in other 
malignancies, with only one report about CEBPA mutations in GC [248]. The mutation 
described, although possibly damaging is a very infrequent event (1 mutation in 142 GC cases) 
and lacks confirmation of the real pathological relevance.  
30
 
 
To examine the role of C/EBPα in epithelial tumour development, Loomis et al. (2007) 
evaluated the function of C/EBPα in an epidermal-specific C/EBPα-/- mouse model. When 
C/EBPα-/- mice were subjected to chemically-induced carcinogenic insults, they displayed 
decreased tumour latency period and dramatic increases in tumour incidence and growth rate 
[222]. 
In lung adenocarcinoma, C/EBPα is frequently found downregulated in a large 
proportion of cases, and in vitro enforced expression led to a significant decrease in cell growth, 
emergence of morphological changes characteristic of differentiation, and apoptosis [249]. 
Tada et al. (2006) demonstrated that DNA hypermethylation and histone acetylation of the 
upstream CEBPA promoter were strongly associated with decreased or absent C/EBPα 
expression in lung cancers [250]. In addition to lung cancer, C/EBPα expression was also found 
downregulated in breast [251] and pancreatic cancers [252]. 
 
3.6.3.2 – C/EBPβ promotes tumourigenesis 
The development of C/EBPβ-/- mice allowed the observation that this transcription factor 
is involved in the development of certain cancer types. One of the first studies suggesting this 
effect was performed to assess the tumorigenic potential of C/EBPβ during carcinogen-induced 
skin tumour formation. In this study, C/EBPβ-/- mice revealed to be totally refractory to tumour 
formation [229]. The reason behind the lack of tumour formation in C/EBPβ-/- mice resides in 
the critical role of C/EBPβ for keratinocyte survival though – a process triggered by activated 
RAS pathway [229]. Because keratinocytes of C/EBPβ-/- mice exhibit a dramatic increase in 
cellular apoptosis when submitted to carcinogens, this abnormal increase in cell death can be 
sufficient to confer total resistance to chemical-induced cancer formation [239]. The increase 
in apoptotic rates are possibly caused by an aberrant overexpression of p53 in the 
keratinocytes of C/EBPβ-/- mice, since C/EBPβ acts as negative regulator of p53 [253]. 
Breast cancer is perhaps the better characterized model for C/EBPβ tumourigenic role. 
In this cancer type, C/EBPβ was found expressed in 70% of cases [254]. Two independent 
studies revealed the importance of C/EBPβ on breast cancer formation and progression. In one 
of those studies, the overexpression of C/EBPβ isoform LIP in the mouse mammary gland was 
sufficient to generate hyperplastic lesions in 30-40% of the glands, and carcinomas in 9% of 
the glands [255]. In the other study, the enforced expression of C/EBPβ isoform LAP was able 
to transform a normal epithelial breast cell line (MCF10A), conferring it anchorage independent 
growth and acquisition of invasive properties [233]. Additionally, and from a mechanistic 
approach, C/EBPβ isoform LIP was described as being involved in breast cancer progression 
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by blocking the cell-growth inhibitory action of TGFβ signalling pathway [256]. Thereafter, 
various studies revealed C/EBPβ-target genes with important roles in breast cancer formation 
and metastization [257-261]. 
Noteworthy, a general oncogenic role for C/EBPβ was proposed by Lamb et al. (2003), 
who examined the gene expression profiles of different human tumours types characterized by 
increased levels of cyclin D1. The authors found that C/EBPβ overexpression was significantly 
correlated with cancer types marked by cyclin D1 up-regulation, indicating a possible functional 
link between C/EBPβ and cyclin D1 [262].  
 In respect to GC, C/EBPβ was shown to be overexpressed in tumour samples when 
compared to adjacent normal mucosa [263]. In independent studies, Regalo et al. (2006) and 
Milne et al. (2006) confirmed the up-regulation of C/EBPβ protein in gastric tumour samples, 
particularly in tumour with an intestinal or atypical histological differentiation [185, 264]. 
Moreover, C/EBPβ was found to be a direct transcriptional repressor of TFF1 expression [263], 
a well-established gastric tumour suppressor [77]. 
 
 
4 – Transcription factors as targets for cancer therapy 
A selective number of transcription factors are overexpressed and/or overactive in most 
human cancers, making them putative relevant targets for the development of anticancer drugs. 
This rationale is supported by knowing that there are more oncogenic proteins and oncogenic 
signalling cascades upstream of these same transcription factors than are oncogenic 
transcription factors. Therefore, being transcription factors the terminal effectors of malignant 
gene expression patterns, they occupy a central role in all classic hallmarks of cancer [139, 
265, 266]. Thus, effective anti-transcription factor drugs could be able to antagonize and inhibit 
the action of various upstream-activated oncogenic pathways [267]. 
Mechanistically, signalling cascade activation begins with the binding of extracellular 
proteins (ligands) to cell-membrane receptors that dimerize or oligomerize at the cell surface 
to start intracellular communication events. Cell-membrane receptors have been frequently 
found mutated or overexpressed in cancer. As examples, epidermal growth-factor receptor 
(EGFR) and platelet-derived growth-factor receptor (PDGFR) have shown to be overexpressed 
or mutated in different cancer types [268]. Then, specific cytoplasmic proteins will act as signal 
transducers, transmitting the information into the nucleus [267]. In this regard, intracellular 
tyrosine kinases activated by mutation are fairly common in cancer. As an example, KRAS is 
frequently found mutated in human cancers, including as previously mentioned GC [267]. 
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Finally, the increase in expression and activity of transcription factors that are activated in a 
direct or indirect way by specific phosphorylation events may act as oncogenes, if involved in 
the transcriptional expression of genes with positive functions in cell proliferation and/or cell 
survival [139, 267]. 
Transcription factors with oncogenic roles in cancer can be classified into three main 
groups according to their functional behaviour [267]. The first group corresponds to the steroid 
receptors, and examples of expression in cancer are oestrogen receptors (OR) in breast and 
androgen receptors (AR) in prostate. Anti-oestrogen and anti-androgen drugs – such as 
tamoxifen and bicalutamide, respectively - have been in clinical use successfully for years [269, 
270]. 
The second group of transcription factors is defined by resident nuclear proteins, which 
are activated by serine kinase signalling cascades [271]. Members of this second group 
comprises, among others, JUN, ATF-CREB-CREM family, and the C/EBP family of 
transcription factors [267, 271]. Regarding this second group, a battery of small-molecule 
inhibitors of CREB activity were recently described [272, 273]. These small-molecule inhibitors, 
designated KIX-KID interaction inhibitors, exert their effect by disrupting the interaction 
between CREB and its co-activators, namely CBP and p300. Notably, one of the KIX-KID 
inhibitors exhibited a strong in vitro effect in inhibiting the proliferation of breast cancer cells but 
not mammary normal epithelial cells, revealing the strong dependence of breast cancer cells 
for CREB-dependent transcriptional activity [273].  
The third group of transcription factors is composed by “latent cytoplasmic factors”. The 
hallmark of this group is residence in the cytoplasm in an inactive form until they are activated 
by proteins that bind cell surface receptors [271]. As members of the latent cytoplasmic factors 
group one can found STATs, NF-κB, and β-catenin [267, 271]. The signal-transducer and 
activator of transcription (STAT)-3 acts as a key player in important oncogenic signalling 
pathways [107]. Constitutive STAT3 activation has been observed in various human cancers, 
usually associated with a poor clinical outcome [106, 274]. During years, numerous strategies 
were developed to inactivate STAT3. The first approach was the development of small-
molecules that reportedly inhibited STAT3 activity. Unfortunately, those small-molecules 
demonstrated a general lack of specificity [275, 276]. Recently, a different approach to directly 
inhibit STAT3 activity was developed using double-stranded oligonucleotide decoys [277]. The 
STAT3 decoy exhibited selective STAT3-binding, resulting in in vitro inhibition of proliferation 
and survival of head and neck squamous cell carcinoma (HNSCC) cells [278]. A phase 0 clinical 
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trial was performed using double-stranded oligonucleotide decoys, confirming the efficacy of 
this approach in inhibiting STAT3 oncogenic signalling in HNSCC tumours [278]. 
NF-κB is a transcription factor that promotes the transcription of inflammatory cytokines 
[279, 280] and whose constitutive activation has been observed in various malignancies [281-
284]. Noteworthy, a small molecule antagonist of NF-κB (DHMEQ) has been recently 
developed, and it acts on NF-κB-dependent signalling inhibition by directly interacting with the 
protein complex and blocking nuclear translocation [285]. 
Another protein with important transactivating properties is β-catenin. Although β-
catenin do not bind DNA, it possess an amino-terminal domain that bind to transcriptional co-
activators and to TCF/LEF DNA binding proteins [271]. Deregulated WNT signalling pathway 
is one of the most frequent and functionally relevant events in colorectal cancer. In this cancer 
model, inactivating mutations in the tumour suppressor APC result in the translocation of β-
catenin to the cell nucleus, leading to the constitutive activation of WNT signalling [286]. A 
recently developed battery of small-molecules that lead β-catenin to degradation via 
proteasome pathway are showing promising results, because those small-molecules were able 
to selectively kill cancer cell lines with constitutive WNT signalling activation [287]. 
Noteworthy, in addition to the position that transcription factors occupy in oncogenic 
signalling pathways as the final cellular effectors, they can also act as the direct mutational 
targets after chromosomal or genetic aberrations. In fact, several genes involved in 
chromosome rearrangements are transcription factors – as examples, the EWS-ATF1 and 
EWS-CREB rearrangements observed in CCS, as previously mentioned [188, 189, 288]. Also, 
an increasing number of pathognomonic tumour-specific genetic and epigenetic events have 
been shown to directly inactivate tumour suppressor or activate oncogenic transcription factors 
[139].The increase in understanding about the role of transcription factors and allied networks 
in the carcinogenesis process provides a hope and a challenge for new innovative treatment 
strategies. Identification of the most appropriate transcriptional targets in distinct tumour types 
and efficient delivery methods are mandatory prerequisites for the development of effective 
pharmacological inhibitors of transcription factors. 
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In clear contrast with other cancer models, there is a general lack of knowledge about 
the natural history of GC, especially the signalling pathways and molecular mechanisms that 
forge tumour formation through the disruption of the normal gastric homeostatic processes. 
The discovery and understanding of the molecular events underlying gastric carcinogenesis 
will ultimately inform about possible and more effective treatment strategies. 
It is well recognized that chronic inflammation is a risk factor for the development of a 
wide range of cancers. In the gastric epithelium context, a robust set of evidences link H. pylori-
associated chronic inflammation with the onset of GC. Moreover, the risk to develop GC further 
increases in individuals that have a genetic background responsible for a more intense 
inflammatory response. However, the signalling pathways modulated by inflammation and the 
mechanisms through which the inflammatory response drives the transformation of gastric 
epithelial cells remains to be elucidated. It is proposed that the link between enhanced chronic 
inflammation and GC depends on the long-term damaging effects of inflammatory mediators 
over the gastric mucosa. Coupled with mutagenic events, this could ultimately lead to increased 
risk of cell transformation and GC development.  
In this regard, IL1Β is particularly interesting because polymorphisms in its promoter 
region have been shown to be associated with increased risk of GC, possibly through the 
differential production of the cytokine. Also, IL1B was shown to act as a growth factor able to 
increase the proliferative rate of gastric epithelial cells and a transgenic mouse model with 
gastric-specific IL1B overproduction develops GC. Hence, inflammatory mediators, such as 
IL1B, are able to disrupt gastric homeostasis possibly through the modulation of signalling 
pathways. The signalling events converge in the activation of transcription factors that act as 
cellular effectors of inflammation-induced biological responses. Furthermore, inflammation-
activated transcription factors are also found to play relevant biological roles in malignancies. 
This observation is highly suggestive of a tight relation between inflammation and cancer, in 
which major molecular effectors play crucial functions in the both inflammatory and 
carcinogenic processes. 
Based on the exposed, the main goal of this work was to increase our 
understanding of the signalling events and associated molecular mechanisms 
underlying inflammation-driven GC development. To achieve our major goal, we focused 
on two specific aims:  
- Determine the expression patterns of inflammation-associated molecular 
effectors on normal gastric mucosa, preneoplastic and GC lesions. 
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By pursuing this goal, we expected to observe and report for the first time the 
histological pattern of distribution of inflammation-associated transcription mediators 
over gastric epithelium. The comparison of the expression profile between normal 
gastric epithelium and different gastric lesions would function as an indication mark 
about the putative biological/pathological role of those transcriptional effectors. 
 
- Determine the inflammation-modulated signalling cascades responsible for 
the expression/activation status of molecular effectors and the underlying 
biological meaning through in vitro and in vivo approaches 
Because the expression/activation status of inflammation-induced transcription 
effectors is the final step of a series of intracellular signalling events, we aimed to 
disclose the underlying inflammation-triggered signalling mechanisms. After that, 
through a series of in vitro and in vivo assays we attempted to translate our findings 
into a biological readout. We expected that the results obtained could help inform 
new strategies for prevention and treatment of GC, including the control of chronic 
inflammation and the identification of new therapy targets. 
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Optimized and applied for article “C/EBP alpha expression is associated with 
homeostasis of the gastric epithelium and with gastric carcinogenesis”. 
 
Tissue Material 
Surgical specimens from 54 GC were resected and diagnosed at Hospital S. 
João/Faculty of Medicine, Porto, Portugal. Tissue fragments were fixed in 10% formaldehyde 
and embedded in paraffin. Serial sections of 3 mm were obtained from each block and used 
for routine staining with haematoxylin and eosin and immunohistochemistry. The procedures 
followed in this study were in accordance with the institutional ethical standards. All the samples 
enrolled in this study were delinked and unidentified from their donors. 
 
Immunohistochemistry 
Tissue sections were first treated with 10mmol/l citrate buffer (pH 6.0) for 40 min at 99ºC. 
Unspecific endogenous peroxidase activity was eliminated with a Hydrogen Peroxide Block 
solution (Labvision, UK) for 10 min. After washing, slides were incubated with monoclonal 
mouse antibody anti-C/EBPα 1:300 (Cell Signaling Technology, USA) or C/EBPβ (1:100, Santa 
Cruz Biotechnology, USA) 1 h at room temperature (RT). Sections were then washed and 
incubated with Dako Real Envision/HRP Rabbit/Mouse solution (DAKO, Denmark) for 30 min 
(RT). The slides were then developed for 10 min in Dako Real diaminobenzidine (DAB) (0.05%, 
DAKO) and sections counterstained with haematoxylin, dehydrated, and mounted. For 
immunofluorescence, after the primary C/EBPα antibody incubation, sections were incubated 
with a biotinylated secondary antibody and signal was obtained with Alexa Fluor (Molecular 
probes, Invitrogen, CA, USA) incubation. For double TFF1 and C/EBPα staining, two 
independent reactions were performed on the same slides. Sections were blocked for 15 min 
in 10% BSA with anti-mouse serum and incubated overnight in monoclonal antibody anti-
C/EBPα at 1:100 (Cell Signaling Technology, USA). After washing, samples were incubated 
with anti-rabbit secondary antibody 1:200 (DAKO, DK) for 30 min and washed again. A final 1 
h incubation with avidin-biotin-peroxidase 1:100 (DAKO, DK) was performed. Slides were then 
developed with DAB (DAKO, DK). After a washing step of 30 min in PBS at 60ºC, slides were 
again incubated overnight with monoclonal antibody anti-TFF1 1:100 (Zymed, USA) and 
developed with alkaline phosphatase (DAKO, DK) and Fast Red (Sigma-Aldrich, USA). Slides 
were reviewed by a pathologist, tumours were classified according to Lauren’s classification, 
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and the sections were semi-quantitatively scored according to the intensity of staining when 
compared with the positive control: intense staining was classified as III; moderate intensity as 
II; and weak intensity or negativity as I. Cases were classified as ‘downregulated’ when >50% 
of the tumour cells were classified as I. All washing steps were performed in PBS buffer. Normal 
gastric mucosa was used as a positive control, and negative controls were performed by 
substitution of the primary antibody with immunoglobulins of the same class and concentration. 
 
Cell Culture, Transfections, and Western Blotting 
AGS and MKN28 cells were grown in RPMI medium with 10% FBS (GIBCO, Invitrogen, 
USA). AGS cells were grown until 60–80% confluence in six-well plates, and transfected using 
3 µg of Plenti-C/EBPα expression vector with an appropriate TFX-50 (Promega, WI, USA) 
concentration and volume. For western blot analysis, cells were scrapped in PBS and lysed in 
RIPA buffer with protease and phosphatase inhibitors. A measure of 40 µg of total protein were 
loaded into acrylamide gels and separated by electrophoresis. The proteins were then 
transferred to Hybond membranes (Amersham Biosciences, UK). For dot blot, 20 µg of 
denatured protein extract were directly pipeted into Hybond membranes. After blocking, blots 
where incubated during 1 h with primary antibodies anti-C/EBPα 1:100 (Cell Signaling, USA), 
anti-P27 and anti-Cyclin D1 1:100 (Santa Cruz Biotechnology, USA), anti-tubulin 1:15000 
(Sigma-Aldrich, USA), and in the case of the dot blot with anti-TFF1 1:100 (Zymed, USA) in 
PBS plus 5% non-fat dried milk and 0.5% tween-20. The blots were then washed three times 
in the same solution and incubated 45 min with an HRP-conjugated secondary antibody 1:1000 
(Santa Cruz Biotechnology, USA) in PBS 0.5% tween-20. Blots were then washed three times 
in PBS 0.5% tween-20 and signal was detected with chemiluminescence using ECL 
(Amersham Biosciences, USA). For MAPK inhibition experiments, MKN28 cells were grown 
until 50–60% confluence and treated for 24 h with 10 µM SB239063 or PD98059 (Sigma-
Aldrich, USA). 
 
BrdU Incorporation Assay and Immunocytochemistry 
AGS cells were harvested in 24-well plates with glass slides, and transfected using 
TFX50 (Invitrogen, USA) with empty vector and full-length C/EBPα expression vectors in 
OPTIMEM medium (GIBCO, USA). After 1 h, complete RPMI medium was added and cells 
were left growing for 48 h. MKN28 cells were grown in six-well plates with glass slides and 
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treated with MAPK inhibitors as described above. After incubating 1 h in 5-bromo-deoxyuridine 
(BrdU), cells in the glass slides were fixed in 4% paraformaldehyde, washed with PBS two 
times, and quenched by incubation with 2M HCl for 20 min. After washing, slides were 
incubated with anti-BrdU antibody 1:100 (DAKO, DK)) for 1h. For simple immunocytochemistry, 
MKN28 cells treated and untreated with MAPK inhibitors were blocked in PBS with 4% BSA 
and incubated in C/EBPα 1:100 (Cell Signaling, USA) antibody for 1 h. In procedures, cells 
were finally incubated with secondary anti-mouse FITC 1:100 (DAKO, DK)-conjugated antibody 
for 30 min. After washing, cells were mounted in Vectashield (Vector Laboratories, USA) with 
DAPI blue and scored for BRDU incorporation or C/EBPα expression on a fluorescence 
microscope. 
 
Inhibition of C/EBPα by siRNA 
MKN28 cells were grown until 50% confluence and pre-incubated in serum-free 
medium. The appropriate anti-C/EBPα target sequence (100 nM), and scrambled control siRNA 
(Qiagen, DE) were mixed with Metafectene (Biontex laboratories GmbH, Germany) in serum-
free medium, incubated for 20 min and added to the cells. After overnight incubation, the 
medium was changed to complete RPMI and cells left to grow for 48 h, after which BRDU 
incorporation and protein expression analyses were performed. 
 
Statistical Analysis 
Comparison of GC cases regarding their clinicopathological features was performed 
using Fisher’s and χ2 test. Three independent measurements were performed for the BRDU 
incorporation experiments and results were compared by Student’s t-test. 
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Optimized and applied for article “C/EBPβ/RUNX1t1 regulatory loop controls cell 
proliferation in gastric cancer”. 
 
Human gastric cancer samples and microarray data 
Human tissue samples were derived from patients that had undergone resection for 
sporadic gastric adenocarcinoma at the Robert-Roessle Hospital (1995–2003). The selection 
of samples, the procedure for histological classification and staging, the second blinded 
evaluation by an independent pathologist including assessment of tumour content in the pieces 
that RNA was extracted from, and RNA extraction and microarray procedure has been 
described elsewhere [289]. 
 
Transgenic mice 
C/EBPβ knockout (KO) animals were previously established in C57Bl/6 background 
[239]. C57Bl/6 RUNX3 KO mice were obtained from the group of Prof. Ito [90], and crossed 
with C/EBPβ KO mice. Due to the lethal phenotype of the single RUNX3 KO, C/EBPβ/RUNX3 
heterozygote animals were bred and the phenotype analysed in the offspring at birth. Animals 
were bred and kept according to the institutional guidelines, and genotyped by PCR as 
previously described [90, 239]. 
 
C/EBPβ knockdown cells and in vivo tumorigenic assay 
MKN45 and MKN74 cells were infected with lentivirus containing GFP-tagged control 
shRNA and shRNA against C/EBPβ. Efficiency of knockdown was assessed by Western Blot 
and proliferation was measured by BrdU incorporation assay. The effect of C/EBPβ expression 
on tumour formation was examined by subcutaneously implanting 3×106 cells of control 
MKN74/45 and ShRNA-mediated C/EBPβ-silenced MKN74/45 into 6-8-week-old male NIH(s) 
II-nu/nu nude mice, four mice per group. The animals were monitored weekly for tumour 
formation for 20 days after inoculation. Tumour sizes in two dimensions were measured with 
calipers, and volumes were calculated with the formula (a × b2) × 0.5, wherein “a” is the long 
axis and “b” is the short axis (in millimeters). Mice were maintained and sacrificed according to 
institutional guidelines, and at termination of the experiment tumours were excised, fixed, 
embedded and analysed by immunohistochemistry for Ki67 and C/EBPβ expression. 
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Co-immunoprecipitation 
Flag-tagged RUNX1t1 was expressed in MKN28 and MKN45 cell lines. Cells were 
harvested and lysed in buffer containing 50 mM Tris pH 8, 1 mM EDTA, 150 mM NaCl, 0.2% 
NP-40, 5 mM MgCl2, 50 μM, ZiCl2 and protease inhibitor cocktail (Roche, CH). Protein lysates 
were incubated at 4 °C with Protein A sepharose beads (Sigma, USA) for 1h. Beads were then 
washed 4 times in lysis buffer and examined by Western Blot analysis. 
 
Immunohistochemistry 
Stomachs were obtained from three month-old C/EBPβ knockout (KO) mice, and new-
born C/EBPβ-/-, RUNX3-/- and compound C/EBPβ/RUNX3 KO animals. Stomachs were 
longitudinally excised, formalin-fixed and embedded in paraffin. Gastric cancer tissue 
microarrays were obtained as described elsewhere [290]. Serial sections were obtained, 
deparaffinised and stained with Haematoxylin and Eosin, examined by a pathologist, and 
measured. An additional group of sections were treated with 10 mM citrate buffer and stained 
with 1:100 anti-Ki67 (DAKO, DK), 1:500 anti-C/EBPβ, 1:50 anti-TFF1 (Santa Cruz 
Biotechnology, USA), or 1:500 anti-RUNX1t1 (Sigma, USA) antibody. After washing with PBS 
with 0.02% Tween and incubation with horseradish peroxidase-bound secondary antibody (GE 
Healthcare, USA) development was performed using DAB. 
 
BrdU proliferation assay 
Cells with stable C/EBPβ knockdown were sorted and plated to 40% confluence. Cells 
were also transfected with RUNX1t1 and analysed for BrdU incorporation after 48 h. Briefly, 
cells were incubated with 1 M BrdU for 20 minutes, trypsinized and harvested in ice-cold PBS. 
Cells were then fixed, permeabilized, and stained with fluorescent anti-BrdU antibody according 
to the APC-BrdU flow kit protocol (BD Biosciences, USA). Dead cells were stained with 7-AAD 
and BrdU positivity was then assessed by flow cytometry. 
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Total RNA extraction, cDNA synthesis and quantitative real-time PCR 
For RNA extraction from mouse tissue, stomach sections were frozen in liquid nitrogen 
after excision, and finely grinded in a mortar. For RNA extraction from gastric cancer cells, 
these were harvested in ice-cold PBS and pelleted at 2000 rpm. Lysis buffer was then added 
to the obtained powder or to the pellet which was then vigorously resuspended using a 3ml 
syringe. RNA was extracted using a universal RNA extraction kit (Roboklon, DE). RNA was 
quantified, cDNA synthesized by standard methods and SYBR green quantitative real-time 
PCR performed. Primers used are listed as follows: 
Primer name Sequence (5’ to 3’) 
Human_CEBPB_Fw GACAAGCACAGCGACGAGTA 
Human_CEBPB_Rv AGCTGCTCCACCTTCTTCTG 
Human_FOG2_Fw TGGGGACACACAGTCAGAGA 
Human_FOG2_Rv CCTCAGAGATGGCCTTCGTA 
Mouse_Fog2_Fw TGGGATGGACCAGGAGAG 
Mouse_Fog2_Rv GACGAGCTCTTCACCCTCTG 
Human_SPARCL1_Fw AGAGCACCAAGAGGCCAAG 
Human_SPARCL1_Rv CTCTCATCCGTAGAGGAAACTGA 
Mouse_Sparcl1_Fw TCCTGCTTGTACGGACTTTG 
Mouse_Sparcl1_Rv TTCCTTCAAGGTGATGTGCTT 
Human_RUNX1t1_Fw CCCTCGCTAGACGTGAACTC 
Human_RUNX1t1_Rv TGCTGTTTGGTAAAGCATCG 
Mouse_Runx1t1_Fw AGTTCGCACCCTTGT 
Mouse_Runx1t1_Rv TTCGTGCTGAGCGAG 
Mouse_Ki67_Fw CCACACTGTGTCGTCGTTTG 
Mouse_Ki67_Rv CCGTGCGCTTATCCATTCA 
Mouse_Pcna_Fw CGAAGCACCAAATCAAGAGA 
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Mouse_Pcna_Rv CGGCATATACGTGCAAATTC 
Mouse_Muc6_Fw CCTCTGCTGCGACTGTCTAA 
Mouse_Muc6_Rv TGGGAGTGGGAAGATAATGG 
Mouse_Muc5ac_Fw CTGTGGAGCATGGGGAAAT 
Mouse_Muc5ac_Rv GAACCACAGACCTGCTCCAC 
Mouse_Cyclin A1_Fw GCTACCTTCCAGAAGCTGAAGT 
Mouse_Cyclin A1_Rv CAGGGTCTCTGTGCGAAGTT 
Mouse_Cyclin E1_Fw GCAGCGAGCAGGAGACAGA 
Mouse_Cyclin E1_Rv GCTGCTTCCACACCACTGTCTT 
Mouse_Cyclin D3_Fw TGCCAAAACGCCCCAGTAC 
Mouse_Cyclin D3_Rv CGGGATGCCCGAAGGA 
Mouse_p15_Fw AGATCCCAACGCCCTGAAC 
Mouse_p15_Rv CCCATCATCATGACCTGGATT 
Mouse_Bcl2_Fw ATGTGTGTGGAGAGCGTCAACC 
Mouse_Bcl2_Rv TGAGCAGAGTCTTCAGAGACAGCC 
Mouse_Birc5_Fw CTGATTTGGCCCAGTGTTTT 
Mouse_Birc5_Rv GCCACAAAACCAAAGAGAGG 
 
Plasmids 
For the construction of C/EBPβ isoform expression vectors, LAP*, LAP and LIP were 
cloned from human cDNA by PCR, following digestion with restriction enzymes, ligation into 
pcDNA3-flagged plasmid and ampicillin selection. TFF1-luciferase reporter plasmid was 
similarly cloned from human cDNA into a pGL3-basic plasmid. RUNX1t1 expression plasmid 
(pCMV-3xFlag-ETO) was obtained from (ADDGENE, UK) (ref: #12507). For the construction 
of C/EBPβ knockdown vectors, shRNA (5’-gccgcgacaaggccaagatgc-3’) was inserted into a 
pLVTH-M lentivral vector. 
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Tissue culture, transfection, and luciferase assays 
MKN28, MKN45 and MKN74 cell lines were grown in RPMI medium (GIBCO, USA). For 
transfection, cells were trypsinized, seeded, and grown to 50-60% confluence. C/EBPβ isoform 
plasmids and/or RUNX1t1 plasmid were re-suspended in serum-free medium with transIT 
(Mirus Bio, USA) transfection reagent and added to the cells. Protein and RNA were extracted 
after 48 h and analysed by Western Blot and real-time PCR. 
 
RUNX1t1 promoter methylation analysis 
Methylation analysis of the RUNX1t1 promoter was determined by methylation-specific 
PCR (MSP), as previously described [291]. MSP method distinguishes unmethylated from 
methylated alleles in a gene based on sequence changes produced after bisulfite treatment of 
DNA, which converts unmethylated but not methylated cytosines to uracil. Subsequently, PCR 
using primers specific to either methylated or unmethylated DNA was performed. Genomic 
DNA (350ng) was bisulfite-treated and purified with EZ DNA Methylation Kit Gold (Zymo 
Research, USA). The primer sequences of RUNX1t1, for methylated and unmethylated 
reactions were as previously described [291]. A quantity of 100 ng of bisulfite-modified DNA 
was used in each PCR. Amplification was carried out for 36 cycles (30 s at 95°C, 30 s at 56°C, 
and 30 s at 72°C). Control PCRs lacking genomic DNA were performed for each set of 
reactions. Amplified products were separated by electrophoresis in a 2.5% agarose gel. 
 
RUNX1t1 gene mutational screening 
Molecular analysis was performed on DNA extracted from a cohort of 26 tumour 
samples. DNA samples were extracted in Hospital São João/ Faculty of Medicine of University 
of Porto and belong to the Tumour Bank of that institution. All primers were newly designed 
using Primer 3 software. Each primer pair was designed to flank each coding exon of RUNX1T1 
gene. We amplified 20 ng of DNA in a 20 μl reaction that included 1× Master Mix Solution 
(Qiagen, DE), and primers at 0.4 mM. PCR was performed with an initial incubation at 95°C for 
15 min, followed by 35 cycles of denaturation at 95°C for 30 s, annealing at 58ºC for 45 s, and 
extension at 72°C for 60 s, and with a final extension for 10 min. We used 5 µl of PCR product 
to run an electrophoresis in 2% agarose gel to check the DNA amplification. Next, we purified 
the remaining PCR product by adding an enzyme mixture of exonuclease I and alkaline 
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phosphatase (Fermentas, USA). After that, PCR fragments were directly sequenced on an ABI 
3100 capillary sequencer (Applied Biosystems, USA) with BigDye terminator mix. The primers 
used for mutational screening are as follows:  
Primer name Sequence (5’ to 3’) 
RUNX1T1_exon1_Fw TGGGTATGATACTTCAGACTGGTT 
RUNX1T1_exon1_Rv TCTGGTACGTAAGTAAATTGCAAAA 
RUNX1T1_exon2_Fw CCACTTGAAAAACTGAGGTGCT 
RUNX1T1_exon2_Rv CCCTTGATTTTTCATTTGCAG 
RUNX1T1_exon3_Fw CTTGGTGGCAATTTCCTCAT 
RUNX1T1_exon3_Rv CTGAGTCTCCCACCCACACT 
RUNX1T1_exon4_Fw TTTGTGTTTTTACTATTTACCAACAGG 
RUNX1T1_exon4_Rv AAATCAAAGAGCCCCTAAATG 
RUNX1T1_exon5_Fw CAACAGGACAGAAGAAAACTTTCAG 
RUNX1T1_exon5_Rv ATGCCACAGGTATGGGAAAA 
RUNX1T1_exon6_Fw CTGAACTGTGCTGGTTTCTGA 
RUNX1T1_exon6_Rv CCCAATCCCGTAAGAAGTGA 
RUNX1T1_exon7_Fw TTACATCGAGTTTGCCCACA 
RUNX1T1_exon7_Rv CCTCACTCCAGTTGTTTTCCA 
RUNX1T1_exon8_Fw TGTGATGATTTATATGCTCTTCCCTA 
RUNX1T1_exon8_Rv CAGCATAAGAAATATGTGTTTTCGAG 
RUNX1T1_exon9_Fw AGGAGAATGGGCATTGCTTA 
RUNX1T1_exon9_Rv ACTGCACACAGCTGCCAGA 
RUNX1T1_exon10_Fw TTCGGCTAACTGAGAGGTGTT 
RUNX1T1_exon10_Rv GCACTCTAATGAATGAAAACTATCTTG 
RUNX1T1_exon11_Fw TGCCTAACATATTTGTCAGACTATTG 
RUNX1T1_exon11_Rv TCGCGTTGGTTGTGTTGT 
51
  
 
Electrophoretic Mobility Shift Assay (EMSA) 
MKN28 and MKN45 cells were transfected with increasing amounts of RUNX1T1. 
Nuclear extracts were prepared from transfected cells, quantified, and incubated with 
previously radioactively labelled (α-32P dCTPs) nucleotides, containing an optimized C/EBPβ 
binding sequence. Protein/Labelled-DNA complexes were then run in a 15% acrylamide gel in 
non-denaturing conditions and binding affinity assessed by intensity of radioactive signal. Anti-
C/EBPβ antibody was added to the protein/labelled-DNA complex as a control, and a supershift 
was observable, confirming that it was C/EBPβ what bond to DNA. Competition with non-
labelled C/EBPβ binding sequence, confirmed the specificity of the observed signal. 
 
Bioinformatic microarray data analysis and statistical analysis 
The raw data files (.text files for murine Agilent Technologies® arrays and excel files for 
human Affymetrix GeneChips) were imported into GeneSpring GX 12.1 software (Agilent 
Technologies, USA) as two separate species-specific experiments. Pre-processing 
(background correction, normalization and probe summarization) was performed according to 
the RMA algorithm followed by baseline transformation to the median of all samples (in one 
experiment). Quality control was done by assessment of inter-array correlation analysis 
calculating the correlation coefficient of each array to every other one. The human arrays 
yielded correlation coefficients between 0.829 and 0.972, with an arithmetic mean of 0.917 and 
the murine arrays between 0.991 and 0.924 with a mean of 0.9. In the murine array experiment, 
only probes owning “detected” flags in at least 3 arrays (34,150 probes) were used for further 
analyses. Genes whose expression between groups of samples was significantly different were 
identified by Welch-test with p≤0.01 being the significance cut-off. The fold change (FC) of 
expression between groups was calculated as the fold difference between group means. Gene 
annotation information was obtained from GeneSpring GX software (state of 08/2012). For 
hierarchical clustering, ‘Euclidean distance’ and ‘complete linkage’ were used as distance 
metric and linkage algorithm. The migration of genes between the murine and human 
microarray experiment was performed using the Orthology Search Tool of bioDBnet at 
http://biodbnet.abcc.ncifcrf.gov/. 
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Optimized and applied for article “Interleukin-1B signalling leads to increased cell 
survival of gastric carcinoma cells through a CREB-C/EBPβ-associated mechanism” 
 
 
Tissue material 
Surgical specimens from 66 GCs were resected and diagnosed at Hospital 
S.João/Faculty of Medicine of University of Porto, Portugal. Tissue fragments were first fixed 
in 10% formaldehyde followed by paraffin embedding. Tumour-representative areas of each 
GC were selected to create a tissue microarray (TMA) block. Briefly, sections of 0,5 mm of 
diameter were extracted from each one of the 66 paraffin embedded GCs and inserted into a 
new paraffin block. Serial sections of 3 μm were obtained from the TMA block and used for 
routine staining with hematoxilin and eosin and immunohistochemistry. The procedures 
followed in this study were in accordance with the institutional ethical standards. All the samples 
enrolled in this study were unidentified.  
 
 
Immunohistochemistry and immunofluorescence 
Tissue sections from formalin fixed paraffin-embedded (FFPE) tissues were first 
deparaffinised, hydrated, and then treated with 1x citrate buffer (pH 6.0) (Thermo Scientific, 
CA, USA) for 45 minutes at 100°C. All the following steps were performed at room temperature 
(RT). Unspecific endogenous peroxidase activity was eliminated with 3% hydrogen peroxidase 
in methanol for 15 minutes. To reduce nonspecific background staining, slides were blocked 
with Ultra V Block (Thermo Scientific, USA) for 10 minutes. Slides were rinsed in PBS-0.1% 
Tween20 and incubated for 1h with antibody anti-CREB [E306] (Abcam, UK) diluted 1:1000, 
overnight (ON) with anti-C/EBPβ (Abcam, UK) diluted 1:1000 in UltraAB Diluent (Thermo 
Scientific, USA). Slides were then incubated with Dako Real EnVision HRP Rabbit/Mouse 
solution (Dako, DK) for 30 minutes. Slides were washed, developed for 1-3 minutes with 2% 
Dako REAL™ DAB+ Chromogen solution (Dako, DK), counterstained with haematoxylin, 
dehydrated, and mounted with mounting medium (Thermo Scientific, USA). All washing steps 
were performed in PBS-0.1% Tween20 buffer. Normal gastric mucosa was used as control, 
and negative controls were obtained by substitution of the primary antibody with 
immunoglobulins of the same class and concentration. Slides were reviewed by a pathologist, 
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and the percentage of positive cells was semi-quantitatively scored as: 0, corresponding to 
positivity in <5% of the tumour cells; 1, corresponding to positivity in >5% and <50% of the 
tumour cells; 2, corresponding to positivity in >50% and <75% of the tumour cells; and 3, 
corresponding to positivity in >75% of the tumour cells. 
For immunofluorescence, FFPE tissue from normal stomach was deparaffinised, 
hydrated, and antigen retrieval was performed with 1x citrate buffer (pH 6,0). After unspecific 
protein blocking with Ultra V Block (Thermo Scientific, USA) for 10 minutes, slides were 
incubated with rabbit antibody anti-CREB [E306] (Abcam, UK) diluted 1:1000 for 1h, followed 
by mouse antibody anti-C/EBPβ (Abcam, UK) diluted 1:1000 ON. After washing twice with 
PBS-Tween 0,021% for 10 minutes, slides were incubated with a mixture of two secondary 
antibodies raised in different species (with Texas Red-conjugated against rabbit and FITC-
conjugated against mouse) for 45 min at room temperature and protected from light. To 
counterstain cell nucleus, slides were mounted with Vectashield Mounting Medium with DAPI 
(Vector Laboratories, USA). Finally, slides were visualized and images captured (Apotome 
acquired) under a fluorescence microscope (Zeiss, DE). 
 
 
Cell culture, chemical treatments, and transfections 
AGS and GP202 cell lines were maintained in RPMI medium (GIBCO, USA), 
supplemented with 10% foetal bovine serum (FBS) (PAA, AUS), and 100 IU/mL penicillin and 
100 μg/mL streptomycin (GIBCO, USA), in a humidified incubator in an atmosphere of 5% CO2 
at 37°C. Cells were grown until 60-80% confluence in 6-well plates, and treated with 10 ng/mL 
of IL1B (Sigma-Aldrich, USA) and incubated for 24 h. 
For ERK1/2 inhibition, cells were treated with 25 μM U0126 (Cayman, USA) alone and 
together with IL1B for 24 h. As U0126 was diluted in DMSO, appropriate DMSO volume was 
added to the cells as the control condition. For CBP-CREB interaction inhibition cells were 
treated with 25 μM specific inhibitor (Merck-Millipore, DE) or vehicle DMSO (Sigma, USA) for 
24 h and 48 h. All experiments were performed in complete RPMI cell culture medium. 
For silencing experiments, AGS cells grown until 60-80% confluence in 6-well plates 
were transfected with 1.0 μg of anti-CREB shRNA expression vector or 1.0 μg scrambled 
shRNA (Origene, USA) using Lipofectamine 2000 (Invitrogen, USA), according to the 
manufacturer’s specifications. At 48 h post-transfection, cells were selected by adding 1.0 
μg/mL of puromycin (Sigma-Aldrich, USA) to culture medium. Individual puromycin-resistant 
54
  
colonies were isolated after 2 weeks of selection and expanded in the presence of puromycin 
(1.0 μg/mL). For transient silencing of CREB, AGS cells were transfected either with 100 nM of 
siRNA against CREB (Qiagen, DE) or with 100 nM of siRNA control, using Lipofectamine 2000 
(Invitrogen, USA) as a vehicle. In parallel, C/EBPβ silencing was performed by transfecting 
AGS cells with 150 nM of siRNA against CEBPB or siRNA control (Qiagen, DE). The protein 
downregulation after gene silencing was evaluated by western blotting following 72 h of culture. 
 
 
Western blotting 
Cells were washed with 1x PBS (pH7.4) and lysed in NP-40 buffer supplemented with 
phosphatase (Sigma, USA) and protease inhibitors (Roche, DE). After Bradford protein 
quantification, 40 μg of total protein were loaded into 12.5% acrylamide gels, separated by 
SDS-PAGE under denaturing conditions and electro-transferred to Hybond ECL Nitrocellulose 
Membrane (GE Healthcare, UK). After blocking, membranes were incubated for 1.5 h with 
primary antibodies anti-ERK1/2 #9102 (Cell Signaling, USA) diluted 1:1000, anti-pERK1/2 # 
9106 (Cell Signaling, USA) diluted 1:1000, anti-CREB [E306] (Abcam, UK) diluted 1:500, anti-
pCREB [E113] (Abcam, UK) diluted 1:1000, anti-C/EBPβ [H-7] (Santa Cruz Biotechnology, 
USA) diluted 1:500, anti-cyclin D1 (Santa Cruz Biotechnology, USA) diluted 1:500, and anti-α-
tubulin (Sigma-Aldrich, USA) diluted 1:10000 in PBS-0.5% Tween20 plus 5% non-fat dried milk 
or 4% BSA (bovine serum albumin). The blots were then washed with PBS-0.5% Tween20 and 
incubated with horseradish peroxidase-conjugated secondary antibodies diluted 1:10000 in 
PBS-0.5% Tween20 plus 0.5% non-fat dried milk. Chemiluminescent bands were visualized 
using Western Blot ECL (GE Healthcare, UK). 
 
 
BrdU incorporation assay 
Previously to AGS, GP202, and MKN28 cells addition to the six-well plates, three glass 
slides (10 mm x 10 mm) were positioned far apart in each well of the six-well plate. Cells were 
allowed to reach 60-80% confluence and 1x BrdU was added to culture medium for 1 h. Cells 
were then washed with 1x PBS and fixed in freshly prepared 4% (v/v) paraformaldehyde at 
room temperature for 30 minutes. The glass slides were removed from the six-well plate, 
transferred to individual wells in a 12-well plate, and washed with 1x PBS. To denature the 
DNA and permeabilize cells, hydrochloric acid (HCl) 2 M was added to each slide during 20 
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minutes following by washings with PBS-0.5% Tween 20 plus 0,05% BSA. Cells in glass slides 
were incubated for 1 h with mouse primary antibody against BrdU (Dako, DK) diluted 1:10, 
washed two times with PBS-0.5% Tween 20 plus 0.05% BSA, and incubated for 30 minutes 
with anti-mouse secondary antibody marked with Alexa Fluor 594 (Invitrogen, CA, USA) diluted 
1:100. Glass slides were rinsed in PBS-0.5% Tween 20 plus 0.05% BSA two times, mounted 
with Vectashield Mounting Medium with DAPI (Vector Laboratories, USA), and finally visualized 
under fluorescent microscopy. For each experiment, BrdU technique was performed in 
triplicates. In each assay, at least 1000 cells were counted and BrdU incorporation expressed 
as the rate between DAPI and BrdU positive cells. 
 
 
Promoter analysis and chromatin immunoprecipitation (ChIP) 
 
The nucleotide sequence of human CEBPB promoter was obtained from the UCSC 
Genome Browser (http://genome.ucsc.edu/). The putative CRE-binding sites present on 
CEBPB promoter were identified using the Genomatix MatInspector software 
(http://www.genomatix.de/solutions/genomatix-genome-analyzer.html). 
 ChIP assay was performed using a Magna ChIP G Kit (Millipore, USA), according to 
the manufacturer’s protocol instructions. Briefly, 1x107 of AGS cells were cross-linked with 1% 
formaldehyde during 10 minutes at RT, and reaction was stopped by 1x Glycine solution for 5 
minutes. Cells were rinsed with 1xPBS, lysed in order to isolate nuclei, and then sonicated in 
Nuclear Lysis to shear the chromatin to sizes of 200-500 base pairs (bp). Then, 50 μl of the 
supernatant was immunoprecipitated by adding 2 μg of rabbit antibody anti-CREB (Abcam, UK) 
or 2 μg of control rabbit polyclonal anti-IgG antibody (Abcam, UK), and the mixture was placed 
on a rotator at 4°C ON in the presence of magnetic G beads. DNA–protein cross-links were 
reversed by heating samples at 62°C for 2 h in a shaking platform. To elute DNA, a series of 
wash steps followed by elution (50 μl) were performed in spin columns. Precipitated DNA was 
analyzed by PCR using the following conditions: 95 °C for 15 min, 35 times (95 °C for 1 min, 
58º - 60ºC for 1 min, 72 °C for 1 min). The reactions were carried out with HotStarTaq DNA 
Polymerase (Qiagen, DE) as described by the manufacturer, using 2 μl of DNA template. The 
PCR products were analyzed by electrophoresis on a 2% agarose gel. PCR primer pairs 
flanking CREB-binding sites and for control region (CR) were designed using Primer 3 software. 
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Primer name Sequence (5’ to 3’) 
CEBPB_BS1_Fw AGGCTCTGTTCTAGGCACCA 
CEBPB_BS1_Rv CTCAGGTCTCAGCCCAAAAG 
CEBPB_BS2_Fw GATGAGGGCATTTCATTTGG 
CEBPB_BS2_Rv CCATGAAGGGTGTCGCTACT 
CEBPB_BS3_Fw GTCCTCCCGGGGGTCTCG 
CEBPB_BS3_Rv CTCCTGAGCCCGGTTATTTA 
Primer_Unspec_Fw GCAACCCACGTGTAACTGTC 
Primer_Unspec_Rv CCCAAAAGGCTTTGTAACCA 
 
 
RNA isolation, cDNA synthesis, and quantification of CEBPB mRNA transcript 
 
Total RNA was isolated from AGS cells grown in 6-well culture plates, using the RNeasy 
Mini Kit (Qiagen, De). RNA concentrations were measured using the Nanodrop 
Spectrophotometer ND-1000 (Thermo Scientific, USA). Reverse transcription was performed 
using SuperScript II Reverse Transcriptase KIT (Invitrogen, USA) with 1000 μg of total RNA in 
a 20 μl volume reaction, after treatment with DNaseI (Invitrogen, USA). 
To determine the relative amount of the CEBPB transcript, we performed quantitative 
target amplification, using cDNA as template, with SYBR Green PCR Kit (Qiagen, DE), 
according to the manufacturer protocol. As an internal control, we quantified the expression 
levels of Beta-actin transcript. 
 
Primer name Sequence (5’ to 3’) 
CEBPB_Fw AAGATGCGCAACCTGGAG 
CEBPB_Rv CGCGAGCTCAGCACCCTG 
Beta-actin_Fw GGCATCGTGATGGACTCCG 
Beta-actin_Rv GCTGGAAGGTGGACAGCGA 
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Analysis of In vivo tumour growth by chicken embryo in vivo tumourigenesis assay 
The chicken embryo chorioallantoic membrane (CAM) model was used to evaluate the 
growth capability of AGS cells, transfected with scrambled or shCREB RNA (n=16). Briefly, 
fertilized chick (Gallus gallus) eggs obtained from commercial sources were incubated 
horizontally at 37.8°C in a humidified atmosphere and referred to embryonic day (E). On E3 a 
square window was opened in the shell after removal of 1.5-2 ml of albumin to allow 
detachment of the developing CAM. The window was sealed with a transparent adhesive tape 
and the eggs returned to the incubator. Cells, re-suspended in 10 µl of complete medium, were 
placed on top of E10 growing CAM and 2x106 cells from each cell line (Scrambled VS shCREB) 
were placed into a 3 mm nylon ring under sterile conditions, per embryo. The eggs were re-
sealed and returned to the incubator for an additional 5 days. After removing the ring, the CAM 
was excised from the embryos, photographed ex ovo under a stereoscope, at 20x magnification 
(Olympus, SZX16 coupled with a DP71 camera). The area of CAM tumours was determined 
using the Cell A (Olympus, JP) program.  
 
Statistical analysis 
The clinicopathological features of GC cases were compared using the χ2-test. 
Independent triplicate measurements were performed for the BRDU incorporation, and 
transcript quantification by real time-PCR. When two conditions were compared, Student’s t-
test was used, whereas ANOVA was employed when the comparison involved more than two 
conditions. For tumour area comparison, the paired t-test was used. In order to accurately 
access putative differences in tumour areas between the two cell lines, only eggs bearing two 
tumours with areas ≥ 1mm2 (n=16) were considered, independently of the cell group. Values of 
p<0.05 were considered statistically significant (*); p<0.01 (**) and p<0.001 (***). 
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Article: C/EBP alpha expression is associated with homeostasis of the gastric 
epithelium and with gastric carcinogenesis 
Gonçalo Regalo, Carlos Resende, Xiaogang Wen, Bárbara Gomes, Cecília Durães, Raquel 
Seruca, Fátima Carneiro and José C Machado. Laboratory Investigation, (2010) 90, 1132–
1139 
 
 
Introduction 
Gastric carcinoma (GC) is still one of the most common cancers worldwide, despite its 
decreasing incidence in the developed countries. The continued inflammation of the gastric 
epithelium by chronic Helicobacter pylori infection is a major contributor to carcinogenesis, 
most likely by promoting disruption of the balance between proliferation and differentiation in 
the regenerating inflamed mucosa. Although this process has been well characterized 
phenotypically, the main molecular players in gastric neoplastic transformation are largely 
unknown [292].  
Proteins of the CCAAT/enhancer-binding protein (C/EBP) family are important 
transcription factors that link gene expression to proliferation/differentiation control [293]. We 
have recently shown that C/EBPβ is overexpressed in preneoplastic lesions and GC [185]. 
Most notably, C/EBPβ overexpression is associated with loss of TFF1, an established 
differentiation marker, and a putative gastric tumour suppressor [121]. 
Members of the C/EBP family are known to heterodimerize among themselves, giving 
rise to different functional transcriptional complexes. Moreover, they often act with a high 
degree of coordination [208]. This is well demonstrated in adipogenesis, where sequential 
expression of different C/EBP members underlies the process of differentiation from 
preadipocytes to fully mature adipocytes [294]. After the differentiation stimulus is given, 
C/EBPβ is expressed in immature preadipocytes and primes cells to differentiate by inducing 
C/EBPα expression [295]. Once active, C/EBPα drastically reduces cell proliferation, and 
promotes the expression of peroxisome proliferator-activated receptor γ (PPARγ) [296]. In this 
and other models, C/EBPα is a crucial effector of lineage commitment and terminal 
differentiation programs. The disruption of these programs has been shown to be oncogenic in 
several cellular contexts. For instance, C/EBPα is a consensual tumour suppressor in acute 
myeloid leukemia (AML) where deleterious mutations have been described in a proportion of 
cases [244]. C/EBPα may also have a role in other cancer models [297] such as lung cancer, 
where it was found downregulated by methylation [250]. However, the expression pattern and 
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functional relevance of C/EBPα in normal stomach and in GC has never been described. In 
this study, we characterized the expression of C/EBPα in the normal gastric mucosa and in 
GC. Furthermore, we investigated the effects of expressing C/EBPα in GC cells, and aimed at 
clarifying the link between pathways of C/EBPα modulation and gastric carcinogenesis. 
 
 
 
Results  
Immunohistochemical analysis of C/EBPα expression 
In the normal mucosa of the stomach, C/EBPα staining was mostly nuclear with some 
residual cytoplasmic positivity and mostly localized in the mucous surface epithelium (Figure 
1a). This expression pattern contrasts with that of C/EBPβ whose expression is concentrated 
to the neck zone (Figure 1b). This expression pattern was confirmed using 
immunofluorescence, where C/EBPα staining was again stronger in the foveolar and surface 
epithelium, with fewer positive cells observed in the neck zone (Figure 1c). As described earlier, 
infiltrating inflammatory cells were also found to express C/EBPα. To confirm that C/EBPα 
expression does correlate with the differentiation status of the gastric epithelium, we performed 
double staining with TFF1, a well-established gastric differentiation marker. A clear overlap was 
observed between TFF1 and C/EBPα in the surface epithelium (Figure 1d). 
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Figure 1. C/EBPs expression in normal gastric mucosa. (a) C/EBPα immunostaining in non-neoplastic mucosa, 
showing strong expression in the superficial epithelium. (b) C/EBPβ expression in normal gastric mucosa of the 
antrum, showing strong localization in the neck zone. (c) C/EBPα immunofluorescence, showing expression in 
differentiated gastric foveolae, and few positive cells toward the neck zone. (d) C/EBPα (brown) and TFF1 (red) 
double staining, showing co-expression of the two proteins in gastric foveolae. 
 
 
Similarly to what was observed in the normal gastric mucosa, in GC C/EBPα staining was 
mostly nuclear with some residual cytoplasmic positivity (Figure 2a). In GC, C/EBPα was 
considered downregulated in 30% of the tumours (Figures 2b–d). No statistical significant 
relationships were found between C/EBPα expression and any clinicopathological features of 
the cases (Table 1). 
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Figure 2. C/EBPα staining in intestinal-type GC. (a) C/EBP positive tumour. (b) Tumour showing complete loss of 
C/EBPα expression. (c) GC displaying downregulation of C/EBPα expression (positive cells to the right are located 
in non-neoplastic gastric epithelium). (d) GC negative for C/EBPα expression. 
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Table 1. Relationship between the clinicopathological features of GC and C/EBPα expression scoring 
 
NS: non-significant. Cases are classified according to the intensity and percentage of positive cells. 
Cases classified as downregulated present >50% of tumour cells classified as I. 
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Effect of C/EBPα expression on cell proliferation and differentiation 
To assess the effect of C/EBPα on the proliferation status of GC cells, we transfected 
the C/EBPα-negative GC cell line AGS with an expression vector for the full-length CEBPA 
gene and measured the incorporation of BRDU after 48 h. We observed that re-expression of 
C/EBPα on AGS cells led to a 15% reduction (P = 0.001) in cell proliferation in comparison with 
the control (Figure 3a). Conversely, inhibition of C/EBPα by siRNA in the MKN28 cell line led 
to an increase (P < 0.001) in cell proliferation in comparison with the control (Figure 3b). 
 
 
Figure 3. BrdU incorporation assay in GC cells. (a) Decreased proliferation rates of C/EBPα -transfected AGS cells 
in comparison with the control (P = 0.001). (b) C/EBPα inhibition by siRNA leads to increased BRDU incorporation 
in MKN28 cells. In all, 1000 cells were counted and BrdU incorporation expressed as the rate between DAPI and 
BrdU positive cells. The y axis represents the % of BrdU positive cells. Error bars represent s.d. Tubulin was used 
as protein-loading control. 
 
 
To confirm this inhibitory effect of C/EBPα on proliferation, we analysed by western 
blotting the expression of two cell-cycle proteins typically associated with the control of gastric 
epithelial cell division. We observed decreased expression of cyclin D1, a cell-cycle inducer, 
and increased expression of p27, a cyclin-dependent kinase inhibitor (Figures 4a and c). Both 
these changes are consistent with an inhibitory effect on proliferation. The results on the effect 
of C/EBPα on proliferation, together with its expression pattern in the normal gastric mucosa, 
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suggested C/EBPα to have a role on proliferation arrest and on the differentiation of gastric 
epithelial cells. That being the case, increased expression of TFF1 would be expected in the 
presence of higher levels of C/EBPα. In accordance with this hypothesis, after transfection of 
AGS cells with the C/EBPα expression vector, we observed an increase in the expression of 
TFF1 (Figures 4b and c). 
 
 
 
Figure 4. Effect of C/EBPα expression on AGS cells. (a) Western blot for cell-cycle proteins, showing increased p27 
and decreased cyclin D1 expression after transfection with C/EBPα. (b) Dot blot showing increased TFF1 expression 
in C/EBPα-transfected cells. (c) Expression of C/EBPα, cyclin D1, p27, and TFF1 shown as ratios to loading controls. 
Error bars represent s.d. *represents statistically significant differences between mock- and C/EBPα-transfected 
cells (P < 0.05). 
 
 
Effect of MAPK inhibitors on the expression of C/EBPα and cell proliferation 
The Ras/MAPK signalling pathway is one of the most consistently altered in human 
cancers. In GC, the Ras/MAPK pathway is constitutively activated through mutation of several 
of its receptors and signal-transducing members [84]. To explore the possibility of C/EBPα 
regulation by the Ras/MAPK pathway in GC, we treated MKN28 cells, which express C/EBPα, 
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with specific p38 (SB239063) and ERK1/2 (PD98059) inhibitors. Treatment with inhibitors led 
to a marked increase in C/EBPα expression and nuclear localization as detected by 
immunocytochemistry (Figure 5). 
 
 
Figure 5. Treatment of MKN28 cells with p38 (SB) and ERK1/2 (PD) inhibitors leads to an increase in C/EBPα 
expression with nuclear localization. C/EBPα is stained green with FITC and nuclei are stained blue with DAPI for 
contrast. 
 
 
This increase in C/EBPα expression was further confirmed by western blotting, and shown to 
be accompanied by an increase in TFF1 expression (Figures 6a and c). Concomitantly, we 
observed a decrease in cell proliferation by BrdU incorporation (Figure 6b) in cells treated with 
p38 inhibitor (P = 0.009) and in cells treated with ERK1/2 inhibitor (P = 0.003). This decrease 
in proliferation was accompanied by a decrease in Cyclin D1 expression (Figure 6c). 
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Figure 6. Effects of the treatment of MKN28 cells with a p38 (SB) and an ERK1/2 (PD) inhibitor in cellular 
proliferation and differentiation. (a) Western blot showing that treatment of MKN28 cells with SB and PD leads to an 
increase in C/EBPα and TFF1 expression and to a decrease in cyclin D1 levels. (b) Decrease of cell proliferation by 
BrdU incorporation assay of MKN28 cells treated with SB (P = 0.009) and PD (P = 0.003) inhibitors. (c) Expression 
of C/EBPα, cyclin D1, and TFF1 shown as ratios to loading controls. Error bars represent s.d. *represents statistically 
significant differences between treated and non-treated cells (P < 0.05). 
 
 
Discussion 
 
We have shown that C/EBPα is expressed in the differentiated epithelial compartment 
of the superficial gastric mucosa. This expression pattern mirrors that described for C/EBPβ, 
which is expressed in the proliferative neck zone of the normal gastric mucosa. We have 
previously argued that C/EBPβ may have a role in maintaining a balance between proliferation 
and differentiation in the normal gastric mucosa [185]. In the proposed model, C/EBPβ would 
have a pro-proliferative activity in gastric epithelial stem-like cells. The presence of C/EBPα in 
differentiated cells, together with its ability to reduce cell proliferation and to up-regulate the 
gastric differentiation marker TFF1, suggest that C/EBPβ and C/EBPα may have 
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complementary roles in maintaining a balance between proliferation and differentiation in the 
normal gastric mucosa. By analogy to the model of adipogenesis, one feels tempted to 
speculate that C/EBPβ is expressed in gastric epithelial stem-like cells and may prime gastric 
epithelial cells to differentiate by inducing C/EBPα expression. Once active, C/EBPα would 
reduce cell proliferation, and promote the expression of gastric differentiation markers such as 
TFF1. C/EBPα was first described as a tumour suppressor gene in AML. In normal 
hematopoiesis, C/EBPα is essential to define cell lineages through interaction with other 
transcription factors. C/EBPα disruption by mutation leaves bone marrow cells in an 
undifferentiated, hyper-proliferative state being this event causal for a percentage of leukemias 
[298]. Downregulation of C/EBPα was additionally found in several epithelial tumour types, 
namely lung, breast, and skin cancers [250, 251, 299, 300]. In all these examples, a role for 
impaired C/EBPα function in tumourigenesis was strengthened by the observation that C/EBPα 
re-expression is able to inhibit tumourigenesis in vivo and in vitro [251, 300]. In our study, we 
observed downregulation of C/EBPα in about 30% of GC cases. In an earlier study, we have 
described a frameshift mutation of C/EBPα in a GC. This mutation was deleterious and absent 
from adjacent non-neoplastic tissue [248]. These results in the GC model are in keeping with 
the before described role of C/EBPα in tumourigenesis, whereby loss of C/EBPα would be 
associated to loss of differentiation and sustained proliferation of tumour cells. On top of 
C/EBPα loss of expression, we have shown earlier that C/EBPβ is overexpressed in cells 
retaining a proliferative phenotype such as those seen in dysplastic and cancer lesions. 
C/EBPβ is able to counteract, either by heterodimerization or repression of expression, the 
differentiating activity of C/EBPα. Altogether, either aberrant overexpression of C/EBPβ or loss 
of expression of C/EBPα are present in the majority of GC cases. Hence, these results suggest 
that changes in expression/function of C/EBPα and C/EBPβ may be pieces of the same puzzle 
rather than independent events in gastric carcinogenesis. This possibility, together with other 
putative mechanisms of post-translational or protein–protein interaction, would help explaining 
why expression of C/EBPα is still seen in about 70% of GC cases. In other cancer models, loss 
of C/EBPα has been linked with oncogenic Ras activation. In GC, activating RAS mutations do 
occur in a subset of microsatellite unstable (MSI) tumours. By using specific inhibitors for p38 
and ERK1/2, downstream effectors of Ras signalling, we were able to show that inhibition of 
C/EBPα expression was dependent on the activation of this pathway. Moreover, inhibition of 
p38 and ERK1/2 increased TFF1 expression and strongly reduced MKN28 cell proliferation 
and cyclin D1 levels, in a set of alterations most likely linked with the observed increase in 
C/EBPα expression. 
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In summary, we show that in normal gastric mucosa, C/EBPα is expressed mainly in the 
differentiated foveolar epithelium where it co-localizes with TFF1. We show that C/EBPα is 
downregulated in a considerable percentage of GC. We additionally show that C/EBPα re-
expression in a C/EBPα -negative cell line leads to a reduction in proliferation that is 
accompanied by an increase in p27 and reduction of cyclin D1 levels. In parallel, we show an 
increase in the expression of TFF1 in C/EBPα -transfected cells. Finally, we show that 
treatment of a C/EBPα expressing cell line with MAPK inhibitors leads to increased C/EBPα 
and TFF1 expression, and a concomitant reduction on cell proliferation and cyclin D1 
expression. Overall, these results substantiate the role of the C/EBP transcription factor family 
in homeostasis of the gastric epithelium and in the process of gastric carcinogenesis. 
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Article: C/EBPβ/RUNX1t1 regulatory loop controls cell proliferation in gastric cancer. 
 
Goncalo Regalo, Susann Förster, Carlos Resende, Bianca Bauer, Barbara Fleige, Wolfgang 
Kemmner, Peter M Schlag, Kosei Ito, Suk-Chul Bae, Thomas F. Meyer, Yoshiaki Ito, José C 
Machado, Achim Leutz (Submitted to JCI)  
 
 
Introduction 
The transcription factor C/EBPβ has been suggested to play a pro-oncogenic role in 
cancer, leukemia, and lymphoma through shielding from apoptosis and promotion of cell 
proliferation in conjunction with cyclin D1 [229, 233, 255, 293, 301-306]. In intestinal type gastric 
cancer (GC), C/EBPβ is highly expressed and associated with enhanced cyclooxygenase-2 
(COX2) expression and loss of the mucous-associated protein TFF1 [185, 263] [75, 307, 308]. 
Mice that overexpress COX2 or are deficient for TFF1 develop gastric tumours, underscoring 
the importance of these proteins and a potential involvement of C/EBPβ in gastric 
carcinogenesis [77, 309]. 
Diffuse type GC is associated with loss of the adhesion protein E-Cadherin, however, 
despite the predominance and histological coherence of the intestinal type of GC, characterized 
by expansive growth and maintenance of a glandular structure, no central common molecular 
pathway has been convincingly shown as aberrantly regulated [53, 310]. Here, we examined 
the homeostatic functions of C/EBPβ in the murine stomach. Our results show that C/EBPβ 
controls the balance between proliferation and differentiation in the murine stomach. Cross-
species analysis of gene expression between mouse C/EBPβ KO stomachs and human GC 
led to the identification of a subgroup of intestinal-type tumours that showed a strong C/EBPβ-
regulation signature. Within this signature, RUNX1t1 was identified as a potential tumour 
suppressor. It interacts with C/EBPβ and causes release from DNA, counteracting the pro-
proliferative properties of C/EBPβ. The RUNX1t1 promoter was also hypermethylated in a large 
fraction of human GC cases and ectopic expression of RUNX1t1 reduced proliferation in GC 
cell lines. Our data suggest C/EBPβ activation and RUNX1t1 silencing as important events in 
the gastric carcinogenesis process.  
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Results 
C/EBPβ knockdown reduces the tumorigenic potential of gastric cancer cells 
Enhanced C/EBPβ expression mainly in the human intestinal type GC subtype has been 
recently reported [185, 263] and was confirmed by real-time PCR, as shown in Figure 1A. The 
functional importance of high C/EBPβ expression in GC was examined by stable knockdown 
in human GC cell lines using a viral-based GFP-tagged short hairpin RNA. C/EBPβ-isoform 
knockdown efficiency in two cell lines approximated 70%, as confirmed by protein 
immunoblotting (Figure 1B). Proliferation of a cell line derived from intestinal-type GC (MKN74) 
and a cell line derived from diffuse GC (MKN45) were examined by BrdU incorporation and, as 
shown in Figure 1C, proliferation of both cell lines was reduced after C/EBPβ knockdown. The 
tumorigenic potential of cell lines, before and after C/EBPβ knockdown, was compared by 
xenotransplantation in immune-compromised mice, as shown in Figure 1D. Equal numbers of 
freshly sorted control and knockdown MKN74 or MKN45 cells were injected. Twenty days post-
injection, C/EBPβ knockdown cells formed markedly smaller tumours than parental cells, with 
less weight and volume (Figure 1D). The difference was more pronounced in MKN74 intestinal 
type-derived tumours than in the diffuse MKN45 cell line. Ki67 staining showed reduction of cell 
proliferation in tumours originating from C/EBPβ knockdown cells in comparison to controls 
(Figure 1C). Interestingly, proliferation in tumours was accompanied by re-expression of 
C/EBPβ and, in tissue culture knockdown cells required frequent sorting to prevent overgrowth 
of cells that regained C/EBPβ expression, suggesting selection for C/EBPβ expression. These 
results show that C/EBPβ plays an important role in GC cell proliferation.  
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Figure 1. C/EBPβ controls gastric cancer cell proliferation. A) RNA expression of C/EBPβ in intestinal and diffuse 
gastric cancer cases as determined by real-time PCR. Tumour versus normal ratios were established for each case. 
Values above 1 entail up-regulation, whereas expression below 1 refers to downregulation (p value refers to normal 
vs Intestinal comparison). B) Stable knockdown of C/EBPβ in gastric cell lines evaluated by protein blotting (left 
panel MKN28, right panel MKN45). C) Cell proliferation was determined by BrdU analysis. Cells were labelled with 
BrdU and incorporation was determined by flow cytometry (FACS) and plotted against 7- AAD-positive cells, as a 
measure of DNA content. FACS plots show a reduced percentage of BrdU incorporation in gastric cells with C/EBPβ 
KO. S-phase percentages are highlighted in the FACS plots. D) Gastric cell lines with stable C/EBPβ KO were 
injected into nude mice and tumour volume and weight was assessed at different time points. Tumours originated 
from C/EBPβ KO cells were smaller than tumours in the controls. E) Ki67 staining revealed reduction of proliferation 
in the KO-derived tumours.  
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C/EBPβ knockout mice display imbalanced differentiation/proliferation of the gastric 
mucosa 
Histological analysis of C/EBPβ expression in the murine stomach revealed restriction 
to the proliferative zone and overlap with Ki67 staining (Figure 2A), concordantly to 
observations in human stomach tissue [185]. Analysis of nullizygous C/EBPβ (C/EBPβ-/-) 
stomachs revealed a significant reduction in the thickness of the gastric epithelium and 
diminished numbers of Ki67-positive cells, as compared to the wild type (WT), particularly in 
the posterior antral section of the stomach, although no histological abnormalities were 
observed (Figure 2B and 2C).  
To gain further insight into the causes of reduced mucosa thickness, expression of cell 
cycle-related genes and apoptosis rates were examined. As shown in Figure 2C, reduction of 
Ki67 and of proliferating cell nuclear antigen (PCNA) in the KO mucosa was evident by 
quantitative PCR (qPCR) in accordance to histological observations. Additionally, reduced 
expression of Cyclin A1, Cyclin D3 and Cyclin E1, and increased expression of the CDK 
inhibitor p15 was found. Apoptosis rate of the C/EBPβ KO mucosa, as revealed by TUNEL 
assay, showed enhanced cell death in C/EBPβ KO mice compared to WT (supplementary 
Figure 1A) and qPCR expression analysis showed decreased expression of BCL2 and BIRC5 
(survivin) (supplementary figure 1B). 
C/EBPβ has previously been reported to repress the gastric differentiation marker and 
tumour suppressor TFF1 [121, 263]. Similarly to human gastric mucosa, expression of TFF1 
was excluded from proliferating cells of the neck zone in murine WT gastric epithelium and 
expression of C/EBPβ and TFF1 were mutually exclusive (Figure 2D, upper panel). qPCR 
confirmed increased expression of TFF1 in C/EBPβ KO mucosa, similar to the differentiation 
genes MUC6 and MUC5AC (Figure 2D, lower panel). Taken together, these data confirmed a 
repressive role of C/EBPβ on gastric differentiation genes in proliferating cells [329, 359] and 
regulation of apoptosis in the normal gastric mucosa.  
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Figure 2. Analysis of the gastric phenotype of the C/EBPβ knockout (KO) mouse. A) Immunohistochemical analysis 
shows overlap of nuclear C/EBPβ expression and Ki67 expression in the proliferative zone in normal mouse mucosa. 
B) HE staining of a longitudinal section of wild type (WT) and C/EBPβ KO mucosa, showing reduction of the 
thickness of the antral KO gastric mucosa. C) Quantification of the C/EBPβ KO mice and WT antral gastric mucosa 
thickness (in arbitrary units). Adjacent immunohistochemical panel depicts the reduction of Ki67-positive cells in the 
C/EBPβ KO mucosa. Lower panels show qPCR evaluation of Ki67, PCNA, Cyclin A1, D3, E1 and p15 in the gastric 
mucosa of WT and C/EBPβ KO mouse stomach (5 animals/group, 3 months old). Values are presented as fold of 
WT expression, and asterisks refer to p-value of 0.05 or inferior. D) Mutually exclusive expression of TFF1 and 
C/EBPβ in the normal human (upper panel) and mouse (lower panel) stomach epithelium; C/EBPβ is expressed in 
proliferative cells of the neck zone and TFF1 in differentiated mucous epithelium. Increased expression of mRNA of 
differentiation proteins TFF1, MUC5AC, and MUC6 in the C/EBPβ KO mouse gastric mucosa as measured by 
qPCR. 
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Supplementary figure 1 Apoptosis analysis of the C/EBPβ KO mouse. A) TUNEL assay showing increased number 
of apoptotic TUNEL positive cells (upper panels FITC positive) in the C/EBPβ KO mucosa when compared to the 
WT stomach. Upper graph shows quantification (p<0.05). B) qPCR analysis of RNA levels shows reduced levels of 
anti-apoptotic proteins BCL2 and BIRC5/survivin in the gastric mucosa of the C/EBPβ KO mice. 
 
 
Cross-species gene expression profiling reveals a subset of intestinal-type gastric 
tumours with a C/EBPβ-regulation signature 
The similarities between human and murine gastric C/EBPβ biology raised the question 
to what extent the homeostatic and oncogenic C/EBPβ-dependent proliferation share common 
molecular mechanisms. We therefore compared gene expression profiles derived from C/EBPβ 
KO mice with previously analysed human GC samples [289]. 
Differentially expressed genes between the C/EBPβ KO (n=5) and WT (n=4) mice were 
identified by Welch-test. Significance in differential expression was accepted at p≤0.01 and a 
meaningful difference in expression at fold change (FC) larger than 1.5. These cut-off criteria 
yielded 171 unique annotated and 25 unique non-annotated transcripts (233 probes) as up-
regulated in the C/EBPβ KO and 79 unique annotated transcripts and 12 unique non-annotated 
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ones (135 probes) as downregulated (supplementary Table 1 and 2 show the 15 most 
significantly regulated genes).  
 
 
Supplemental table 1. List of the 15 genes with higher up-regulation score in the C/EBPβ KO stomach. 
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Supplemental Table 2. List of the 15 genes with higher downregulation score in the C/EBPβ KO mucosa 
 
 
Next, the combined list of up- and downregulated genes (FC>1.5, p≤0.01) derived from 
the C/EBPβ KO mouse profiling data was used to cluster the human GC microarray samples. 
The resulting gene expression heatmap suggested that the majority of genes did not show any 
overt deregulation in human cancers (whitish spots in heatmap). However, a group of genes 
showed explicitly strong regulation (indicated by dark bluish and reddish spots in the heatmap) 
across the cancer samples (Supplementary Figure 2, regulated gene cluster, indicated by box). 
Genes contained in this subset were then used to re-cluster the human cancer samples. The 
resultant cancer sample dendrogram and expression heatmap (Figure 3) revealed a group of 
cancer samples (Figure 3, black box) that exhibit downregulation of the majority of these genes. 
The group consisted of 16 of the original 59 (≈27%) samples and contained primarily cancers 
of the intestinal histological type. Importantly, genes downregulated in this particular cancer 
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subgroup are mostly up-regulated in the C/EBPβ KO gastric mucosa (changes ranging from 
1.5 to 2.3 fold; Table 1) identifying them as C/EBPβ repressed genes. 
 
 
Table 1. Genes from the C/EBPβ clustered intestinal type genes, showing their regulation in the glandular tumours 
and C/EBPβ KO stomachs. The genes downregulated in intestinal type tumours are exclusively up regulated in 
C/EBPβ KO. 
 
 
 To validate the results obtained by microarray comparison, we selected three C/EBPβ 
repressed genes, FOG2, SPARCL1, and RUNX1t1, and analysed their expression by qPCR. 
Examination of the expression of these genes in WT and C/EBPβ KO stomach confirmed up-
regulation in the gastric mucosa of C/EBPβ KO mice (5 animals/group; supplementary figure 
3B). It was also important to examine the expression of FOG2, SPARCL1, and RUNX1t1 in 
normal human gastric mucosa as no normal tissue samples were available for the initial human 
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GC microarray analysis [289]. As shown in supplementary Figure 3A, expression of all three 
genes was downregulated in intestinal type GC, however, a subset of diffuse type tumours 
overexpressed RUNX1t1, compliant with the different aetiology of these tumours. 
 
 
Supplementary figure 2. Heat map originated by the comparison of mouse microarray data displaying differences 
between C/EBPβ KO and WT mouse stomach, and a set of human gastric cancer samples. The majority of murine 
genes were not regulated in human gastric cancer (whitish spots in the map). However, one cluster of genes showed 
explicitly strong regulation (highlighted). The members of this strongly regulated gene cluster showed 
downregulation in the intestinal tumours compared to the diffuse-type ones with differences ranging between 1.8 
and 6.2 with and overall classification correctness for histological type of 78%. 
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Figure 3. Cross-species comparison of gene expression. Two-way hierarchical clustering was performed using a 
strongly-regulated gene cluster (shown in Supplementary Figure 2) from microarray-derived murine genes that 
differed between C/EBPβ KO and WT stomach (p≤0.01, FC≥1.5) and human gastric cancer samples. Depicted are 
the resultant gene and sample dendrograms and the corresponding expression intensity heat map. The black box 
indicates a tumour cluster in which most of the genes show downregulation (bluish spots). This tumour group 
consisted of 16 of the original 59 (≈27%) samples and contained primarily cancers of the intestinal histological type. 
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Supplemental Figure 3. Confirmation of the microarray expression analysis results. A) RNA expression analysis of 
FOG2, SPARCL1 and RUNX1t1 in intestinal and diffuse gastric cancer cases as determined by real-time PCR. 
Tumour vs. normal ratios were established for each case. Values above 1 entail up-regulation, whereas expression 
bellow 1 refers to downregulation. Visible is the decreased expression of the gene set in intestinal type gastric cancer 
cases in comparison to normal. Significance displayed in graphic refers to Normal Vs Intestinal-type comparison. B) 
Expression evaluation of FOG2, SPARCL1 and RUNX1t1 expression in wild-type (WT) and C/EBPβ KO stomach 
(5 animals/group) by qPCR, showing upregulation in the C/EBPβ KO. 
 
 
C/EBPβ expression is mandatory for the hyperplastic phenotype in the RUNX3 KO mice 
stomach  
The RUNX3 KO mouse is an established model of early GC initiation and hyper-
proliferation [90], although the mechanism underlying the RUNX3-deficient neoplastic 
phenotype remains under debate [311, 312]. As shown in Figure 4A, Ki67 staining confirmed 
increased proliferation of the epithelial stomach layer of new-born RUNX3-null mice and E-
Cadherin staining confirmed the epithelial nature of the proliferating cells. C/EBPβ is highly 
expressed in the hyper-proliferative gastric mucosa of RUNX3 KO mice and staining of serial 
sections showed co-localization of C/EBPβ and Ki67 in the proliferative mucosa of the RUNX3 
KO (Figure 4A). 
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C/EBPβ null animals were crossed with RUNX3 KO mice to evaluate the functional 
contribution of C/EBPβ in the neoplastic RUNX3 KO stomach tissue. Analysis of the stomach 
tissue of single RUNX3 KO and the compound C/EBPβ/RUNX3 KO showed that stomach wall 
thickness was reduced to WT levels in double KO animals. Ki67 staining confirmed an almost 
complete reversion of the hyper-proliferative phenotype in RUNX3 KO by removal of C/EBPβ 
(Figure 4A and 4B) that was accompanied by a substantial increase in the number of apoptotic 
cells (supplementary Figure 4A and 4B). We conclude that expression of C/EBPβ is mandatory 
for the neoplastic gastric phenotype of RUNX3 deficient mice. 
To understand to what extent the role of C/EBPβ in the RUNX3 KO gastric phenotype 
reflects the gene regulation identified in the microarray analysis, we compared FOG2, 
SPARCL1, and RUNX1t1 in RUNX3 KO and in the compound C/EBPβ/RUNX3 KO. In the 
hyper-proliferative RUNX3 KO mucosa only RUNX1t1 displayed reduced expression, whereas 
FOG2 and SPARCL1 remained within the range of WT mucosa. Importantly, RUNX1t1 
expression was partially rescued in the compound KOs, as shown in Figure 4C. These data 
suggested opposing functions and regulation of RUNX1t1 and C/EBPβ in proliferation control. 
Indeed, transfecting C/EBPβ isoforms (LAP*, LAP and LIP) into MKN28 and MKN45 cell lines 
led to the repression of RUNX1t1 expression (Figure 4D). 
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Figure 4. C/EBPβ in the RUNX3 knockout (KO) mouse. A) Immuno-staining shows increased C/EBPβ and Ki67 
expression in the RUNX3 KO mouse stomach and reversion in the C/EBPβ/RUNX3 double KO. E-cadherin staining 
shows that hyper-proliferation is confined to the epithelial compartment. B) Quantification of the mucosal thickness 
and Ki67 expression (p<0.05) in the wild type (WT) and RUNX3 KO and reversal of the mucosal thickness and 
hyper-proliferative phenotype in the compound C/EBPβ/RUNX3 double KO. C) qPCR analysis of RUNX1t1, FOG2, 
and SPARCL1 in RUNX3 KO and C/EBPβ/RUNX3 KO stomachs shows that only RUNX1t1 is downregulated in the 
hyper-proliferative mucosa of the RUNX3 KO (p<0.005) and reverted to almost WT levels in the compound 
C/EBPβ/RUNX3 KO stomach. D) Transfection of C/EBPβ isoforms LAP*, LAP, and LIP into gastric cell lines MKN28 
and MKN45 repressed RUNX1t1 expression as measured by quantitative PCR. 
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Supplemental figure 4. A) Apoptosis in the gastric mucosa of the single KO and compound C/EBPβ/Runx3 double 
KO was analyzed by TUNEL assay, being observable an increase in the cell death rate in the compound 
C/EBPβ/Runx3 KO when compared with the other mutants. B) shows quantification of TUNEL-positive cells 
(p<0.05). 
 
 
 
RUNX1t1 plays a tumour suppressive role in human gastric cancer and modulates 
C/EBPβ activity 
Expression of RUNX1t1 protein was evaluated by tissue microarray 
immunohistochemistry on 64 human GC samples. Nuclear staining was classified as strong, 
moderate, weak or absent, referencing to the expression of RUNX1t1 in the normal mucosa 
(classified as moderate). From the analysed tumours, 25 out of 64 (38%) showed weak or 
absent RUNX1t1 protein staining (Figure 5A). To further assess whether C/EBPβ is responsible 
for downregulation of RUNX1t1 in GC, we selected tumour-RNAs showing reduced levels of 
RUNX1t1 (supplementary Figure 3A). The majority of cases (7 out of 10, Figure 5B), however, 
failed to show a convincing inverse correlation between low RUNX1t1 and high C/EBPβ 
expression, suggesting alternative means of RUNX1t1 downregulation in GC. Sequencing of 
RUNX1t1 from 26 GC patients failed to disclose mutations that would explain loss of RUNX1t1 
protein (data not shown), however, analysis of the RUNX1t1 promoter by methylation-specific 
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PCR revealed hypermethylation in 10 out of 20 GC DNA samples (Figure 5C). Next, we 
examined the functional consequences of RUNX1t1 downregulation in GC cells. As shown in 
Figure 5D, overexpression of RUNX1t1 in MKN28 and MKN45 cell lines led to decreased cell 
proliferation, as determined by BrdU incorporation. These data suggest that RUNX1t1 inhibits 
proliferation and is frequently downregulated in GC. 
RUNX1t1 has previously been reported to interact with C/EBPβ, to inhibit its DNA 
binding, and to block its pro-proliferative functions during the clonal expansion phase in 
adipogenic differentiation [313]. Ectopic expression of flag-tagged RUNX1t1 in MKN28 and 
MKN45 cell lines and subsequent immunoprecipitation showed that RUNX1t1 interacts with all 
endogenous C/EBPβ isoforms in cell lines (Figure 5E). Electrophoretic mobility shift assay 
(EMSA) led to a dose dependent decrease of C/EBPβ binding to its DNA consensus sequence 
in  cell lines, although RUNX1t1 did not significantly alter nuclear C/EBPβ expression (Figure 
5F). These results suggest that the tumour-suppressive function of RUNX1t1 is mechanistically 
connected to the suppression of pro-oncogenic C/EBPβ functions. 
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Figure 5. RUNX1t1 and gastric cancer. A) RUNX1t1 expression was evaluated by immunohistochemistry in 64 
human gastric cancer samples, and staining was classified by comparison to the expression in the normal mucosa 
(left panel). 38% of the cases showed reduced expression of RUNX1t1 (right panel). B) In 10 gastric tumours with 
reduced RUNX1t1 RNA levels were examined for C/EBPβ expression by qPCR. Only 3 out of 10 cases showed 
higher C/EBPβ expression as compared to WT. C) The methylation status of the RUNX1t1 promoter was evaluated 
by methylation-specific PCR. Bisulfite treatment of tumour DNA converts unmethylated but not methylated cytosines 
to uracil, and subsequent methylation-specific PCR detects either methylated (M) or unmethylated (U) DNA. 50% of 
the analysed human gastric cancer cases (rows a-b, columns 1-5) present RUNX1t1 promoter hypermethylation. D) 
Ectopic expression of RUNX1t1 in MKN28 and MKN45 gastric cancer cell lines reduces gastric cancer cell 
proliferation as measured by BrdU incorporation assay. S-phase percentages are indicated in the FACS plots. E) 
Immunoprecipitation of flag-tagged RUNX1t1 co-precipitates C/EBPβ. Visible in the input Western Blot is also that 
RUNX1t1 does not affect C/EBPβ expression. F) Electrophoretic mobility shift assay (EMSA) using a radiolabeled 
C/EBPβ DNA probe and nuclear extracts from MKN28 and MKN45 cells. Transfection of RUNX1t1 reduces the 
binding of C/EBPβ to DNA in cell lines in a dose dependent manner. Arrow indicates the super-shift. 
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Discussion 
GC is one of the leading causes of cancer-related death in the developing world [314] 
and our data suggest a function of C/EBPβ particularly in the intestinal type of GC. Comparison 
of gene expression profiles from C/EBPβ KO mice and human GC samples provided insight in 
C/EBPβ-related molecular mechanisms. Absence of C/EBPβ from the murine stomach shifts 
the balance from epithelial proliferation towards differentiation and apoptosis. 
Data presented here suggest that the function of C/EBPβ in GC is embedded in the 
homeostatic regulation of the gastric mucosa. Deregulation of pathways that sustain C/EBPβ 
functions such as inflammatory signals may favour uncontrolled proliferation and repression of 
differentiation genes such as TFF1 that ultimately unbalances the physiological homeostasis 
of the gastric epithelium and promotes tumour development [77]. 
C/EBPβ is mandatory for the hyper-proliferative phenotype of the RUNX3 KO mice and 
for the tumorigenic potential of GC cell lines. Expression profiling data of human GC samples 
and comparison with C/EBPβ KO mouse-derived expression data identified a subset of 
tumours owning a C/EBPβ-regulated signature. These tumours mostly belong to the intestinal 
type and may define a novel subtype. One of the genes characterizing this tumour cluster, 
RUNX1t1, has previously been connected to gastrointestinal abnormalities [315] and to 
suppression of C/EBPβ functions [313] and was consistently downregulated in the murine 
RUNX3 KO tumour model. RUNX1t1 is also a candidate tumour suppressor in ovarian cancer 
[291] and loss of RUNX1t1 expression has been associated with metastasis in pancreatic 
cancer [316]. Downregulation of RUNX1t1 during homeostasis and initially in intestinal type GC 
may occur through C/EBPβ. However, analysis of DNA methylation showed that the RUNX1t1 
promoter was frequently methylated in human GC samples. RUNX1t1 promoter 
hypermethylation has also been observed in ovarian cancer [291] and suggests alternative 
routes of RUNX1t1 gene silencing in gastric carcinogenesis. 
RUNX1t1, also known as MTG8 or ETO, is the recurrent t(8;21) translocation partner of 
the AML-ETO (RUNX1/MTG8) fusion protein. AML-ETO accounts for 15% of acute myeloid 
leukemia and 40% of M2-type leukemia, probably by interference with the differentiation 
inducing functions of C/EBPα and PU.1 [317, 318]. Few reports have focused on RUNX1t1 
independently of the AML-ETO context, yet suggest involvement of RUNX1t1 in several co-
repressor complexes [318]. Our results support the notion of RUNX1t1 as a suppressor of GC 
development and suggest a regulatory loop between C/EBPβ and RUNX1t1 in homeostasis 
and disruption in cancer. High expression of C/EBPβ leads to reduction of RUNX1t1 expression 
and high RUNX1t1 expression leads to the inhibition of C/EBPβ functions. Antagonism between 
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both proteins was reported in the adipogenic clonal expansion phase, which requires balanced 
expression of C/EBPβ and RUNX1t1 to prevent premature induction of C/EBPα and terminal 
fat cell differentiation [313]. The connection between C/EBPβ and RUNX1t1 may also be 
relevant in hematopoietic malignancies involving the AML-ETO translocation. It has recently 
been shown that RUNX1 and C/EBPβ bind to all hematopoietic genes in embryonic stem cells 
that undergo hematopoietic differentiation [319]. It thus seems plausible that the fusion of 
RUNX1 and RUNX1t1 in the t(8;21) AML-ETO translocation may counteract distinct functions 
of C/EBPβ in earmarking lineage commitment and differentiation genes and thus contribute to 
oncogenic conversion. 
It is proposed that most neoplasms arise from a single cell of origin, and tumour 
progression results from acquired genetic variability within the original clone allowing sequential 
selection of more aggressive sublines. Tumour cell populations are genetically more unstable 
than normal cells, perhaps from activation of specific gene loci in the neoplasm, continued 
presence of carcinogen, impact of inflammatory mediators, or even nutritional deficiencies 
within the tumour. Hence, each patient's cancer may require individual specific therapy, and 
even this may be thwarted by emergence of a genetically variant subline resistant to the 
treatment. More research should be directed toward understanding and controlling the 
evolutionary process in tumours before it reaches the late stage usually seen in clinical cancer. 
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Article: Interleukin-1B signalling leads to increased cell survival of gastric carcinoma 
cells through a CREB-C/EBPβ-associated mechanism 
 
Carlos Resende, Gonçalo Regalo, Cecília Durães, Marta Teixeira Pinto, Wen Xiaogang, Ceu 
Figueiredo, Fátima Carneiro, José C. Machado (accepted for publication on Gastric Cancer) 
 
 
INTRODUCTION 
Gastric carcinoma (GC) is the second cancer-related cause of death in the world. 
Although its incidence is decreasing in developed countries, it remains a health burden in the 
developing world. The main risk factor for the onset of GC is life-time infection with Helicobacter 
pylori (H. pylori), a stomach colonizing bacterium [314]. Infection with H. pylori leads to chronic 
gastritis that may progress to gastric atrophy, intestinal metaplasia, dysplasia and finally GC 
[1, 14]. 
The risk of developing GC depends both on environmental factors and host-related 
factors [6, 39]. In this model, gene polymorphisms that increase the production of pro-
inflammatory mediators, lead to enhanced chronic inflammatory response to H. pylori infection 
and to increased risk of progression towards GC [31, 39]. There are numerous studies 
demonstrating that polymorphisms in genes such as IL1Β, IL1RN, TNFA and IFNGR1 are 
associated with risk of developing GC [32, 40, 47, 50, 320]. Moreover, these polymorphisms 
have been shown to be associated with increased gene expression, both in vitro and in vivo 
[44]. Perhaps the most striking evidence favouring this model comes from a transgenic mouse 
model showing that overexpression of the IL1Β gene in gastric mucosa leads to increased risk 
of developing gastric disease, including dysplasia and GC, even in the absence of H. pylori 
infection [127]. 
According to the prevailing model, the link between enhanced chronic inflammation and 
GC depends essentially on the "destructive" effects of inflammation over the gastric epithelium, 
resulting in atrophy of the gastric mucosa and increased cell turnover and mucosal repair [49, 
321]. However, it is well demonstrated that inflammatory mediators, and other growth factors 
secreted by inflammatory cells, can act directly on other cell types, such as epithelial cells. 
Therefore, in addition to the mucosal destruction and repair effect, enhanced chronic 
inflammation could also play a role in gastric carcinogenesis by providing gastric epithelial cells 
with a survival stimulus through the secretion of growth factors [322, 323]. Coupled with 
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mutagenic events, this could ultimately lead to increased risk of cell transformation and GC 
development. 
In this regard, IL1Β is particularly interesting since polymorphisms in its promoter region, 
have been shown to be associated with increased risk of GC [32, 40, 47, 48]. IL1Β is a powerful 
pro-inflammatory cytokine that activates different transcriptions factors [324], some of which 
are also activated by H. pylori infection [182, 325]. One of the IL1Β-activated transcription 
factors is CCAAT/enhancer-binding protein beta (C/EBPβ) [326]. We previously reported that 
C/EBPβ is overexpressed in pre-malignant lesions and in GC, suggesting that this protein might 
be relevant for gastric carcinogenesis by inducing the expression of COX-2 [185]. Furthermore, 
C/EBPβ expression in GC was significantly associated with loss of expression of the putative 
gastric tumour-suppressor TFF1 [263, 327]. 
Another important IL1Β-activated transcription factor is cAMP response element-binding 
protein (CREB), which has been described as a major player in inflammation [324, 328]. In non-
small cell lung cancer, IL1Β induces the activation of CREB through ERK1/2 signalling, 
resulting in the expression of a set of pro-angiogenic cytokines that are crucial factors for 
tumour progression [329]. Furthermore, CREB was recently described to play an important pro-
oncogenic role in both cancer development and progression, being found overexpressed in 
several cancer types [193, 201, 204, 330]. It has been demonstrated, both in hepatocytes [174] 
and in preadipocytes [176], that CREB is able to regulate the transcription of the CEBPB gene 
by directly interacting with its promoter. 
The main objective of this study was to determine whether chronic inflammation-
associated IL1Β signalling, as seen in the context of H. pylori infection, could be linked to gastric 
carcinogenesis by modulating the behaviour of gastric epithelial cells. We addressed this 
objective by showing that CREB and C/EBPβ transcription factors can be activated by IL1Β 
signalling in the GC context. We also demonstrate that CREB acts upstream of C/EBPβ in GC 
cell lines. Finally, we show in vitro and in vivo that this signalling mechanism promotes GC cell 
survival. 
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RESULTS 
IL1B increases C/EBPβ and CREB expression in an ERK1/2-dependent manner 
To evaluate the effect of IL1B over the expression and activation status of C/EBPβ and 
CREB, we incubated GC cell lines AGS and GP202 with IL1B for 24 hours. Both in AGS and 
in GP202 cells, the incubation with IL1B led to an increase in expression of all isoforms (LAP*, 
LAP, and LIP) of C/EBPβ (Fig. 1). Regarding CREB, we observed an increase in both 
expression and phosphorylation levels in both cell lines (Fig. 1). 
Since ERK1/2 has been previously implicated in the regulation of C/EBPβ and CREB, we 
investigated whether it could mediate the effect of IL1B over those two transcription factors. 
Incubation of AGS and GP202 cells with the ERK1/2 inhibitor U0126 led to a decrease in 
expression of C/EBPβ and CREB and to a decrease in phosphorylation levels of CREB (Fig. 
1). The level of ERK1/2 phosphorylation in both cell lines was measured as a control for the 
efficacy of inhibition with U0126 (Fig. 1). These results demonstrate that IL1B is able to regulate 
the expression/activation status of both C/EBPβ and CREB in GC cells. 
 
Figure 1: IL1B stimulation and ERK1/2 inhibition effects on CREB, pCREB, and C/EBPβ protein levels. Both AGS 
and GP202 cells, treated with 10 ng/mL of IL1B for 24h, exhibited an increase in activated ERK1/2 (pERK1/2). In 
parallel, the expression levels of CREB, pCREB, and C/EBPβ were also increased. The ERK1/2 chemical inhibitor 
U0126 (25 μM) reverted the effect of IL1B on CREB, pCREB, and C/EBPβ protein levels. 
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CREB is a transcriptional regulator of C/EBPβ in GC cells 
Knowing that CREB is a transcriptional regulator of the CEBPB gene in other cell types, 
we decided to investigate whether the same regulatory mechanism could be at work in GC 
cells. Since both AGS and GP202 cells yielded the same results and the IL1B-stimulatory effect 
was more pronounced in AGS cells, we decided to perform the next set of experiments only in 
the AGS cells. Using both small interfering RNA (siRNA) and short-hairpin RNA (shRNA), we 
found that knocking-down CREB results in downregulation of C/EBPβ expression (Fig. 2a). 
Conversely, silencing of C/EBPβ by siRNA had no impact on CREB expression (Fig. 2a). These 
results show that CREB acts upstream of C/EBPβ in this regulatory mechanism. 
To verify if CREB acts directly on the CEBPB gene, we analysed the CEBPB promoter 
(2663 base pairs) in order to find putative cAMP response element (CRE)-binding motifs. We 
employed the nucleotide position numbering as previously described [174]. The analysis 
revealed the presence of three CRE-binding sites, ranging from nucleotides -2174 to -2171 
(BS1), from -959 to -956 (BS2), and from -66 to -63 (BS3) (Fig. 2b). Using chromatin 
immunoprecipitation (ChIP) we observed that CREB binds all three CRE-binding sites on the 
CEBPB promoter (Fig. 2c). 
These results were validated by showing that 24h chemical inhibition of the interaction 
between CREB and its co-activator CREB binding protein (CBP), led to a reduced binding of 
CREB to the CRE-binding sites on the CEBPB gene promoter (Fig. 3a). To confirm that the 
decrease in CREB binding to the CEBPB promoter actually leads to downregulation of 
transcription and protein synthesis, we evaluated the relative amount of C/EBPβ mRNA and 
protein after 48 hours of treatment with the CBP-CREB interaction inhibitor. This experiment 
resulted in a significant reduction of both C/EBPβ transcript levels (Fig. 3b) and C/EBPβ protein 
levels (Fig. 3c). 
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Figure 2. Effect of CREB downregulation on C/EBPβ protein levels. a) CREB silencing (CREB-specific bands are 
indicated by arrows; the upper bands on the CREB blots represent unspecific binding of the CREB antibody) was 
followed by a downregulation of C/EBPβ protein levels, whereas the silencing of C/EBPβ had no impact on CREB 
protein; b) schematic representation of the CEBPB promoter (2663 bp) with identification of the three CRE-binding 
sites (BS1, BS2, and BS3) and a control region (CR) located at the 3’ end of CEBPB; c) CREB interacts with all 
three CRE-binding motifs present on the CEBPB promoter. No Ab: no antibody used; Input: 1/100 of the sheared 
initial chromatin; CREB: chromatin immunoprecipitated using an anti-CREB antibody; IgG: chromatin 
immunoprecipitated with an unspecific antibody of the same family of the anti-CREB antibody. 
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Figure 3. Effects of CBP-CREB interaction inhibition on CREB activity over C/EBPβ. a) ChIP performed on AGS 
cells after treatment with CBP-CREB interaction inhibitor (+) revealed a decrease in the amount of CREB linked to 
the CEBPB promoter comparatively to untreated cells (-); b) AGS cells treated with CREB-CBP interaction inhibitor 
(25 μM) for 48h showed a significant decrease in C/EBPβ transcript levels d) and in protein expression. Real-time 
PCR results represent the mean ± S.D. of three independent experiments. *: significant (p<0.05), ** (p<0.01) and 
*** (p<0.001). 
 
 
CREB and C/EBPβ proteins are co-expressed in normal gastric mucosa and in GC 
To determine whether there is an association between the expression of CREB and 
C/EBPβ, we analysed the immunohistochemical (IHC) expression of these two proteins in a 
series of 66 cases of GC. In normal gastric mucosa we found that both C/EBPβ and CREB are 
expressed in the nucleus of epithelial cells in a glandular region within which is located the 
proliferative isthmus/neck zone (Fig. 4a and 4b). To confirm that CREB and C/EBPβ are 
expressed in the same cells, we performed double immunofluorescence in a tissue fragment 
of normal gastric mucosa. (Fig. 4g – 4j). In GC, we observed that CREB and C/EBPβ are 
expressed in the cell nucleus of 93% and 73% of the cases, respectively. The comparison of 
the IHC results, shows that there is a statistically significant association (P=0.04) between 
CREB and C/EBPβ expression in our series of GC. We also observed that GC cases with a 
higher CREB expression score were significantly associated with intestinal and mixed 
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histological subtypes (P=0.003) (Table 1). No associations were detected between the 
expression of CREB and other clinicopathological characteristics of the tumours. 
 
 
Figure 4. Immunohistochemical expression of CREB and C/EBPβ in normal gastric mucosa and in GC cases. a) 
CREB is expressed in epithelial cells located in the neck/isthmus region of normal gastric glands; b) C/EBPβ is also 
expressed in neck/isthmus normal epithelial cells; c) and e) examples of CREB-positive GC cases (scoring 3); d) 
and f) C/EBPβ is overexpressed in the same GC cases that are positive for CREB. Magnification 100x; g-j) double 
immunofluorescence staining for CREB and C/EBPβ in normal gastric mucosa, showing co-expression of the two 
proteins in gastric epithelial cells; g) DAPI nuclear staining; h) C/EBPβ staining; i) CREB staining; j) merged image 
for DAPI, C/EBPβ, and CREB staining. Magnification 400x. 
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Table 1. Relationship between the clinicopathological features of gastric cancer and CREB expression scoring. 
 
 
CREB modulates IL1B-induced proliferation of GC cells 
To determine whether IL1B is able to increase cell survival of GC cells we measured 
BrdU incorporation and performed TUNEL assays in the AGS GC cell line after incubation of 
cells with IL1B. In parallel, we determined whether any of the effects of IL1B is mediated by 
CREB. Our control experiments shows that CREB expression is downregulated by the shRNA 
used (Fig. 5a). Figure 5b shows that IL1B is able to significantly increase cellular proliferation 
and that this effect can be reverted by downregulating CREB levels. IL1B had no significant 
effect on the rate of apoptosis (data not shown). 
To explore the role of CREB in GC cell proliferation we evaluated the expression of the 
cell-cycle regulator cyclin D1. After performing a dose-response experiment to determine the 
effect of the CBP-CREB interaction inhibitor over cell proliferation we selected a concentration 
of 25uM. In the AGS cell line, CREB inhibition had a significant inhibitory effect over cell 
proliferation (Fig. 5c). The effect was more pronounced after 48h of treatment. Moreover, this 
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effect could also be confirmed by measuring the expression level of cyclin D1 after CREB 
inhibition both at 24 and 48-h of treatment (Fig. 5f). These results were confirmed in the GP202 
GC cell line (Figs. 5d and 5g) and in the intestinal-type GC cell line MKN28 (Figs. 5e and 5h). 
Overall, these results further support that CREB plays an important role in GC cell survival, 
both in diffuse and intestinal histological types, by regulating proliferation of GC cells. 
 
 
Figure 5. CREB modulates both IL1B-induced and basal cell proliferation. a) Downregulation of CREB expression 
using shRNA; b) AGS cells expressing normal levels of CREB (transfected with scrambled shRNA) showed an 
increase in cell proliferation after 24h of treatment with 10 ng/mL IL1B, while CREB downregulation (transfected with 
anti-CREB shRNA) was responsible for a significant decrease in IL1B-induced cell proliferation. sc shRNA (control 
scrambled shRNA); shRNA CREB (anti-CREB shRNA); c) AGS, d) GP202, and e) MKN28 cells were treated for 24 
and 48h to assess the time-dependent impact of treatment over GC cell proliferation; the protein levels of cyclin D1 
were checked in f) AGS, g) GP202, and h) MKN28 cells after 24 and 48h of CBP-CREB interaction inhibitor 
treatment. BrdU results represent the mean ± S.D. of three independent experiments. *(p<0.05), **(p<0.01) and 
***(p<0.001). 
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CREB inhibition decreases GC cell growth in vivo 
To evaluate the effect of CREB on tumour growth, we used the chicken embryo 
chorioallantoic membrane (CAM) model. The CAM effectively supports the growth of inoculated 
human cancer cells due to the chick immunodeficiency during early developmental stages. 
Before CAM inoculation, we confirmed the knockdown of CREB protein on AGS cells 
transfected with anti-CREB shRNA (figure 6a). To avoid inter-animal differences in the results, 
scrambled shRNA and anti-CREB shRNA transfected AGS cells were inoculated in distinct 
areas of the CAM of the same egg and allowed to proliferate for 6 days. At this end point, the 
tumour area was quantified. As can be seen in figure 6b, inhibition of CREB led to reduced 
growth of the inoculated cells. Figure 6c shows that on average the tumour growth area was 
significantly smaller in cells with CREB inhibition. These results demonstrate that CREB-
mediated signalling is important for GC cell growth in vivo. 
 
 
Figure 6. CREB inhibition reduces in vivo cell growth. a) Before inoculation of AGS cells in the chorioallantoic 
membrane (CAM), CREB protein knockdown was checked by western blotting; b) AGS cells transfected with shRNA 
against CREB give rise to small sized tumours compared with scramble transfected cells; c) images representing 
the different sizes (delimited by red dashed lines) of scramble and shRNA CREB tumours in two paired CAM 
experiments (#1 and #2). Values of p<0.05 were considered to be statistically significant. 
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DISCUSSION 
Our results demonstrate that IL1B is able to activate CREB and C/EBPβ in GC cells. 
This process is mediated by ERK1/2 since its inhibition by U0126 reverted the effects induced 
by IL1B. This is in agreement with previously reported results showing that IL1B is able to 
induce GC cell proliferation in an ERK1/2 dependent manner [322]. We could also demonstrate 
that in GC cells CREB is able to transactivate C/EBPβ. 
Our in vitro observations were reinforced by the analysis of the expression of CREB and 
C/EBPβ in a series of GC samples and normal gastric mucosa. We showed that in normal 
gastric mucosa CREB is expressed in the proliferative neck/isthmus region of the gastric 
glands, whereas in GC it is overexpressed in the majority of tumour samples. These results are 
in accordance with those published by Chen et al [331], showing that CREB mRNA levels are 
upregulated in GC samples when compared with adjacent normal mucosa. 
CREB expression was also significantly associated with the expression of C/EBPβ in 
GC. The observation that in normal gastric mucosa CREB and C/EBPβ are expressed in a 
cellular compartment that includes progenitor cells, suggests that CREB and C/EBPβ may be 
involved in maintaining a proliferative phenotype in gastric epithelial cells. This would be in 
accordance with the observed pattern of overexpression of both proteins in the majority of the 
GC cases included in the present study. These results are also in keeping with our previous 
demonstration that C/EBPβ is overexpressed in preneoplastic lesions and in GC, suggesting 
that this protein might be relevant for transformation of gastric epithelial cells by inducing the 
expression of COX-2 [185] and by inhibiting the expression of the putative gastric tumor 
suppressor gene TFF1 [263, 327] 
In order to complement the aforementioned observations with a biological readout, we 
evaluated the role of CREB in mediating IL1B-induced changes in cell proliferation and 
apoptosis. Although no significant effect was observed in relation to apoptosis, our results show 
that CREB is an effector of IL1B-induced cell proliferation, since downregulation of CREB 
impairs the pro-mitogenic action of IL1B on GC cells in vitro. These results were further 
supported by the CAM assays showing that inhibition of CREB reduces the ability of GC cells 
to survive in this in vivo model. 
Infection with H. pylori leads to chronic inflammation and increased risk of developing 
GC. Our results support the hypothesis that the effect of chronic inflammation on 
tumourigenesis includes modulation of critical signalling pathways that regulate survival in 
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epithelial cells. In this scenario, H. pylori infection leads to overexpression of IL1B which, in 
turn, activates CREB and C/EBPβ. This effect may be more pronounced in individuals that 
carry genetic susceptibility polymorphisms that have been demonstrated to be associated with 
enhanced chronic inflammation, such as those in the IL1B gene promoter. If one couples 
increased cell survival with increased likelihood to accumulate genetic mutations, this may help 
explain why individuals with pro-inflammatory genetic polymorphisms have an increased risk 
of developing GC. 
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The onset and progression of GC, in analogy with other cancer models, must rely on 
the deregulation of critical signalling pathways and modulation of associated molecular 
effectors. However, the general lack of knowledge about those mechanisms remains a major 
gap in GC research. In that sense, the identification of the aberrant/deregulated mechanisms 
underlying gastric carcinogenesis could facilitate early diagnosis and help to inform about 
putative valuable therapeutic targets. 
A consistent amount of evidences establishes chronic inflammation-associated with H. 
pylori infection with risk of GC. The association is even more significant in infected individuals 
that due to their genetic makeup, develop a more intense inflammatory response. So, chronic 
inflammation must have the ability to continually modulate crucial signalling pathways involved 
in processes such as cell proliferation and survival, In fact, inflammatory mediators deeply 
perturb the normal gastric homeostasis, inducing behavioural changes in gastric epithelial cells 
at the level of proliferation [322, 323, 332, 333], apoptosis [321, 334] and overall gene 
expression, caused by the differential modulation of cell signalling pathways [182, 325]. 
Ultimately, the deregulated signalling cascades will nurture the conditions to turn gastric 
epithelial cells more susceptible to genetic aberrations that will drive gastric carcinogenesis. 
With this work we proposed to understand the biological roles of signalling events and 
associated molecular mechanisms underlying inflammation-driven GC development. We have 
previously reported the transcription factor C/EBPβ to be overexpressed in GC and also in early 
preneoplastic lesions of gastric epithelium, such as gastritis. Moreover, we found C/EBPβ to 
regulate the promoter activation of the inflammatory mediator COX2 [185]. Taken together, 
those results led us to hypothesize about a possible inflammation-driven role of C/EBPβ on 
gastric carcinogenesis. Additionally, and to understand the reason/s behind C/EBPβ 
deregulation, we wanted to determine the upstream signalling mechanisms and/or molecular 
events responsible for this phenomenon. In a first approach, CEBPB was the target of 
mutational screening conducted in a series of 35 GC cases to clarify if the up-regulation of 
C/EBPβ could have a genetic basis. Because only one mutation was found, although we did 
not explored the pathogenicity of the mutation, the reason behind C/EBPβ up-regulation must 
reside in aberrations in upstream regulatory mechanisms (unpublished data). 
To understand the signalling mechanisms involved in C/EBPβ deregulation in GC, we 
first need to understand the mechanisms that control C/EBP expression in normal mucosa. In 
normal gastric mucosa, we observed that C/EBPβ positive cells also express the proliferation 
marker Ki67 [185]. That observation suggests C/EBPβ as playing a role in normal gastric 
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epithelial cell proliferation. Taking the advantage of the existence of a C/EBPβ null (C/EBPβ-/-) 
mouse model [239] we observed, for the first time, the in vivo role of C/EBPβ on normal gastric 
epithelium proliferation. We observed that C/EBPβ-/- mice exhibited a reduction in the thickness 
of the epithelium and decreased amounts of Ki67 positive cells. Furthermore, gastric mucosa 
of C/EBPβ-/- mice constitutively showed decreased levels of cell-cycle inducers Cyclin A1, 
Cyclin D3, and Cyclin E1. These results give support to our first observations on human gastric 
tissue [185] and show that C/EBPβ is a necessary effector for normal gastric epithelial cell 
proliferation. 
It is well known that RUNX3-/- mice develop gastric mucosa hyperplasia, although the 
mechanism underlying RUNX3-deficient phenotype remains unclear [90]. We found C/EBPβ 
strongly expressed in the hyper-proliferative gastric mucosa of RUNX3-/- mice. Furthermore, by 
crossing RUNX3-/- with C/EBPβ-/- mice and comparing with control mice, we found the 
expression of C/EBPβ to be a mandatory requisite for the hyperplastic phenotype of RUNX3 
deficient mice. Besides being a gastric tumour suppressor [91], RUNX3 is also an important 
transcriptional effector of the TGFβ pathway [335], which exerts powerful anti-proliferative and 
anti-inflammatory actions on different cell types [128]. Thus, our results suggest an antagonistic 
relation between TGFβ signalling, mediated by RUNX3, and C/EBPβ in the modulation of 
proliferation of normal gastric epithelial cells. Giving support to our rationale, C/EBPβ was 
previously reported to be involved in the cytostatic activity of TGFβ [256]. To explore the 
possible duality between TGFβ and C/EBPβ, we performed a series of in vitro experiments in 
which we blocked TGFβ-dependent signalling with different chemical inhibitors (SIS3 – SMAD3 
phosphorylation inhibitor; SB505124 – TGFBRI inhibitor). After 12 to 48 hours of chemical 
inhibition, we observed a significant increase in C/EBPβ protein levels (>3 fold increase), 
suggesting that TGFβ possibly exerts its anti-proliferative actions by controlling C/EBPβ protein 
levels (unpublished data).  
C/EBPβ was previously reported to exert a repressive role on gastric differentiation 
genes, such as TFF1 [121, 263, 327]. Validating those studies through an in vivo approach, we 
demonstrated that the gastric mucosa of C/EBPβ-/- mice express significantly higher levels of 
TFF1 protein. Additionally, we observed the levels of other two gastric differentiation markers 
(MUC5AC and MUC6) strongly up-regulated in the gastric mucosa of C/EBPβ-/- mice. It is 
possible that the repressive action of C/EBPβ upon gastric cell differentiation can be a direct 
consequence of its effect on cell growth, promoting the expression of proliferation markers, 
while inhibiting the expression of differentiation proteins. Future studies are needed to 
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understand whether the observed results are a direct or indirect action of C/EBPβ-dependent 
transcriptional activity. 
Based on our previous results of C/EBPβ expression in preneoplastic lesions and GC 
[185] and in our in vivo results from C/EBPβ-/- mice, in which we revealed the proliferative role 
of this protein, we asked about its the true impact on GC cell biology. Through a series of in 
vivo tumorigenic assays with GC cell lines silenced for C/EBPβ we could observe that cells with 
C/EBPβ knockdown gave rise to smaller tumours when compared to control GC cells. Also, in 
addition to the impaired tumorigenic ability, GC cells with C/EBPβ knockdown also exhibited 
decreased proliferation and survival. Looking at our data, where C/EBPβ appears to be a 
crucial effector in normal and neoplastic cell proliferation, it seems logical to consider C/EBPβ 
as a gastric proliferative transcription factor that modulates biological processes that are 
transversal from normal to GC cell. Possibly these observations may have a more profound 
biological meaning, going deeper till the initial GC cell. It is generally accepted, at least 
conceptually, that the probability of occurrence of the necessary cancer-driver events is higher 
in a tissue progenitor cell – due to the increased lifespan – than in the derived differentiated 
cells [58]. Thus, one can hypothesize about a possible cellular origin of GC emerging from a 
C/EBPβ-positive gastric progenitor cell. However, this hypothesis was not yet addressed, 
deserving particular attention in future work. 
The similarities of C/EBPβ biology between human and mouse gastric epithelial cells 
raised the question: to what extent the homeostatic and oncogenic C/EBPβ-dependent 
proliferation share common molecular mechanisms? After the comparison and validation of 
gene expression assays between C/EBPβ-/- mouse gastric mucosa and GC cases, we found 
RUNX1t1 to be up-regulated in C/EBPβ-/- gastric epithelium and downregulated in intestinal-
type GC, revealing an inverse correlation with the expression of C/EBPβ. RUNX1t1 was 
previously reported as a potent inhibitor of adipogenesis by blocking C/EBPβ-dependent 
transcriptional activity through the direct physical interaction of the two proteins [313]. 
Moreover, RUNX1t1 expression was reported to play an essential role in the gastrointestinal 
system, regulating normal morphogenesis [315]. Thereby, our results suggest RUNX1t1 as a 
putative GC tumour suppressor, because its expression was lost in 38% of GC cases and it 
exerts an effective role in decreasing GC cell proliferation. Also, RUNX1t1 seems to play a 
tumour suppressor role in other cancer types, because it has been reported as an ovarian 
tumour suppressor [291], and its loss of expression was found to be necessary for liver 
metastization by pancreatic endocrine cancer cells [316]. An important aspect to be addressed 
in future work is to characterize the expression of RUNX1t1 in gastric preneoplastic lesions. By 
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doing this we expect to clarify if RUNX1t1 deregulation is a GC specific event or if it is an early 
GC development – as previously seen for C/EBPβ [185] – helping to reveal a possible 
reciprocal expression pattern and oncogenic mechanism between the two proteins. 
 From our first observations of C/EBPβ histological expression in normal gastric mucosa 
and its proliferative and anti-differentiation effects on gastric epithelial cells, we wonder about 
a possible factor that would play the opposite functions: stops cell proliferation and induces 
differentiation. The adipogenesis model seemed attractive to us, because preadipocytes highly 
express C/EBPβ during the first steps of differentiation, while in an immature proliferating state, 
diminishing the protein levels during the terminal phase of differentiation, a point in which 
C/EBPα starts to be highly expressed [235, 236]. So, we proposed to evaluate the expression 
pattern of C/EBPα on normal gastric mucosa and GC samples. Strikingly, we observed C/EBPα 
to be expressed in the differentiated epithelial compartment of the superficial foveolar region of 
the normal gastric mucosa, co-localizing with the differentiation marker TFF1. Moreover, we 
observed a downregulation or loss of C/EBPα expression in 30% of our cohort of GC cases. 
However, we could not observe an evident C/EBPα downregulation in preneoplastic lesions. 
These results suggested us that C/EBPα downregulation is a late-stage cancer-specific event 
in gastric carcinogenesis. Next, we wanted to disclose the biological impact of C/EBPα over 
GC cell biology. The in vitro modulation of C/EBPα expression allowed us to observe that this 
protein plays anti-proliferative (decreasing cyclin D1 levels, and increasing p27) and pro-
differentiation (increasing the expression of TFF1) roles on GC cells. The results obtained by 
us with the GC model are similar with previous results obtained for different cancer cell models, 
suggesting C/EBPα as a tumour suppressor in different cellular contexts [247, 249, 251, 252]. 
Although we did not addressed how C/EBPα inhibits cell proliferation, it would be 
mechanistically relevant to determine if the inhibition occurs through induction of p21 
expression [218], repression of E2F-dependent transcription [220], or interaction with SWI/SNF 
complex [221]. 
Curiously, in normal gastric mucosa, we observed a few C/EBPα positive cells located 
in the neck region of gastric glands – the glandular compartment where we had previously 
detected C/EBPβ-positive cells. We demonstrated by immunohistochemistry that TFF1, as 
initially expected, was not present in cells from the proliferative neck region. One possible 
explanation for this observation – sparse expression of C/EBPα and absence of TFF1 
expression on neck region – can reside on a dominant inhibitor effect caused by the physical 
interaction between different proteins. It is known that C/EBP-family members can homo and 
heterodimerize [208, 209, 211], resulting in differential transactivation activities. Thus, C/EBPβ 
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can heterodimerize with C/EBPα in the epithelial cells of the neck zone, and exerting a 
dominant effect over C/EBPα can counteract the transcriptional potential of this last protein. 
However, this hypothesizes was not addressed in this work, deserving particular attention the 
next future. 
An aspect that we have not explored in this work was the ascertainment of the 
underlying mechanism/s behind C/EBPα loss of expression in GC. From our previous work, we 
knew that, in opposition to leukemias [244, 245], genetic alterations are not the major 
mechanism for the observed C/EBPα downregulation, because we only found one mutated GC 
from a cohort of a hundred and forty-two GC cases [248]. A possible underlying mechanism, 
as observed in lung cancer, is promoter hypermethylation [250]. Alternatively, the loss of 
expression can reside in a transcriptional repressive effect of C/EBPβ (or other transcription 
repressor) over CEBPA promoter. So, further work is needed to decipher the causes behind 
C/EBPα loss of expression. 
As mentioned above, in clear opposition to C/EBPα whose loss of expression appears 
to be a relatively late event in gastric carcinogenesis, C/EBPβ overexpression is observed even 
at very initial stages of the process, such as in gastritis. So, being chronic inflammation a risk 
factor for GC development and because we observed C/EBPβ deregulation in inflamed gastric 
mucosa, we asked if inflammatory mediators can regulate C/EBPβ expression. Strengthening 
our rationale, the results we obtained in vitro with TGFβ inhibitors and in vivo with RUNX3-/- 
mice strongly suggested that association. One of the most relevant pro-inflammatory cytokines 
in the context of H. pylori is IL1B, which is highly up-regulated in response to infection and 
contributes to the development of hypochlorhydria, gastric atrophy and other pre-cancerous 
lesions [36, 38]. However, the signalling mechanisms involved in IL1B signalling in GC are still 
very obscure. With this in our minds, we proposed to dissect the IL1B-induced signalling events 
in GC cells. From published works, we knew two critical points: first, transcription factors that 
are involved in progenitor cell homeostasis are target of inflammation-induced modulation 
[106]; second, in non-gastric cell models IL1B was able to induce the expression/activation of 
C/EBPβ [326]. So, after treating different GC cell lines with IL1B we observed an up-regulation 
in C/EBPβ protein levels. Next, and based on our results that indicated C/EBPβ has a gastric 
pro-mitogenic effector, we assessed if MAPK signalling would be involved in IL1B-dependent 
increase in C/EBPβ expression. Through chemical inhibition, we established a functional link 
between IL1B and C/EBPβ through an ERK1/2-dependent mechanism. Noteworthy, MAPK 
signalling pathway is one of the most consistently altered and biological relevant pathways in 
human cancers [83]. Also, activation of the MAPK pathway was found to be increased in H. 
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pylori-induced chronic inflammation [122] and in GC [123-125].Thus, we wonder if MAPK 
signalling could be a possible mechanism behind the differential pattern of expression of 
C/EBPα and C/EBPβ observed in normal gastric mucosa and in GC. After in vitro chemical 
inhibition of MAPK signalling we were able to observe a significant protein increase and nuclear 
accumulation of C/EBPα, suggesting that MAPK activation exerts a strong inhibitory effect over 
C/EBPα expression. Strikingly, this observation clearly contrasts with what we had observed 
for the role of MAPK signalling in the control of C/EBPβ expression, and reinforce the 
conception that the two C/EBP family members are inversely regulated and have antagonistic 
roles in the gastric carcinogenesis model. 
Nevertheless, we faced with a crucial question: mechanistically, how does MAPK 
signalling induced the expression of C/EBPβ? Because ERK1/2 transduce signals through the 
phosphorylation of specific downstream proteins, we hypothesized that possibly ERK1/2 
induced the expression of C/EBPβ not directly, but in an indirect way through the activation a 
transcription factor involved in the regulation of CEBPB. Based on a few studies: one in 
hepatocytes [174] and the other two in preadipocytes [175, 176]; and after a deep analysis of 
CEBPB promoter, we identified CREB as a putative transcriptional regulator of CEBPB. 
Strengthening our rationale, we observed that CREB and phosphorylated-CREB (pCREB) 
were also increased after IL1B stimulation through an ERK1/2-dependent action. Through a 
series of ChIP and gene silencing experiments we confirmed CREB as a direct transactivator 
of CEBPB in GC cells. Therefore, our results put CREB in an upstream signalling position in 
relation to C/EBPβ, suggesting that it may be involved not only in the transcription of CEBPB 
but also in control of a broader range of biological processes. In fact, that assumption was 
confirmed because we found CREB expression to be a mandatory requisite for both basal and 
IL1B-induced gastric cell proliferation. In addition to the crucial role in cell proliferation, we also 
found CREB as a pro-survival effector in GC cell lines (unpublished results). 
CREB has been recently described as a real culprit in cancer, whose deregulated 
protein expression is frequently observed in different tumour types [192-195, 200, 201, 204]. 
So, based on the results of our in vitro experiments we asked about the histological expression 
pattern of CREB in human gastric primary tumours. In normal gastric mucosa, CREB was 
expressed in a region of the gastric gland within which is located the neck/isthmus – in analogy 
with C/EBPβ. However, when we observed the GC samples we found CREB overexpressed in 
the vast majority of the cohort studied (94%), particularly in intestinal and atypical cases. 
Moreover, the pattern of expression that we observed for CREB in GC was significantly 
associated with C/EBPβ expression. To evaluate if CREB acts as a pro-oncogenic effector, we 
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performed a series of in vivo tumourigenic experiments using the chicken CAM assay as an 
animal model. With this assay, we observed that GC cells with CREB knockdown gave rise to 
significantly smaller tumours when compared with control GC cells, indicating undoubtedly that 
CREB is a gastric pro-oncogenic factor. 
Curiously, we observed more GC cases positive for CREB than for C/EBPβ. This 
observation suggests the action of a possible CEBPB transcriptional repressor in the cases 
negative for C/EBPβ, whose repressional action must be stronger than the CREB activity. One 
possible repressor of CEBPB transactivation could be the CREB-family inhibitor ICER, because 
it recognizes the same CRE-binding sites and has the ability to bind them with greater affinity 
than the other CREB family members [156]. Nevertheless, we did not assessed the expression 
of ICER in our GC cases. However, it is possible that, in accordance with other cancer models 
[195, 336, 337], ICER expression would be lost in a percentage of GC cases, with underlying 
biological implications This is a relevant point, with important functional impact that needs to 
be addressed in future work.  
Our results revealed a mechanism through which CREB regulates C/EBPβ expression 
not only in the scenarios of inflammation and GC but also in normal gastric epithelium. As 
aforementioned, C/EBPβ was found to transactivate the expression of the powerful 
inflammatory mediator COX2, at least at the promoter level [185]. Additionally, CREB was also 
reported to be necessary for the expression of COX2 in intestinal epithelial cells [338]. Thus, it 
seemed logical that in a GC cell context and in combination with C/EBPβ, CREB could also be 
involved in COX2 expression. Our rationale was strengthened because in osteogenic cells the 
expression of the proto-oncogene FOS is modulated by a CREB–C/EBPβ dimer [339]. Thus, it 
was highly tempting for us to hypothesize about a possible CREB–C/EBPβ dimer that would 
underlie the expression of COX2 – and possible other important genes in GC biology. Pursuing 
this idea, we performed a series of co-immunoprecitation experiments in GC cells with the 
objective to detect CREB–C/EBPβ interactions in a GC cell context. However, we were unable 
to detect any physical interaction between the two proteins. These result suggested us that in 
a GC cell context, and in unstimulated conditions, CREB and C/EBPβ do not stably interact 
with each other. However, if they really interact, the process may be too short-lived to be 
detected and possibly may lack any biological implication (unpublished data). Nevertheless, 
and due to the possible relevant biological implications, this subject needs to be further 
explored in future work. 
It has been reported that CREB acts as the final effector of various signalling pathways 
[144, 145], and our results indicate CREB as a critical effector of IL1B signalling in GC cells. 
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Further, according to Mantovani et al. (2008) transcription factors are at the crossing point 
between inflammatory and oncogenic signalling pathways [104], and CREB is possibly one of 
those transcription factors, which is involved in cell proliferation and survival in both extrinsic 
pathways. Regarding oncogenic activation, in HER2-positive breast tumours CREB was 
reported as a major cellular effector, whose expression is necessary for cellular proliferation, 
survival, and tumour formation ability [203]. Noteworthy, HER2 expression is also found 
deregulated in up to 20% of intestinal type GC [39, 69] and although we did not explored this 
subject, it is possible that GC cases that are HER2-positive could depend on the activity of 
CREB to confer them a growth and survival advantage. Although at low frequencies, alterations 
in other molecular targets have been reported in GC [39, 53, 69]. One example is PTEN, whose 
expression is lost in approximately 20% of GC cases [87]. It is possible that the 20% of GC 
cases in which PTEN expression is lost are the ones in which we observed a stronger 
immunoreactivity for C/EBPβ. The rationale for this possibility resides in the fact that PTEN, 
when translocated to the cell nucleus, acts as a potent inhibitor of CREB-dependent 
transcriptional activity [340]. So, in GC cases with loss of PTEN it should be possible to detect 
increased expression levels of C/EBPβ – because we found it to be a CREB transcriptional 
target in GC cells. Regarding target genes, CREB was reported to be involved in the expression 
of a plethora of genes in a cell-specific manner [171-173]. One cell-specific target gene is quite 
interesting: CREB itself – as reported in Sertoli cells where CREB was observed to directly 
transactivate its own gene [341]. Knowing this, we looked for a positive-feedback mechanism 
that, once activated by an oncogenic event could justify the observed overexpression of CREB 
in gastric primary tumours. In fact, after performing ChIP in a GC cell line, we detected the 
physically interaction of CREB with its own promoter (unpublished data). The underlying 
mechanisms behind this auto-regulatory mechanism can be of major biological relevance and 
will be the focus of research in future work. 
Looking forward, and due to the limited number and frequency of molecular aberrations 
observed in GC that could potentially explain the functional basis by which CREB crosses the 
boundaries of the proliferative neck-zone in normal gastric mucosa and become overexpressed 
in the majority of GC cases, in future work we expect to apply high-throughput sequencing 
technology in a panel of GC cases to identify molecular alterations that could give a solid 
genetic support to our results. 
A broad number of studies suggested that only a restricted number of transcription 
factors are overexpressed and/or overactive in most human cancers, making them tempting 
targets for the development of anticancer drugs. This rationale is even more attractive by 
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knowing that are more oncogenic signalling mediators upstream of those transcription factors 
than there are oncogenic transcription factors. Therefore, being transcription factors the final 
executors of malignant gene expression signatures, they occupy a central role in all classic 
hallmarks of carcinogenesis [139, 265, 266]. Thus, one effective anti-transcription factor drug 
could be able to fight and inhibit the action of various upstream-activated oncogenic signalling 
pathways [267]. CREB has been pointed as a central target for cancer therapy. In fact, a battery 
of small-molecule inhibitors of CREB activity was recently described [272, 273]. These small-
molecule inhibitors, designated KIX-KID interaction inhibitors, abrogate CREB-dependent 
transcription by inhibiting the interaction between CREB and the transcriptional apparatus. 
Noteworthy, one of the referred inhibitors exhibited a strong effect in downregulating the 
proliferative and survival potential of the cancer cells but showed no impact on normal cells 
[273]. With this on our minds, we used this same small-molecule inhibitor in GC cell lines and 
we observed a significant decrease in cell proliferation and cell survival. The protein levels of 
cell-cycle inducer Cyclin D1 were also drastically decreased. Nevertheless, the use of small-
molecule inhibitors of CREB activity was only reported in in vitro experiments, with no animal 
or human trials described to date. In future, and maybe after additional chemical refinements, 
some of these chemical inhibitors could open new promising therapeutic options in cancer 
treatment. 
 
In conclusion, in this thesis we show that in normal gastric mucosa, C/EBPα is 
expressed in the differentiated foveolar gastric epithelium where it co-localizes with gastric 
differentiation marker TFF1. In primary gastric tumours, we observed a downregulation or loss 
of C/EBPα expression in 30% of the cases analysed. Further, through expression modulation 
we found C/EBPα to act as a potent anti-proliferative effector on GC cells. Moreover, C/EBPα 
expression was found to be negatively regulated by p38 and ERK1/2 signalling, two critical 
MAPK branches previously reported as activated in gastric inflammation and GC. On the other 
hand, we show that C/EBPβ is positively associated with cell proliferation and survival of both 
normal gastric epithelium and GC cell lines. Also, C/EBPβ expression was found to be 
necessary for the full tumorigenic ability of GC cells. Moreover, we observed that the 
transcriptional activity of C/EBPβ was inhibited through the physical interaction with RUNX1t1, 
whose expression was lost in 38% of primary gastric tumours. These results suggest that the 
biological function of RUNX1t1 is mechanistically connected to the suppression of the pro-
oncogenic functions of C/EBPβ. 
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Exploring the association between inflammatory mediators and C/EBPβ expression, we 
demonstrate that IL1B is able to induce the expression of C/EBPβ through the activation of 
MAPK signalling cascade. Remarkably, we observed a differentially modulatory role of MAPK 
signalling over C/EBPα and C/EBPβ expressions, strengthening the conception that the two 
C/EBP family members are inversely regulated and have antagonistic roles in the gastric 
carcinogenesis model. Based on other cell models, we observed MAPK-activated CREB 
transcriptional activity as a mechanism underlying C/EBPβ expression in GC cells lines. We 
also demonstrate that in normal gastric mucosa C/EBPβ and CREB are expressed in a 
compartmentalized glandular region within which gastric progenitor cells are located, while in 
GC samples both proteins are associated and overexpressed in the majority of cases studied. 
Moreover, we demonstrate that CREB acts as a crucial effector in both basal and IL1B-induced 
GC cell proliferation and survival, and in in vivo tumorigenic ability of GC cells.  
Finally, our results provide further support to the hypothesis that the effect of chronic 
inflammation on gastric carcinogenesis, as seen in the context of genetically susceptible 
individuals infected with H. pylori, includes modulation of signalling pathways that regulate 
critical biological mechanisms in gastric epithelial cells. Furthermore, we reinforce this view by 
identifying the MAPK-CREB-C/EBPβ signalling mechanism linking inflammation and GC. Our 
results may help inform new strategies for prevention and treatment of GC, including the control 
of chronic inflammation and the identification of new therapy targets. 
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C/EBPa expression is associated with homeostasis of the
gastric epithelium and with gastric carcinogenesis
Gonc¸alo Regalo1,2, Carlos Resende1, Xiaogang Wen1, Ba´rbara Gomes1,2, Cecı´lia Dura˜es1, Raquel Seruca1,2,
Fa´tima Carneiro1,2 and Jose´ C Machado1,2
Transcription factors from the CCAAT/enhancer-binding protein (C/EBP) family are fundamental for the control of
differentiation and proliferation of many adult tissues. C/EBPa has a crucial role in inducing terminal differentiation and is
an established tumor suppressor gene in several cancer models. The objective of this study was to analyze the putative
role of C/EBPa in gastric carcinoma (GC). We analyzed the expression of C/EBPa in normal and neoplastic gastric tissues,
and assessed the role of C/EBPa on proliferation and differentiation of GC cells. In normal gastric mucosa, C/EBPa is
expressed in the foveolar epithelium and co-localizes with the gastric differentiation marker trefoil factor 1 (TFF1).
The expression of C/EBPa was found to be lost in 30% of GC cases. To evaluate the role of C/EBPa in cell proliferation
and differentiation, we transfected GC cells with a full-length C/EBPa protein. We observed a significant decrease in
proliferation in C/EBPa-transfected cells. This was accompanied by a decrease in Cyclin D1, an increase in P27 expression,
and an increased expression of TFF1. Finally, we showed that inhibition of the Ras/MAPK pathway leads to increased
C/EBPa and TFF1 expression, and decreased cell proliferation and cyclin D1 expression in GC cells. Our results suggest that
C/EBPa (together with other members of the C/EBP family) has an active role in the control of differentiation and
proliferation in normal gastric mucosa. In GC, loss of C/EBPa may be associated with the switch from a cellular differ-
entiation to a cellular proliferation program, presumably as a consequence of Ras/MAPK pathway activation.
Laboratory Investigation (2010) 90, 1132–1139; doi:10.1038/labinvest.2010.79; published online 12 April 2010
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Gastric carcinoma (GC) is still one of the most common
cancers worldwide, despite its decreasing incidence in the
developed countries. The continued inflammation of the
gastric epithelium by chronic Helicobacter pylori infection
is a major contributor to carcinogenesis, most likely by
promoting disruption of the balance between proliferation
and differentiation in the regenerating inflamed mucosa.
Although this process has been well characterized phenoti-
pically, the main molecular players in gastric neoplastic
transformation are largely unknown.1
Proteins of the CCAAT/enhancer-binding protein (C/EBP)
family are important transcription factors that link gene ex-
pression to proliferation/differentiation control.2 We have re-
cently shown that C/EBPb is over-expressed in pre-neoplastic
lesions and GC.3 Most notably, C/EBPb over-expression is as-
sociated with loss of trefoil factor 1 (TFF1), an established
differentiation marker, and a putative gastric tumor suppressor.4
Members of the C/EBP family are known to hetero-
dimerize among themselves, giving rise to different func-
tional transcriptional complexes. Moreover, they often act
with a high degree of coordination.5 This is well demon-
strated in adipogenesis, where sequential expression of
different C/EBP members underlies the process of differ-
entiation from pre-adipocytes to fully mature adipocytes.6
After the differentiation stimulus is given, C/EBPb is ex-
pressed in immature pre-adipocytes and primes cells to
differentiate by inducing C/EBPa expression.7 Once active,
C/EBPa drastically reduces cell proliferation, and promotes
the expression of peroxisome proliferator-activated receptor g.8
In this and other models, C/EBPa is a crucial effector of
lineage commitment and terminal differentiation programs.
The disruption of these programs has been shown to be
oncogenic in several cellular contexts. For instance, C/EBPa is
a consensual tumor suppressor in acute myeloid leukemia
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where deleterious mutations have been described in a pro-
portion of cases.9 C/EBPa may also have a role in other
cancer models10 such as lung cancer, where it was found
downregulated by methylation.11,12 However, the expression
pattern and functional relevance of C/EBPa in normal sto-
mach and in GC has never been described.
In this study, we characterized the expression of C/EBPa
in the normal gastric mucosa and in GC. Furthermore, we
investigated the effects of expressing C/EBPa in GC cells, and
aimed at clarifying the link between pathways of C/EBPa
modulation and gastric carcinogenesis.
MATERIALS AND METHODS
Tissue Material
Surgical specimens from 54 GC were resected and diagnosed
at Hospital S. Joa˜o/Faculty of Medicine, Porto, Portugal.
Tissue fragments were fixed in 10% formaldehyde and
embedded in paraffin. Serial sections of 3 mm were obtained
from each block and used for routine staining with hemato-
xylin and eosin and immunohistochemistry.
The procedures followed in this study were in accordance
with the institutional ethical standards. All the samples enrolled
in this study were delinked and unidentified from their donors.
Immunohistochemistry
Tissue sections were first treated with 10mmol/l citrate
buffer (pH 6.0) for 40min at 991C. Unspecific endogenous
peroxidase activity was eliminated with a Hydrogen Peroxide
Block solution (Labvision, UK) for 10min. After washing,
slides were incubated with monoclonal mouse antibody
anti-C/EBPa (1:300, Cell Signaling Technology, MA, USA) or
C/EBPb (1:100, Santa Cruz Biotechnology, CA, USA) 1 h at
room temperature (RT). Sections were then washed and in-
cubated with Dako Real Emvision/HRP Rabbit/Mouse solu-
tion (DAKO, Denmark) for 30min (RT). The slides were
then developed for 10min in Dako Real diaminobenzidine
(DAB) (0.05%, DAKO) and sections counterstained with
hematoxylin, dehydrated, and mounted. For immuno-
fluorescence, after the primary C/EBPa antibody incubation,
sections were incubated with a biotinylated secondary anti-
body and signal was obtained with Alexa Fluor (Molecular
probes, Invitrogen, CA, USA) incubation.
For double TFF1 and C/EBPa staining, two independent
reactions were performed on the same slides. Sections were
blocked for 15min in 10% BSA with anti-mouse serum and
incubated overnight in monoclonal antibody anti-C/EBPa
(1:100, Cell Signaling Technology). After washing, samples
were incubated with anti-rabbit secondary antibody (1:200,
DAKO) for 30min and washed again. A final 1 h incubation
with avidine-biotin-peroxidase (1:100, DAKO) was per-
formed. Slides were then developed with DAB (DAKO). After
a washing step of 30min in PBS at 601C, slides were
again incubated overnight with monoclonal antibody
anti-TFF1 (1:100, Zymed, CA, USA) and developed with
alkaline phosphatase (DAKO) and Fast Red (Sigma-Aldrich,
MO, USA).
Slides were reviewed by a pathologist, tumors were classified
according to Laure´n, and the sections were semi-quantitatively
scored according to the intensity of staining when compared
with the positive control: intense staining was classified as III;
moderate intensity as II; and weak intensity or negativity as I.
Cases were classified as ‘downregulated’ when 450% of the
tumor cells were classified as I. All washing steps were per-
formed in PBS buffer. Normal gastric mucosa was used as a
positive control, and negative controls were performed by
substitution of the primary antibody with immunoglobulins of
the same class and concentration.
Cell Culture, Transfections, and Blotting
AGS and MKN28 cells were grown in RPMI medium with
10% FBS (GIBCO, Invitrogen, CA, USA). AGS cells were
grown until 60–80% confluence in six-well plates, and then
transfected using 3 mg of Plenti-C/EBPa expression vector
with an appropriate TFX-50 (Promega, WI, USA) con-
centration and volume. For western blot analysis, cells were
scrapped in PBS and then lysed in RIPA buffer with protease
and phosphatase inhibitors. A measure of 40 mg of total
protein were loaded into acrylamide gels and separated
by electrophoresis. The proteins were then transferred to
Hybond membranes (Amersham Biosciences, UK). For dot
blot, 20 mg of denatured protein extract were directly pipeted
into Hybond membranes. After blocking, blots where
incubated 1 h with primary antibodies anti-C/EBPa (1:100,
Cell Signaling), anti-P27 and anti Cyclin D1 (1:100, Santa
Cruz Biotechnology), anti-tubulin (1:15 000, Sigma-Aldrich),
and in the case of the dot blot with anti-TFF1 (1:100, Zymed)
in PBS plus 5% non-fat dried milk and 0.5% tween-20. The
blots were then washed three times in the same solution and
incubated 45min with an HRP-conjugated secondary anti-
body (1:1000, Santa Cruz Biotechnology) in PBS 0.5%
tween-20. Blots were then washed three times in PBS 0.5%
tween-20 and signal was detected with chemiluminescence
using ECL (Amersham Biosciences). For MAPK inhibition
experiments, MKN28 cells were grown until 50–60% con-
fluence and treated for 24 h with 10 mM SB239063 or
PD98059 (Sigma-Aldrich).
BRDU Incorporation Assay and Immunocytochemistry
AGS cells were harvested in 24-well plates with glass slides,
and transfected using TFX50 (Invitrogen) with empty vector
and full-length C/EBPa expression vectors in OPTIMEM
medium (GIBCO). After 1 h, complete RPMI medium was
added and cells were left growing for 48 h. MKN28 cells were
grown in six-well plates with glass slides and treated with
MAPK inhibitors as described above. After incubating 1 h in
5-bromo-20-deoxy-uridine (BRDU), cells in the glass slides
were fixed in 4% paraformaldehyde, washed with PBS
two times, and quenched by incubation with 2M HCl for
20min. After washing, slides were incubated with anti-BRDU
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antibody (1:100, DAKO) for 1 h. For simple immuno-
cytochemistry, MKN28 cells treated and untreated with
MAPK inhibitors were blocked in PBS with 4% BSA and
incubated in C/EBPa (1:100, Cell Signaling) antibody for 1 h.
In both procedures, cells were finally incubated with
secondary anti-mouse FITC (1:100, DAKO)-conjugated anti-
body for 30min. After washing, cells were mounted in
vectashield (Vector Laboratories) with DAPI blue and scored
for BRDU incorporation or C/EBPa expression on a fluor-
escence microscope.
Inhibition of C/EBPa by siRNA
MKN28 cells were grown until 50% confluence and pre-
incubated in serum-free medium. The appropriate anti-
C/EBPa target sequence (100 nM) as well as scrambled control
siRNA (Qiagen) were mixed with Metafectene (Biontex
laboratories GmbH, Germany) in serum-free medium, in-
cubated for 20 min and added to the cells. After overnight
incubation, the medium was changed to complete RPMI and
cells left to grow for 48 h, after which BRDU incorporation and
protein expression analyses were performed.
Statistical Analysis
Comparison of GC cases regarding their clinicopathological
features was performed using Fisher’s and w2 test. Three
independent measurements were performed for the BRDU
incorporation experiments and results were compared by
Student’s t-test.
RESULTS
Immunohistochemical Analysis of C/EBPa Expression
In the normal mucosa of the stomach, C/EBPa staining
was mostly nuclear with some residual cytoplasmic positivity
and mostly localized in the mucous surface epithelium
(Figure 1a). This expression pattern contrasts with that of
C/EBPb whose expression is concentrated to the neck zone
Figure 1 C/EBP expression in normal gastric mucosa. (a) C/EBPa immunostaining in non-neoplastic mucosa, showing strong expression in the superficial
epithelium. (b) C/EBPb expression in normal gastric mucosa of the antrum, showing strong localization in the neck zone. (c) C/EBPa immunofluorescence,
showing expression in differentiated gastric foveolae, and few positive cells toward the neck zone. (d) C/EBPa (brown) and TFF1 (red) double staining,
showing co-expression of the two proteins in gastric foveolae.
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(Figure 1b). This expression pattern was confirmed using
immunofluorescence, where C/EBPa staining was again
found to be stronger in the foveolar and surface epithelium,
with fewer positive cells observed in the neck zone
(Figure 1c). As described earlier, infiltrating inflammatory
cells were also found to express C/EBPa. To confirm that
C/EBPa expression does correlate with the differentiation
status of the gastric epithelium, we performed double stain-
ing with TFF1, a well-established gastric differentiation
marker. A clear overlap was observed between TFF1 and C/
EBPa in the surface epithelium (Figure 1d).
Similarly to what was observed in the normal gastric
mucosa, in GC C/EBPa staining was mostly nuclear with
some residual cytoplasmic positivity (Figure 2a). In GC, C/
EBPa was considered downregulated in 30% of the tumors
(Figures 2b–d). No statistical significant relationships were
found between C/EBPa expression and any clin-
icopathological features of the cases (Table 1).
Effect of C/EBPa Expression on Cell Proliferation and
Differentiation
To assess the effect of C/EBPa on the proliferation status of
GC cells, we transfected the C/EBPa-negative GC cell line
AGS with an expression vector for the full-length C/EBPa
gene and measured the incorporation of BRDU after 48 h. We
observed that re-expression of C/EBPa on AGS cells led to a
15% reduction (P¼ 0.001) in cell proliferation in compar-
ison with the control (Figure 3a). Conversely, inhibition of
C/EBPa by siRNA in the MKN28 cell line led to an increase
(Po0.001) in cell proliferation in comparison with the
control (Figure 3b).
To confirm this inhibitory effect of C/EBPa on prolifera-
tion, we analyzed by western blotting the expression of
two cell-cycle proteins typically associated with the control
of gastric epithelial cell division. We observed decreased
expression of Cyclin D1, a cell-cycle inductor, and increased
expression of P27, a cyclin-dependent kinase inhibitor
(Figures 4a and c). Both these changes are consistent with an
inhibitory effect on proliferation.
The results on the effect of C/EBPa on proliferation, to-
gether with its expression pattern in the normal gastric
mucosa, suggested C/EBPa to have a role both on pro-
liferation arrest and on the differentiation of gastric epithelial
cells. That being the case, increased expression of TFF1 would
be expected in the presence of higher levels of C/EBPa. In
accordance with this hypothesis, after transfection of AGS
Figure 2 C/EBPa staining in intestinal-type GC. (a) C/EBPa positive tumor. (b) Tumor showing complete loss of C/EBPa expression. (c) GC displaying
downregulation of C/EBPa expression (positive cells to the right are located in non-neoplastic gastric epithelium). (d) GC negative for C/EBPa expression.
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cells with the C/EBPa expression vector, we observed an
increase in the expression of TFF1 (Figures 4b and c).
Effect of MAPK Inhibitors on the Expression of C/EBPa
and Cell Proliferation
The Ras/MAPK signaling pathway is one of the most con-
sistently altered in human cancers. In GC, the Ras/MAPK
pathway is constitutively activated through mutation of several
of its receptors and signal-transducing members.13 To explore
the possibility of C/EBPa regulation by the Ras/MAPK pathway
in GC, we treated MKN28 cells, which express C/EBPa, with
specific p38 (SB239063) and ERK1/2 (PD98059) inhibitors.
Treatment with both inhibitors led to a marked increase in
C/EBPa expression and nuclear localization as detected by
immunocytochemistry (Figure 5). This increase in C/EBPa ex-
pression was further confirmed by western blotting, and shown
to be accompanied by an increase in TFF1 expression (Figures
6a and c). Concomitantly, we observed a decrease in cell pro-
liferation by BRDU incorporation (Figure 6b) both in cells
treated with p38 inhibitor (P¼ 0.009) and in cells treated with
ERK1/2 inhibitor (P¼ 0.003). This decrease in proliferation was
accompanied by a decrease in Cyclin D1 expression (Figure 6c).
Table 1 Relationship between the clinicopathological features
of GC and C/EBPa expression scoring
C/EBPa downregulation
No. of cases (%) Yes No P-value
Age (years)
r40 2 (4) 1 (50) 1 (50) NS
40–65 18 (36) 2 (11.1) 16 (88.9) NS
Z65 30 (60) 12 (40) 18 (60) NS
Gender
Male 30 (60) 11 (36.7) 19 (63.3) NS
Female 20 (40) 4 (20) 16 (80) NS
Histological type
Intestinal 27 (54) 11 (40.7) 16 (59.3) NS
Diffuse 16 (32) 1 (6.3) 15 (93.7) NS
Atypical 7 (14) 3 (42.9) 4 (57.1) NS
Depth of invasion
T1 2 (4) 0 (0) 2 (100) NS
T2 26 (52) 10 (38.5) 16 (61.5) NS
ZT3 22 (44) 5 (22.7) 17 (77.3) NS
Vascular invasion
Absent 15 (30) 5 (33.3) 10 (66.7) NS
Present 35 (70) 10 (28.6) 25 (71.4) NS
Metastasis
Absent 12 (24) 6 (50) 6 (50) NS
Present 38 (76) 9 (23.7) 29 (76.3) NS
Total 50 (100) 15 (30) 35 (70)
NS, non-significant.
Cases are classified according to the intensity and percentage of positive cells.
Cases classified as ‘downregulated’ present450% of tumor cells classified as I.
Figure 3 BRDU incorporation assay in GC cells. (a) Decreased proliferation
rates of C/EBPa-transfected AGS cells in comparison with the control
(P¼ 0.001). (b) C/EBPa inhibition by siRNA leads to increased BRDU
incorporation in MKN28 cells. In all, 1000 cells were counted and BRDU
incorporation expressed as the rate between DAPI and BRDU positive cells.
The y axis represents the % of BRDU positive cells. Error bars represent s.d.
Tubulin was used as protein-loading control.
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Figure 4 Effect of C/EBPa expression on AGS cells. (a) Western blot for cell-cycle proteins, showing increased P27 and decreased cyclin D1 expression after
transfection with C/EBPa. (b) Dot blot showing increased TFF1 expression in C/EBPa-transfected cells. (c) Expression of C/EBPa, cyclin D1, p27, and TFF1
shown as ratios to loading controls. Error bars represent s.d. *represents statistically significant differences between mock- and C/EBPa-transfected cells.
Figure 5 Treatment of MKN28 cells with p38 (SB) and ERK1/2 (PD) inhibitors leads to an increase in C/EBPa expression with nuclear localization. C/EBPa is
stained green with FITC and nuclei are stained blue with DAPI for contrast.
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DISCUSSION
We have shown that C/EBPa is expressed in the differentiated
epithelial compartment of the superficial gastric mucosa.
This expression pattern mirrors that described for C/EBPb,
which is expressed in the proliferative neck zone of the
normal gastric mucosa. We have previously argued that
C/EBPb may have a role in maintaining a balance between
proliferation and differentiation in the normal gastric
mucosa.3 In the proposed model, C/EBPb would have a pro-
proliferative activity in gastric epithelial stem-like cells. The
presence of C/EBPa in differentiated cells, together with its
ability to reduce cell proliferation and to upregulate the
gastric differentiation marker TFF1, suggest that C/EBPb
and C/EBPa may have complementary roles in maintaining
a balance between proliferation and differentiation in the
normal gastric mucosa. By analogy to the model of adipo-
genesis,6 one feels tempted to speculate that C/EBPb is
expressed in gastric epithelial stem-like cells and may
prime gastric epithelial cells to differentiate by inducing
C/EBPa expression. Once active, C/EBPa would reduce
cell proliferation, and promote the expression of gastric
differentiation markers such as TFF1.
C/EBPa was first described as a tumor suppressor gene in
acute myeloid leukemias. In normal hematopoiesis, C/EBPa
has a key role in defining cell lineages through interaction with
other transcription factors. C/EBPa disruption by mutation
leaves bone marrow cells in an undifferentiated, hyperproli-
ferative state being this event causal for a large percentage of
leukemias.14 Downregulation of C/EBPa was additionally
found in several epithelial tumor types, namely lung, breast,
and skin carcinomas.11,12,15,16 In all these examples, a role for
impaired C/EBPa function in tumourigenesis was strengthened
by the observation that C/EBPa re-expression is able to inhibit
tumourigenesis both in vivo and in vitro.15,16
In our study, we observed downregulation of C/EBPa in
about 30% of GC cases. In an earlier study, we have described
a frameshift mutation of C/EBPa in a GC. This mutation was
deleterious and absent from adjacent non-neoplastic tissue.17
These results in the GC model are in keeping with the
aforedescribed role of C/EBPa in tumourigenesis, whereby
loss of C/EBPa would be associated to loss of differentiation
and sustained proliferation of tumor cells. On top of C/EBPa
loss of expression, we have shown earlier that C/EBPb is
over-expressed in cells retaining a proliferative phenotype
such as those seen in dysplastic and cancer lesions. C/EBPb is
able to counteract, either by heterodimerization or repres-
sion of expression, the differentiating activity of C/EBPa.
Altogether, either aberrant over-expression of C/EBPb or loss
of expression of C/EBPa are present in the majority of GC
cases. Hence, these results suggest that changes in expression/
function of both C/EBPa and C/EBPb may be pieces of
the same puzzle rather than independent events in gastric
carcinogenesis. This possibility, together with other putative
mechanisms of post-translational or protein–protein inter-
action, would help explaining why expression of C/EBPa is
still seen in about 70% of GC cases.
Figure 6 Effects of the treatment of MKN28 cells with a p38 (SB) and an ERK1/2 (PD) inhibitor in cellular proliferation and differentiation.
(a) Western blot showing that treatment of MKN28 cells with SB and PD leads to an increase in C/EBPa and TFF1 expression and to a decrease in Cyclin
D1 levels. (b) Decrease of cell proliferation by BRDU incorporation assay of MKN28 cells treated with SB (P¼ 0.009) and PD (P¼ 0.003) inhibitors.
(c) Expression of C/EBPa, cyclin D1, and TFF1 shown as ratios to loading controls. Error bars represent s.d. *represents statistically significant differences
between treated and non-treated cells.
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In other cancer models, loss of C/EBPa has been linked
with oncogenic Ras activation.16 In GC, activating RAS
mutations do occur in a subset of microsatellite unstable
tumors.13 By using specific inhibitors for p38 and ERK1/2,
both downstream effectors of Ras signaling, we were able to
show that inhibition of C/EBPa expression was dependent on
the activation of this pathway. Moreover, inhibition of p38
and ERK1/2 increased TFF1 expression and strongly reduced
MKN28 cell proliferation and Cyclin D1 levels, in a set
of alterations most likely linked with the observed increase in
C/EBPa expression.
In summary, we show that in normal gastric mucosa,
C/EBPa is expressed mainly in the differentiated foveolar
epithelium where it co-localizes with TFF1. We show that
C/EBPa is downregulated in a considerable percentage of
GC. We additionally show that C/EBPa re-expression in a
C/EBPa-negative cell line leads to a reduction in proliferation
that is accompanied by an increase in P27 and reduction
of cyclin D1 levels. In parallel, we show an increase in the
expression of TFF1 in C/EBPa-transfected cells. Finally,
we show that treatment of a C/EBPa expressing cell line
with MAPK inhibitors leads to increased C/EBPa and TFF1
expression, and a concomitant reduction on cell proliferation
and Cyclin D1 expression. Overall, these results substantiate
the role of the C/EBP transcription factor family in homeo-
stasis of the gastric epithelium and in the process of gastric
carcinogenesis.
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Abstract 
 
Background: The transcription factor C/EBPβ represents a central hub in cell 
differentiation/proliferation control and is overexpressed in gastric cancer. 
Here we aim at understanding the relevance of C/EBPβ expression to gastric 
homeostasia and tumorigenesis, and to unravel novel related molecular 
pathways in gastric carcinogenesis. 
Methods: C/EBPβ and Runx3 single and double knockout mice. Cross-
species gene expression profiling with human gastric cancer samples and 
mouse knockout stomachs. ShRNA-based knockdown of C/EBPβ expression 
in gastric cancer cells.  
Results: We show that the murine C/EBPβ knockout stomach displays 
changes in the homeostatic balance between cell differentiation and 
proliferation. Tumorigenesis was suppressed by knockdown of C/EBPβ in 
human-murine xenograft tumor models and by C/EBPβ deletion in a mouse 
model of gastric hyperproliferation. Cross-species comparison of gene 
expression profiles revealed a subset of tumors that are characterized by a 
strong C/EBPβ-regulation. Within this tumor set expression signature the 
tumor suppressor RUNX1t1 was identified, and shown to be downregulated in 
38% of gastric tumors. Finally we show that the tumor suppressor activity of 
RUNX1t1 is mechanistically connected to C/EBPβ functions in gastric cancer 
cells 
Conclusions: C/EBPβ expression is confirmed as being mandatory for 
gastric cancer cell proliferation, and a new C/EBPβ-related tumor suppressor 
gene, RUNX1t1 is identified, as well as of a subset of gastric cancer with a 
clear genetic signature and a potential molecular mechanism.  
 
Keywords: C/EBPβ; Gastric Cancer; Transcription factor; RUNX1t1; 
proliferation 
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Background 
Gastric cancer is among the leading causes of death by cancer worldwide, yet 
the molecular pathways in the etiology of gastric cancer remain elusive  [1]. 
The majority of the gastric tumors belong to the intestinal sub-type, 
characterized by expansive growth and maintenance of a glandular structure. 
Diffuse-type gastric cancer is associated with loss of the adhesion protein E-
Cadherin, however, despite the predominance and histological coherence of 
the intestinal type of gastric cancer no central common molecular pathway 
has been convincingly shown as aberrantly regulated [2-4]. 
The transcription factor C/EBPβ has been suggested to play a pro-oncogenic 
role [5-14]. In intestinal-type gastric cancer, C/EBPβ is highly expressed and 
associated with both, enhanced Cyclooxygenase-2 (COX2) expression and 
loss of the mucous-associated protein Trefoil Factor 1 (TFF1) [15, 16] [17-20]. 
Mice that over-express COX2 or are deficient for TFF1 develop gastric tumors, 
underscoring the destabilizing potential of the enhanced expression of 
C/EBPβ in gastric carcinogenesis [21, 22]. Nevertheless, a causal role of 
C/EBPβ in the development of gastric cancer has never been determined.  
Here, we examined the functions of C/EBPβ in the murine stomach. Our 
results show that C/EBPβ controls the balance between proliferation and 
differentiation in the murine stomach. C/EBPβ expression is also mandatory 
for hyperproliferation in the RUNX3 KO mucosa. Cross-species analysis of 
gene expression between mouse C/EBPβ KO stomachs and human gastric 
cancer identified a C/EBPβ regulated gene signature in a sub-group of 
intestinal-type tumors. Within this signature, RUNX1t1 stood out as a potential 
tumor suppressor. RUNX1t1 inhibits C/EBPβ functions and ectopic 
expression of RUNX1t1 reduced pr oliferation in gastric cancer cell lines. The 
RUNX1t1 promoter was found to be frequently hypermethylated in human 
gastric cancer cases. Our data suggest C/EBPβ activation and RUNX1t1 
silencing as important events in the process of gastric carcinogenesis. 
 
 
5 
 
Methods 
 
Human gastric cancer samples and microarray data  
Human tissue samples were derived from patients that had undergone 
resection for sporadic gastric adenocarcinoma at the Robert Roessle Hospital 
(1995–2003). The selection of samples, the procedure for histological 
classification and staging, the second blinded evaluation by an independent 
pathologist including assessment of tumor content in the pieces that RNA was 
extracted from, as well as RNA extraction and microarray procedure has been 
described elsewhere [25]. 
 
Transgenic mice 
C/EBPβ knockout (KO) animals were previously established in C57-Bl6 
background [36]. Bl6 RUNX3 KO mice were obtained from the group of Prof. 
Ito [26], and crossed with C/EBPβ KO mice. Due to the lethal phenotype of 
the single RUNX3 KO, C/EBPβ/RUNX3 heterozygote animals were bred and 
the phenotype analyzed in the offspring at birth. Animals were bred and kept 
according to the institutional guidelines, and genotyped by PCR as previously 
described [26, 36].  
 
C/EBPβ knockdown cells and in vivo tumorigenic assay 
MKN45 and MKN74 cells were infected with lentivirus containing GFP-tagged 
control shRNA and shRNA against C/EBPβ. Knockdown efficiency was 
assessed by Western Blot and proliferation was measured by BrdU 
incorporation assay. The effect of C/EBPβ expression on tumor formation was 
examined by subcutaneously implanting 3 × 106 cells of both control 
MKN74/45 and ShRNA-mediated C/EBPβ-silenced MKN74/45 into 6-8-week-
old male NIH(s) II-nu/nu nude mice, four mice per group. The animals were 
monitored weekly for tumor formation for 20 days after inoculation. Tumor 
sizes in two dimensions were measured with calipers, and volumes were 
calculated with the formula (a × b2) × 0.5, wherein “a” is the long axis and “b” 
is the short axis (in millimeters). Mice were maintained and sacrificed 
according to institutional guidelines, and at termination of the experiment 
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tumors were excised, fixed, embedded and analyzed by 
immunohistochemistry for Ki67 and C/EBPβ expression.  
 
Co-immunoprecipitation  
Flag-tagged RUNX1t1 was expressed in MKN28 and MKN45 cell lines. Cells 
were harvested and lysed in buffer containing 50 mM Tris pH 8, 1 mM EDTA, 
150 mM NaCl, 0.2% NP-40, 5 mM MgCl2, 50 µM, ZiCl2 and protease inhibitor 
cocktail (Roche®). Protein lysates were incubated at 4 °C with Protein A 
sepharose beads (Sigma®) for 1h. Beads were then washed 4 times in lysis 
buffer and examined by Western Blot analysis.  
 
Immunohistochemistry 
Stomachs were obtained from three month-old C/EBPβ knockout (KO) mice, 
and newborn C/EBPβ -, RUNX3 - and compound C/EBPβ/RUNX3 KO 
animals. Stomachs were longitudinally excised, formalin-fixed and embedded 
in paraffin. Gastric cancer tissue microarrays were obtained as described 
elsewhere [37]. 
Serial sections were obtained, deparaffinized and stained with Hematoxylin 
and Eosin, examined by a pathologist, and measured. An additional group of 
sections were treated with 2M (I always use 10mM) citrate buffer and stained 
with 1:100 anti-Ki67 (DAKO), 1:500 anti-C/EBPβ,1:50 anti-TFF1 (Santa Cruz 
Biotechnology), or 1:500 anti-RUNX1t1 (Sigma®) antibody. After washing with 
PBS with 0.02% Tween and incubation with horseradish peroxidase-bound 
secondary antibody (GE Healthcare®) development was performed using di-
amido-benzidine.  
 
BrdU assay  
Cells with stable C/EBPβ knockdown were sorted and plated to 40% 
confluence. Cells were also transfected with RUNX1t1 and analyzed for BrdU 
incorporation after 48 h. Briefly, cells were incubated with 1M Bromo-deoxy-
uridine for 20 min. and then trypsinized and harvested in ice-cold PBS. Cells 
were then fixed, permeabilized, and stained with fluorescent anti-BrdU 
antibody according to the APC-BrdU flow kit protocol (BD Biosciences®). 
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Dead cells were stained with 7-AAD and BrdU-positivity was then assessed 
by flow cytometry.  
 
Total RNA extraction, cDNA synthesis and quantitative real-time PCR  
For RNA extraction from mouse tissue, stomach sections were frozen in liquid 
nitrogen after excision, and finely grinded in a mortar. For RNA extraction 
from gastric cancer cells, these were harvested in ice-cold PBS and pelleted 
at 2000 rpm. Lysis buffer was then added to the obtained powder or to the 
pellet which was then vigorously resuspended using a 3ml syringe. RNA was 
extracted using a universal RNA extraction kit (Roboklon®). RNA was 
quantified, cDNA synthesized by standard methods and SYBER green 
quantitative real-time PCR performed (see supplementary table 4 for primer 
sequences). 
 
Plasmids  
For the construction of C/EBPβ isoform expression vectors, LAP*, LAP and 
LIP were cloned from human cDNA by PCR, following digestion with 
restriction enzymes, ligation into pcDNA3-flagged plasmid and ampicillin 
selection. TFF1-luciferase reporter plasmid was similarly cloned from human 
cDNA into a pGL3-basic plasmid. RUNX1t1 expression plasmid (pCMV-
3xFlag-ETO) was obtained from ADDGENE® (ref: #12507).  
For the construction of C/EBPβ knockdown vectors, shRNA (5’-
gccgcgacaaggccaagatgc-3’) was inserted into a pLVTH-M lentivral vector.  
 
Tissue culture, transfection, and luciferase assays 
MKN28, MKN45 and MKN74 cell lines were grown in RPMI medium (Gibco®). 
For transfection, cells were trypsinized, seeded, and grown to 50-60% 
confluence. C/EBPβ isoform plasmids and/or RUNX1t1 plasmid were 
resuspended in serum-free medium with transIT (Myrus®) transfection 
reagent and added to the cells. Protein and RNA were extracted after 48 h 
and analyzed by Western Blot and real-time PCR.  
 
RUNX1T1 promoter methylation analysis 
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Methylation analysis of the RUNX1t1 promoter was determined by 
methylation-specific PCR (MSP), as previously described [31]. MSP method 
distinguishes unmethylated from methylated alleles in a given gene based on 
sequence changes produced after bisulfite treatment of DNA, which converts 
unmethylated but not methylated cytosines to uracil. Subsequently, PCR 
using primers specific to either methylated or unmethylated DNA was 
performed. Genomic DNA (350ng) was bisulfite-treated and purified with EZ 
DNA Methylation Kit Gold (Zymo Research, CA, USA®). The primer 
sequences of RUNX1t1, for both methylated and unmethylated reactions were 
as previously described [31]. 100ng of bisulfite-modified DNA was used in 
each PCR. Amplification was carried out for 36 cycles (30 s at 95 °C, 30 s at 
56 °C, and then 30 s at 72 °C). Control PCRs lacking genomic DNA were 
performed for each set of reactions. Amplified products were separated by 
electrophoresis in a 2.5% agarose gel.  
 
Electrophoretic Mobility Shift Assay (EMSA) 
MKN28 and MKN45 cells were transfected with increasing amounts of 
RUNX1t1. Nuclear extracts were prepared from transfected cells, quantified, 
and incubated with previously radioactively labeled (α-32P dCTPs) 
nucleotides, containing an optimized C/EBPβ binding sequence. 
Protein/Labeled-DNA complexes were then run in a 15% acrylamide gel in 
non-denaturing conditions and binding intensity assessed by intensity of 
radioactive signal. Anti-C/EBPβ antibody was added to the protein/labeled-
DNA complex as a control, and a supershift was observable, confirming that it 
was C/EBPβ what bond to DNA. Competition with non-labeled C/EBPβ 
binding sequence, confirmed the specificity of the observed signal.  
 
Bioinformatic microarray data analysis and statistical analysis  
The raw data files (.text files for murine Agilent Technologies® arrays and .cel 
files for human Affymetrix GeneChips®) were imported into GeneSpring GX 
12.1 software (Agilent Technologies®) as two separate species-specific 
experiments. All subsequent microarray data analyses were performed using 
this software. Preprocessing (background correction, normalization and probe 
summarization) was performed according to the RMA algorithm followed by 
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baseline transformation to the median of all samples (in one experiment). 
Quality control was done by assessment of inter-array correlation analysis 
calculating the correlation coefficient of each array to every other one. By this 
means, one array of the murine gene expression experiment was identified to 
show relatively weak correlation to most of the other samples and thus 
excluded from further analysis. The human arrays yielded correlation 
coefficients between 0.829 and 0.972, with an arithmetic mean of 0.917 and 
the murine arrays between 0.991 and 0.924 with a mean of 0.9. In the murine 
array experiment, only probes owning “detected” flags in at least 3 arrays 
(34,150 probes) were used for further analyses. Genes whose expression 
between groups of samples was significantly different were identified by 
Welch-test with p≤0.01 being the significance cut-off. The fold change (FC) of 
expression between groups was calculated as the fold difference between 
group means. Gene annotation information was obtained from GeneSpring 
GX software (state of 08/2012). For hierarchical clustering, ‘Euclidean 
distance’ and ‘complete linkage’ were used as distance metric and linkage 
algorithm. The migration of genes between the murine and human microarray 
experiment was performed using the Orthology Search Tool of bioDBnet 
athttp://biodbnet.abcc.ncifcrf.gov/. 
Microarray data is available at: 
 http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE59585 
 
 
Results  
 
C/EBPβ knockdown reduces the tumorigenic potential of gastric cancer 
cells  
C/EBPβ expression in gastric cancer was evaluated by real-time PCR, and 
shown to be enhanced predominantly in intestinal-type gastric cancer (Figure 
1A), confirming the previously published data [15,16]. The functional 
importance of high C/EBPβ expression in gastric cancer was examined by 
stable knockdown in human gastric cancer cell lines using a viral-based GFP-
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tagged short hairpin RNA. C/EBPβ-isoform knockdown efficiency in two cell 
lines approximated 70%, as confirmed by protein immunoblotting (Figure 1B). 
Proliferation in two cell lines (MKN74, MKN45) were examined by BrdU 
incorporation and, as shown in Figure 1C, proliferation of both cell lines was 
reduced after C/EBPβ knockdown.  
The tumorigenic potential of both cell lines, before and after C/EBPβ 
knockdown, was compared by xenotransplantation in immune-compromised 
mice, as shown in Figure 1D. Equal numbers of freshly sorted control and 
knockdown MKN74 or MKN45 cells were injected. Twenty days post-injection, 
C/EBPβ knockdown cells formed markedly smaller tumors than parental cells, 
with less weight and volume (Figure 1D). The difference was more 
pronounced in MKN74 than in MKN45 cell line. Ki67 staining showed 
reduction of cell proliferation in tumors originating from C/EBPβ knockdown 
cells in comparison to controls (Figure 1C). Interestingly, proliferation in 
tumors was accompanied by re-expression of C/EBPβ and, in tissue culture 
knockdown cells required frequent sorting to prevent overgrowth of cells that 
regained C/EBPβ expression, suggesting selection for C/EBPβ re-expression. 
These results show that C/EBPβ plays an important role in gastric cancer cell 
proliferation.  
 
C/EBPβ knockout mice display imbalanced differentiation/proliferation 
of the gastric mucosa 
Analysis of nullizygous C/EBPβ stomachs (n=5) revealed a small but 
significant (p<0.001) reduction in the thickness of the antral gastric mucosa 
and diminished numbers of Ki67-positive cells, as compared to the wild type 
(WT) (n=8). No other histological abnormalities were observed, being the 
corpus region from the knockout largely indistinguishable from the WT. To 
gain further insight into the causes of reduced mucosa thickness, expression 
of cell cycle-related genes and apoptosis rates were examined. As shown in 
Figure 2C, reduction of Ki67 and of proliferating cell nuclear antigen (PCNA) 
in the KO antral mucosa was evident by quantitative PCR (qPCR) in 
accordance to histological observations. Additionally, reduced expression of 
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Cyclin A1, Cyclin D3 and Cyclin E1, and increased expression of the CDK 
inhibitor p15 was found. Apoptosis rate of the C/EBPβ KO mucosa, as 
revealed by TUNEL assay, showed enhanced cell death in C/EBPβ KO mice 
(n=5) compared to WT (n=8) (supplementary Figure 1A) and qPCR 
expression analysis showed decreased expression of BCL2 and BIRC5 
(survivin) (supplementary figure 1B).  
C/EBPβ has previously been suggested to repress the gastric differentiation 
marker and tumor suppressor TFF1 [23, 24]. Similarly to human gastric 
mucosa, expression of TFF1 was excluded from proliferating cells of the neck 
zone in murine WT gastric epithelium and expression of C/EBPβ and TFF1 
was mutually exclusive (Figure 2D, upper panel). Increased expression of 
TFF1 in C/EBPβ KO mucosa was confirmed by qPCR, similar to the gastric 
differentiation marker MUC5AC (Figure 2D, lower panel). Taken together, 
these data confirmed a general repressive role of C/EBPβ on gastric 
differentiation genes expression [23, 24] and regulation of apoptosis in the 
normal gastric mucosa.  
 
Cross-species gene expression profiling reveals a subset of intestinal-
type gastric tumors with a C/EBPβ regulated signature 
The apparent similarities between human and murine gastric C/EBPβ biology 
raised the question whether the homeostatic and oncogenic C/EBPβ-
dependent proliferation share common molecular mechanisms. We therefore 
compared the gene expression profiles derived from C/EBPβ KO mice with 
previously analyzed human gastric adenocarcinoma samples [25].  
Differentially expressed genes between the C/EBPβ KO (n=5) and WT (n=4) 
mice were identified by Welch-test. Significance in differential expression was 
accepted at p≤0.01 and a fold change (FC) of larger than >1.5. These cut-off 
criteria yielded 171/25 annotated/non-annotated unique transcripts 
(represented in 233 probes) as upregulated in the C/EBPβ KO and 79/12 
annotated/non-annotated unique transcripts (represented in 135 probes) as 
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downregulated (supplementary Table 1 and 2 show the 20 most significantly 
regulated genes).  
Next, the combined list of up- and downregulated genes (FC>1.5, p≤0.01) 
derived from the C/EBPβ KO mouse profiling data was used to cluster human 
gastric cancer microarray samples. The resulting gene expression heatmap 
suggested that the majority of genes did not show any overt deregulation in 
human cancers (whitish spots in heatmap). However, a group of genes 
showed explicit regulation (indicated by dark bluish and reddish spots in the 
heatmap) across the human cancer samples (Supplementary Figure 2, 
regulated gene cluster, indicated by box). Genes contained in this subset 
were then used to re-cluster the human cancer samples. The resultant cancer 
sample dendrogram and expression heatmap (Figure 3) revealed a group of 
cancer samples (Figure 3, black box) that exhibit downregulation of the 
majority of these genes. The group consisted of 16 of the original 59 (≈27%) 
samples and contained primarily cancers of the intestinal histological type. 
Importantly, genes downregulated in this particular cancer subgroup are 
mostly upregulated in the C/EBPβ KO gastric mucosa (changes ranging from 
1.5 to 2.3 fold; Table 1), identifying them as C/EBPβ repressed genes.  
In order to validate the results obtained by microarray comparison, we 
selected three C/EBPβ repressed genes, FOG2, SPARCL1, and RUNX1t1, 
and analyzed their expression by qPCR. Examination of WT and C/EBPβ KO 
stomach confirmed upregulation of these genes in the gastric mucosa of 
C/EBPβ KO mice (5 animals/group; supplementary figure 3B). It was also 
important to examine the expression of FOG2, SPARCL1, and RUNX1t1 in 
normal human gastric mucosa as no normal tissue samples were available for 
the initial human gastric cancer microarray analysis [25]. As shown in 
supplementary Figure 3A, expression of all three genes was downregulated in 
intestinal-type gastric cancer in comparison to normal tissue, however, a 
subset of diffuse-type tumors overexpressed RUNX1t1, compliant with the 
different etiology of these tumors. 
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C/EBPβ expression is mandatory for the hyperplastic phenotype in the 
RUNX3 KO mice stomach 
The RUNX3 KO mouse is an established model of early gastric cancer 
initiation and hyperproliferation [26], although the mechanism underlying the 
RUNX3-deficient neoplastic phenotype remains under debate [27, 28]. As 
RUNX3 KO mice die shortly after birth, all the analysis was performed in 
newborn mice. As shown in Figure 4A, Ki67 staining confirmed increased 
proliferation of the epithelial stomach layer of newborn RUNX3-null mice and 
E-Cadherin staining confirmed the epithelial nature of the proliferating cells. 
Staining of serial longitudinal sections showed high expression and 
colocalization of C/EBPβ and Ki67 in the hyperproliferative gastric mucosa of 
the RUNX3 KO (Figure 4A). 
C/EBPβ null animals were crossed with RUNX3 KO mice to determine the 
functional contribution of C/EBPβ in the neoplastic RUNX3 KO stomach tissue. 
Analysis of the stomach tissue of single RUNX3 KO and the compound 
C/EBPβ/RUNX3 KO showed that in the double KO animals stomach wall 
thickness was reduced back to WT levels. Ki67 staining confirmed almost 
complete reversion of the hyperproliferative phenotype by removal of C/EBPβ 
in RUNX3 KO (Figure 4A and 4B) that was accompanied by a substantial 
increase in the number of apoptotic cells (supplementary Figure 4A and 4B). 
These results strongly suggest that expression of C/EBPβ is mandatory for 
the neoplastic gastric phenotype of RUNX3 deficient mice. 
In order to understand if downstream gene regulation associated with the 
reversion of gastric hyperproliferation by deletion of  C/EBPβ would reflect the 
gene signature we previously identified by cross species gene expression 
analysis, we compared expression of C/EBPβ target genes in RUNX3 KO and 
compound C/EBPβ/RUNX3 KO. Whereas mucosal expression of all three 
genes (FOG2, SPARCL1, RUNX1t1) was enhanced in C/EBPβ KO (data not 
shown) only RUNX1t1 also displayed reduced expression in the 
hyperproliferative RUNX3 KO mucosa. Importantly, RUNX1t1 expression was 
partially rescued by removal of C/EBPβ in the compound KO, as shown in 
Figure 4C, suggesting RUNX1t1 to be inversely correlated with C/EBPβ in 
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association with proliferation control. Indeed, transfecting C/EBPβ isoforms 
(LAP*, LAP and LIP) into MKN28 and MKN45 cell lines led to the repression 
of RUNX1t1 expression (Figure 4D), further suggesting C/EBPβ mediated 
repression of RUNX1t1.  
 
RUNX1t1 plays a tumor suppressive role in human gastric cancer and 
modulates C/EBPβ activity 
Expression of RUNX1t1 protein was evaluated by tissue microarray 
immunohistochemistry on 64 human gastric cancer samples. Nuclear staining 
was classified as strong, moderate, weak or absent, relative to the expression 
of RUNX1t1 in the normal mucosa (classified as moderate). From the 
analyzed tumors, 25 out of 64 (38%) showed weak or absent RUNX1t1 
protein staining (Figure 5A). To further assess whether C/EBPβ is responsible 
for downregulation of RUNX1t1 in gastric tumors, we selected tumor-RNAs 
showing reduced levels of RUNX1t1 (supplementary Figure 3A). The majority 
of cases (7 out of 10, Figure 5B), however, failed to show a convincing 
inverse correlation between low RUNX1t1 and high C/EBPβ expression, 
suggesting alternative means of RUNX1t1 downregulation in gastric cancer. 
Sequencing of RUNX1t1 from 26 gastric cancer patients failed to disclose 
mutations that would explain loss of RUNX1t1 protein (data not shown), 
however, analysis of the RUNX1t1 promoter by methylation-specific PCR 
revealed hypermethylation in the majority of the gastric cancer DNA samples 
(Figure 5C). Next, we examined the functional consequences of RUNX1t1 
downregulation in gastric cancer. As shown in Figure 5D, overexpression of 
RUNX1t1 in MKN28 and MKN45 gastric cancer cell lines led to decreased cell 
proliferation, as determined by BrdU incorporation. These data suggest that 
RUNX1t1 inhibits proliferation and is frequently downregulated in gastric 
cancer. 
RUNX1t1 has previously been reported to interact with C/EBPβ, to inhibit its 
DNA binding, and to block its pro-proliferative functions during the clonal 
expansion phase in adipogenic differentiation (Rochford et al, MCB 2004). 
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Ectopic expression of flag-tagged RUNX1t1 in MKN28 and MKN45 cell lines 
and subsequent immunoprecipitation showed that RUNX1t1 interacts with all 
endogenous C/EBPβ isoforms in both cell lines (Figure 5E). Electrophoretic 
mobility shift assay (EMSA) led to a dose dependent decrease of C/EBPβ 
binding to its DNA consensus sequence in both cell lines, although RUNX1t1 
did not significantly alter nuclear C/EBPβ expression (Figure 5F). These 
results suggest that the tumor-suppressive function of RUNX1t1 is 
mechanistically connected to the suppression of pro-oncogenic C/EBPβ 
functions.  
 
Discussion 
Our data suggest a causal function of C/EBPβ in the development of a subset 
of gastric tumours. Comparison of gene expression profiles from C/EBPβ KO 
mice and human gastric cancer samples provided mechanistic insight in 
C/EBPβ-related molecular mechanisms.  
Data presented here suggest that the function of C/EBPβ in gastric cancer is 
embedded in the homeostatic regulation of the gastric mucosa. Absence of 
C/EBPβ from the murine stomach shifts the balance from epithelial 
proliferation towards differentiation and apoptosis. Deregulation of pathways 
that sustain C/EBPβ functions such as inflammatory signals may favor 
uncontrolled proliferation and repression of differentiation genes such as 
TFF1 that ultimately promotes tumor development [22] 
C/EBPβ is mandatory for the hyperproliferative phenotype of the RUNX3 KO 
mice and for the tumorigenic potential of gastric cancer cell lines. Expression 
profiling data of human gastric cancer samples and comparison with C/EBPβ 
KO mouse-derived expression data identified a subset of tumors with a 
C/EBPβ-regulated signature. These tumors mostly belong to the intestinal 
type and may define a novel subtype. One of the deregulated genes 
characterizing this tumor cluster, RUNX1t1, has previously been connected to 
gastrointestinal abnormalities [29] and to suppression of C/EBPβ functions 
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[30] and was consistently downregulated in the murine RUNX3 KO tumor 
model. RUNX1t1 is also a candidate tumor suppressor in ovarian cancer [31] 
and loss of RUNX1t1 expression has been associated with metastasis in 
pancreatic cancer [32]. Downregulation of RUNX1t1 during homeostasis and 
initially in gastric cancer may occur through C/EBPβ, however, analysis of 
DNA methylation showed that the RUNX1t1 promoter was frequently 
methylated in human gastric cancer samples, similarly to ovarian cancer [31] 
and suggests alternative routes of RUNX1t1 gene silencing in gastric 
carcinogenesis.  
RUNX1t1, also known as MTG8 or ETO, is the recurrent t(8;21) translocation 
partner of the AML-ETO (RUNX1/MTG8) fusion protein. AML-ETO accounts 
for 15% of acute myeloid leukemia and 40% of M2-type leukemia, probably by 
interference with the differentiation inducing functions of C/EBPα and PU.1 
[33] [34]. Few reports have focused on RUNX1t1 independently of the AML-
ETO context, yet suggested involvement of RUNX1t1 in several corepressor 
complexes [34]. Our results support the notion of RUNX1t1 as a suppressor of 
gastric cancer development and suggest a regulatory loop between C/EBPβ 
and RUNX1t1 in homeostasis and disruption in cancer. High expression of 
C/EBPβ leads to reduction of RUNX1t1 expression and high RUNX1t1 
expression leads to the inhibition of C/EBPβ functions. Antagonism between 
both proteins was reported in the adipogenic clonal expansion phase, which 
requires balanced expression of C/EBPβ and RUNX1t1 to prevent premature 
induction of C/EBPα and terminal differentiation [30]. The connection between 
C/EBPβ and RUNX1t1 may also be relevant in hematopoietic malignancies 
involving the AML-ETO translocation product. It has recently been shown that 
RUNX1 and C/EBPβ bind to all hematopoietic genes in embryonic stem cells 
that are committed to hematopoietic differentiation [35]. It thus appears that 
the fusion of RUNX1 and RUNX1t1 in the t(8;21) AML-ETO translocation may 
counteract distinct functions of C/EBPβ in earmarking lineage commitment 
and expression of differentiation genes.  
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Conclusions  
In this paper a subset of gastric tumors characterized by a strong C/EBPβ 
regulation is described. Our genetic data firmly establishes a functional role of 
C/EBPβ in proliferation control, as well as a major factor bridging gastric 
homeostasis and tumorigenesis. RUNX1t1 is identified as a novel gastric 
tumor suppressor gene in close functional and regulatory connection with 
C/EBPβ. The identification of novel molecular targets for potential therapies, 
as well as previously unknown pathways of oncogenic transformation is of 
outmost importance in the study of a disease lacking solid knowledge on 
molecular mechanisms of development, such as it is the case of gastric 
cancer.  
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Figure Legends 
Figure 1. C/EBPβ controls gastric cancer cell proliferation. A) RNA 
expression of C/EBPβ in intestinal and diffuse gastric cancer cases as 
determined by real-time PCR. Tumor versus normal ratios were established 
for each case. Values above 1 entail upregulation, whereas expression below 
1 refers to downregulation (p value refers to normal vs Intestinal comparison). 
B) Stable knockdown of C/EBPβ in gastric cancer cell lines evaluated by 
protein blotting (left panel MKN28, right panel MKN45), showing reduction of 
all the C/EBPβ isoforms (LAP*, LAP and LIP). C) Cell proliferation was 
determined by BrdU analysis. Cells were labeled with BrdU and incorporation 
was determined by flow cytometry (FACS) and plotted against 7-AAD-positive 
cells, as a measure of DNA content. Depicted FACS plots are representative 
of one of three replicates, and show a reduced percentage of BrdU 
incorporation in gastric cells with C/EBPβ KO. S-phase percentages are 
highlighted in the FACS plots. D) Gastric cell lines with stable C/EBPβ KO 
were injected into nude mice and tumor volume and weight was assessed at 
different time points. Tumors originated from C/EBPβ KO cells were smaller 
than tumors in the controls (p<0.005). E) Ki67 staining revealed reduction of 
proliferation in the KO-derived tumors.  
 
Figure 2. Analysis of the gastric phenotype of the C/EBPβ knockout (KO) 
mouse. A) Quantification of the C/EBPβ KO mice and WT antral gastric 
mucosa thickness showing small but significant (p<0.001) reduction. Adjacent 
immunohistochemical panel depicts the reduction of Ki67-positive cells in the 
C/EBPβ KO mucosa. Lower panels show qPCR evaluation of Ki67, PCNA, 
Cyclin A1, D3, E1 and p15 in the gastric mucosa of WT and C/EBPβ KO 
mouse stomach (5 animals/group, 3 months old). Values are presented as 
fold of WT expression, and asterisks refer to p-value of 0.05 or inferior. D) 
Mutually exclusive expression of TFF1 and C/EBPβ in the normal human 
(upper panel) and mouse (lower panel) stomach epithelium; C/EBPβ is 
expressed in proliferative cells of the neck zone and TFF1 in differentiated 
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mucous epithelium. Increased expression of mRNA of differentiation proteins 
TFF1 and MUC5AC in the C/EBPβ KO mouse mucosa as measured by qPCR. 
 
Figure 3. Cross-species comparison of gene expression. Two-way 
hierarchical clustering was performed using a strongly-regulated gene cluster 
(shown in Supplementary Figure 2) from microarray-derived murine genes 
that differed between C/EBPβ KO and WT stomach (p≤0.01, FC≥1.5) and 
human gastric cancer samples. Depicted are the resultant gene and sample 
dendrograms and the corresponding expression intensity heat map. The black 
box indicates a tumor cluster in which most of the genes show downregulation 
(bluish spots). This tumor group consisted of 16 of the original 59 (≈27%) 
samples and contained primarily cancers of the intestinal histological type. 
 
 
Figure 4. C/EBPβ in the RUNX3 knockout (KO) mouse. A) Immuno-staining 
of longitudinal sections of newborn stomachs shows increased C/EBPβ and 
Ki67 expression in the RUNX3 KO mouse stomach and reversion in the 
C/EBPβ/RUNX3 double KO. E-cadherin staining shows that hyperproliferation 
is confined to the epithelial compartment. B) Quantification of the mucosal 
thickness and Ki67 expression (p<0.05) in the wild type (WT) and RUNX3 KO 
and reversal of the mucosal thickness and hyperproliferative phenotype in the 
compound C/EBPβ/RUNX3 double KO. C) qPCR analysis of RUNX1t1, FOG2, 
and SPARCL1 in RUNX3 KO and C/EBPβ/RUNX3 KO stomachs shows that 
only RUNX1t1 is downregulated in the hyperproliferative mucosa of the 
RUNX3 KO (p<0.005) and reverted to almost WT levels in the compound 
C/EBPβ/RUNX3 KO stomach. D) Transfection of C/EBPβ isoforms LAP*, LAP, 
and LIP into gastric cell lines MKN28 and MKN45 repressed RUNX1t1 
expression as measured by quantitative PCR. 
 
Figure 5. RUNX1t1 and gastric cancer. A) RUNX1t1 expression was 
evaluated by immunohistochemistry in 64 human gastric cancer samples, and 
staining was classified by comparison to the expression in the normal mucosa 
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(left panel). 38% of the cases showed reduced expression of RUNX1t1 (right 
panel). B) In 10 gastric tumors with reduced RUNX1t1 RNA levels were 
examined for C/EBPβ expression by qPCR. Only 3 out of 10 cases showed 
higher C/EBPβ expression as compared to WT. C) The methylation status of 
the RUNX1t1 promoter was evaluated by methylation-specific PCR. Bisulfite 
treatment of tumor DNA converts unmethylated but not methylated cytosines 
to uracil, and subsequent methylation-specific PCR detects either methylated 
(M) or unmethylated (U) DNA. 90% of the analyzed human gastric cancer 
cases (rows a-b, columns 1-5) present some degree of RUNX1t1 promoter 
hypermethylation. D) Ectopic expression of RUNX1t1 in MKN28 and MKN45 
gastric cancer cell lines reduces gastric cancer cell proliferation as measured 
by BrdU incorporation assay. S-phase percentages are indicated in the FACS 
plots. E) Immunoprecipitation of flag-tagged RUNX1t1 co-precipitates C/EBPβ. 
Visible in the input Western Blot is also that RUNX1t1 does not affect C/EBPβ 
expression. F) Electrophoretic mobility shift assay (EMSA) using a 
radiolabeled C/EBPβ DNA probe and nuclear extracts from MKN28 and 
MKN45 cells. Transfection of RUNX1t1 reduces the binding of C/EBPβ to 
DNA in both cell lines in a dose-dependent manner. Arrow indicates the 
super-shift.  
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Abstract
Background Polymorphisms in inflammation-related ge-
nes have been associated with a risk of gastric carcinoma
(GC). However, the biological mechanisms underlying
these associations are still elusive. Our objective was to
determine whether chronic inflammation-associated IL1B
signalling, as seen in the context of Helicobacter pylori
infection, could be linked to gastric carcinogenesis by
modulating the behaviour of gastric epithelial cells.
Methods The effect of IL1B was assessed by studying the
expression and activation status of the IL1B-activated
transcription factors C/EBPb and CREB in GC cell lines.
Interaction between CREB and C/EBPb was explored
through interference RNA, chromatin immunoprecipitation
and chemical inhibition. CREB and C/EBPb expression
was analysed in 66 samples of primary GC and in normal
gastric mucosa. GC cell growth was analysed in vitro by
BrdU incorporation and in vivo employing a chicken em-
bryo chorioallantoic membrane model.
Results We found that IL1B regulates the expression/
activation status of both C/EBPb and CREB in GC cells
through an ERK1/2-dependent mechanism. Our results
show that CREB is a direct transactivator of CEBPB, act-
ing as an upstream effector in this regulatory mechanism.
Furthermore, we found CREB to be overexpressed in 94 %
of GC samples and significantly associated with C/EBPb
expression (P \ 0.05). Finally, we demonstrated both
in vitro and in vivo that CREB can mediate IL1B-induced
GC cell proliferation.
Conclusions Our results support the hypothesis that the
effect of chronic inflammation on gastric carcinogenesis, as
seen in the context of genetically susceptible individuals
infected with Helicobacter pylori, includes the modulation
of signalling pathways that regulate survival mechanisms
in epithelial cells.
Summary IL1B is able to increase the expression/activa-
tion status of CREB and its target gene C/EBPb, which are
mandatory for GC cell survival. Our results may help in-
form new strategies for the prevention and treatment of
GC, including the control of chronic inflammation.
Keywords Helicobacter pylori  Gastric cancer  IL1B 
Inflammation  Genetic susceptibility
Introduction
Gastric carcinoma (GC) is the second most common cause
of cancer-related death in the world. The main risk factor
for the onset of GC is life-time infection with Helicobacter
pylori (H. pylori), a stomach-colonising bacterium [1].
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Infection with H. pylori leads to chronic gastritis that may
progress to gastric atrophy, intestinal metaplasia, dysplasia
and finally GC [2, 3].
The risk of developing GC depends both on environ-
mental factors and host-related factors [4, 5]. In this model,
gene polymorphisms that increase the production of pro-
inflammatory mediators lead to an enhanced chronic in-
flammatory response to H. pylori infection and to an in-
creased risk of progression towards GC [5, 6]. There are
numerous studies demonstrating that polymorphisms in ge-
nes such as IL1B, IL1RN, TNFA and IFNGR1 are associated
with a risk of developing GC [7–11]. Moreover, these
polymorphisms have been shown to be associated with in-
creased gene expression, both in vitro and in vivo [12].
Perhaps the most striking evidence favouring this model
comes from a transgenic mouse model showing that over-
expression of the IL1B gene in gastric mucosa leads to an
increased risk of developing gastric disease, including dys-
plasia and GC, even in the absence of H. pylori infection [13].
According to the prevailing model, the link between
enhanced chronic inflammation and GC depends essen-
tially on the ‘‘destructive’’ effects of inflammation over the
gastric epithelium, resulting in atrophy of the gastric mu-
cosa and increased cell turnover [14, 15]. However, it is
well demonstrated that inflammatory mediators, and other
growth factors secreted by inflammatory cells, can act di-
rectly on other cell types, such as epithelial cells. There-
fore, in addition to the mucosal destruction and repair
effect, enhanced chronic inflammation could also play a
role in gastric carcinogenesis by providing gastric epithe-
lial cells with a survival stimulus through the secretion of
growth factors [16, 17]. Coupled with mutagenic events,
this could ultimately lead to an increased risk of cell
transformation and GC development.
In this regard, IL1B is particularly interesting since
polymorphisms in its promoter region have been shown to
be associated with an increased risk of GC [7–9, 18]. IL1B
is a powerful pro-inflammatory cytokine that activates
different transcription factors [19], some of which are also
activated by H. pylori infection [20, 21]. One of the IL1B-
activated transcription factors is CCAAT/enhancer-binding
protein beta (C/EBPb) [22]. We previously reported that
C/EBPb is overexpressed in pre-malignant lesions and in
GC, suggesting that this protein may facilitate gastric
carcinogenesis by inducing the expression of COX-2 [23].
Furthermore, C/EBPb expression in GC was significantly
associated with loss of expression of the putative gastric
tumour-suppressor TFF1 [24, 25].
Another important IL1B-activated transcription factor is
cAMP response element-binding protein (CREB), which
has been described as a major player in inflammation [19,
26]. In non-small cell lung cancer, IL1B induces the acti-
vation of CREB through ERK1/2 signalling, resulting in
the expression of a set of pro-angiogenic cytokines that are
crucial factors in tumour progression [27]. Furthermore,
CREB was recently described to play an important pro-
oncogenic role in both cancer development and progres-
sion; it was found to be overexpressed in several cancer
types [28–31]. It has been demonstrated, both in hepato-
cytes [32] and in pre-adipocytes [33], that CREB is able to
regulate the transcription of the CEBPB gene by directly
interacting with its promoter.
The main objective of this study was to determine
whether chronic inflammation-associated IL1B signalling,
Fig. 1 Effects of IL1B
stimulation and ERK1/2
inhibition on CREB, pCREB,
and C/EBPb protein levels.
Both AGS and GP202 cells,
when treated with 10 ng/mL of
IL1B for 24 h, exhibited an
increase in activated ERK1/2
(pERK1/2). In parallel, the
expression levels of CREB,
pCREB and C/EBPb also
increased. The ERK1/2
chemical inhibitor U0126
(25 lM) reverted the effect of
IL1B on CREB, pCREB and
C/EBPb protein levels
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as seen in the context of H. pylori infection, could be linked
to gastric carcinogenesis by modulating the behaviour of
gastric epithelial cells. We addressed this objective by
showing that CREB and C/EBPb transcription factors can
be activated by IL1B signalling in the GC context. We also
demonstrated that CREB acts upstream of C/EBPb in GC
cell lines. Finally, we showed in vitro and in vivo that this
signalling mechanism promotes GC cell survival.
Results
IL1B increases C/EBPb and CREB expression
in an ERK1/2-dependent manner
To evaluate the effect of IL1B on the expression and ac-
tivation status of C/EBPb and CREB, we incubated GC cell
lines AGS and GP202 with IL1B for 24 h. In both AGS
and GP202 cells, incubation with IL1B led to an increase in
the expression of all isoforms (LAP*, LAP and LIP) of
C/EBPb (Fig. 1). Regarding CREB, we observed an
increase in both expression and phosphorylation levels in
both cell lines (Fig. 1).
Since ERK1/2 has been previously implicated in the
regulation of C/EBPb and CREB, we investigated whether
it could mediate the effect of IL1B over those two tran-
scription factors. Incubation of AGS and GP202 cells with
the ERK1/2 inhibitor U0126 led to a decrease in the ex-
pression of C/EBPb and CREB and to a decrease in
phosphorylation levels of CREB (Fig. 1). The level of
ERK1/2 phosphorylation in both cell lines was measured as
a control for the efficacy of inhibition with U0126 (Fig. 1).
These results demonstrate that IL1B is able to regulate the
expression/activation status of both C/EBPb and CREB in
GC cells.
CREB is a transcriptional regulator of C/EBPb in GC
cells
Knowing that CREB is a transcriptional regulator of the
CEBPB gene in other cell types, we decided to investigate
whether the same regulatory mechanism could be at work
Fig. 2a–c Effect of CREB downregulation on C/EBPb protein
levels. a CREB silencing (CREB-specific bands are indicated by
arrows; the upper bands on the CREB blots represent unspecific
binding of the CREB antibody) was followed by a downregulation of
C/EBPb protein levels, whereas the silencing of C/EBPb had no
impact on CREB protein. b Schematic representation of the CEBPB
promoter (2663 bp) showing the three CRE-binding sites (BS1, BS2
and BS3) and a control region (CR) located at the 30 end of CEBPB.
c CREB interacts with all three CRE-binding motifs present on the
CEBPB promoter. No Ab no antibody used, Input 1/100 of the sheared
initial chromatin, CREB chromatin immunoprecipitated using an anti-
CREB antibody, IgG chromatin immunoprecipitated with an un-
specific antibody of the same family as the anti-CREB antibody
IL1B induces cell survival by CREB–CEBPb pathway
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in GC cells. Since both AGS and GP202 cells yielded the
same results and the IL1B-stimulatory effect was more
pronounced in AGS cells, we decided to perform the next
set of experiments only in the AGS cells. Using both small
interfering RNA (siRNA) and short-hairpin RNA (shRNA),
we found that knocking down CREB results in down-
regulation of C/EBPb expression (Fig. 2a). Conversely,
silencing C/EBPb using siRNA had no impact on CREB
expression (Fig. 2a). These results show that CREB acts
upstream of C/EBPb in this regulatory mechanism.
To check whether CREB acts directly on the CEBPB
gene, we analysed the CEBPB promoter (2663 base pairs)
in order to find putative cAMP response element (CRE)-
binding motifs. We employed a previously described [32]
nucleotide position numbering scheme. The analysis re-
vealed the presence of three CRE-binding sites, ranging
from nucleotides -2174 to -2171 (BS1), from -959 to
-956 (BS2), and from -66 to -63 (BS3) (Fig. 2b). Using
chromatin immunoprecipitation (ChIP), we observed that
CREB binds all three CRE-binding sites on the CEBPB
promoter (Fig. 2c).
These results were validated by showing that 24-h
chemical inhibition of the interaction between CREB and
its co-activator CREB binding protein (CBP) led to a
reduced binding of CREB to the CRE-binding sites on the
CEBPB gene promoter (Fig. 3a). To confirm that the de-
crease in CREB binding to the CEBPB promoter actually
leads to downregulation of transcription and protein syn-
thesis, we evaluated the relative amount of C/EBPb mRNA
and protein after 48 h of treatment with the CBP–CREB
interaction inhibitor. This experiment resulted in a sig-
nificant reduction in both C/EBPb transcript levels
(Fig. 3b) and C/EBPb protein levels (Fig. 3c).
CREB and C/EBPb proteins are co-expressed in normal
gastric mucosa and in GC
To determine whether there is an association between the
expression of CREB and C/EBPb, we analysed the im-
munohistochemical (IHC) expression of these two proteins
in a series of 66 cases of GC. In normal gastric mucosa, we
found that both C/EBPb and CREB are expressed in the
nuclei of epithelial cells in the proliferative isthmus/neck
zone (Fig. 4a, b). To confirm that CREB and C/EBPb are
expressed in the same cells, we performed double im-
munofluorescence in a tissue fragment of normal gastric
mucosa (Fig. 4g, j). In GC, we observed that CREB and
C/EBPb were expressed in cell nuclei in 94 and 73 % of
Fig. 3a–d Effects of CBP–CREB interaction inhibition on CREB
activity and C/EBPb. a ChIP performed on AGS cells after treatment
with CBP–CREB interaction inhibitor (?) revealed a decrease in the
amount of CREB linked to the CEBPB promoter compared to
untreated cells (-). AGS cells treated with CREB–CBP interaction
inhibitor (25 lM) for 48 h showed a significant decrease in C/EBPb
b transcript levels and c protein expression. Real-time PCR results
represent the mean ± S.D. of three independent experiments.
Significance: *(P \ 0.05), **(P \ 0.01) and ***(P \ 0.001)
C. Resende et al.
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the cases, respectively. A comparison of the IHC results
indicates that there is a statistically significant association
(P = 0.04) between CREB and C/EBPb expression in our
series of GC. We also observed that GC cases with higher
CREB expression scores were significantly associated with
intestinal and mixed histological subtypes (P = 0.003)
(Table 1). No associations were detected between the ex-
pression of CREB and other clinicopathological charac-
teristics of the tumours.
CREB modulates IL1B-induced proliferation of GC
cells
To determine whether IL1B is able to increase the sur-
vival of GC cells, we measured BrdU incorporation and
performed TUNEL assays in the AGS GC cell line after
incubating cells with IL1B. In parallel, we determined
whether any of the effects of IL1B are mediated by
CREB. Our control experiments showed that CREB ex-
pression is downregulated by the shRNA used (Fig. 5a).
Figure 5b shows that IL1B is able to significantly
increase cellular proliferation, and that this effect can be
reverted by downregulating CREB levels. IL1B had no
significant effect on the rate of apoptosis (data not
shown).
To explore the role of CREB in GC cell proliferation,
we evaluated the expression of the cell-cycle regulator
cyclin D1. After performing a dose–response experiment to
determine the effect of the CBP–CREB interaction in-
hibitor on cell proliferation, we selected a concentration of
25 lM. In the AGS cell line, CREB inhibition had a sig-
nificant inhibitory effect on cell proliferation (Fig. 5c). The
effect was more pronounced after 48 h of treatment.
Moreover, this effect was also confirmed by measuring the
expression level of cyclin D1 after CREB inhibition after
24 and 48 h of treatment (Fig. 5f). The effect was also seen
in the GP202 GC cell line (Fig. 5d, g) and in the intestinal-
type GC cell line MKN28 (Fig. 5e, h). Overall, these re-
sults further support the notion that CREB plays an im-
portant role in GC cell survival, in both diffuse and
intestinal histological types, by regulating the proliferation
of GC cells.
Fig. 4a–j Immunohistochemical expression of CREB and C/EBPb in
normal gastric mucosa and in GC cases. a CREB is expressed in
epithelial cells located in the neck/isthmus region of normal gastric
glands. b C/EBPb is also expressed in neck/isthmus normal epithelial
cells. c, e Examples of CREB-positive GC cases (scoring 3); d, f C/
EBPb is overexpressed in the same GC cases that are positive for
CREB. Magnification 1009. g–j Double immunofluorescence stain-
ing for CREB and C/EBPb in normal gastric mucosa, showing co-
expression of the two proteins in gastric epithelial cells: g DAPI
nuclear staining, h C/EBPb staining, i CREB staining, j merged
image for DAPI, C/EBPb and CREB staining. Magnification 4009
IL1B induces cell survival by CREB–CEBPb pathway
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CREB inhibition decreases GC cell growth in vivo
To evaluate the effect of CREB on tumour growth, we used
the chicken embryo chorioallantoic membrane (CAM)
model. The CAM effectively supports the growth of
inoculated human cancer cells due to the immunodeficiency
of the chick during its early developmental stages. Before
CAM inoculation, we confirmed the knockdown of CREB
protein on AGS cells transfected with anti-CREB shRNA
(Fig. 6a). To avoid inter-animal differences in the results,
scrambled shRNA and anti-CREB shRNA transfected AGS
cells were inoculated in distinct areas of the CAM of the
same egg and allowed to proliferate for 6 days. At this end
point, the tumour area was quantified. As can be seen in
Fig. 6b, inhibition of CREB led to reduced growth of the
inoculated cells. Figure 6c shows that, on average, the tu-
mour growth area was significantly smaller in cells with
CREB inhibition. These results demonstrate that CREB-
mediated signalling is important for GC cell growth in vivo.
Discussion
Our results demonstrate that IL1B is able to activate CREB
and C/EBPb in GC cells. This process is mediated by
ERK1/2, since its inhibition by U0126 reverted the effects
induced by IL1B. This is in agreement with previously
reported results showing that IL1B is able to induce GC
cell proliferation in an ERK1/2-dependent manner [16].
We also demonstrated that CREB is able to transactivate
C/EBPb in GC cells.
Our in vitro observations were reinforced by the analysis
of the expression of CREB and C/EBPb in a series of GC
samples and normal gastric mucosa. We showed that in
normal gastric mucosa, CREB is expressed in the prolif-
erative neck/isthmus region of the gastric glands; in GC, it
is overexpressed in the majority of tumour samples. These
results are in accordance with those published by Chen et al.
[34], showing that CREB mRNA levels are upregulated in
GC samples when compared with adjacent normal mucosa.
Table 1 Relationship between
the clinicopathological features
of gastric cancer and CREB
expression score
Guide to scores: 0, IHC
positivity in \5 % of tumour
cells; 1, IHC positivity in
6–50 % of tumour cells; 2, IHC
positivity in 51–75 % of tumour
cells; 3, IHC positivity in
[75 % of tumour cells
No of cases (%) CREB score (%) P value
0 1 2 3
C/EBPb score
0 18 (27.3) 4 (22.2) 3 (16.7) 5 (27.8) 6 (33.3) 0.04
1 23 (34.8) 0 (0) 4 (17.4) 9 (39.1) 10 (43.5)
2 12 (18.2) 0 (0) 1 (8.3) 4 (33.3) 7 (58.3)
3 13 (19.7) 0 (0) 0 (0) 3 (23.1) 10 (76.9)
Histological type
Intestinal 25 (37.9) 1 (4.0) 2 (8.0) 7 (28) 15 (60.0) 0.003
Diffuse 11 (16.7) 0 (0) 3 (27.3) 7 (63.6) 1 (9.1)
Mixed 20 (30.3) 0 (0) 3 (15.0) 4 (20.0) 13 (65.0)
Unclassified 10 (15.1) 3 (30.0) 0 (0) 3 (30.0) 4 (40.0)
Venous invasion
Present 48 (72.7) 3 (6.2) 6 (12.5) 13 (27.1) 26 (54.2) NS
Absent 18 (27.3) 1 (5.6) 2 (11.1) 8 (44.4) 7 (38.9)
Perineural invasion
Present 42 (63.6) 3 (7.1) 6 (14.3) 12 (28.6) 21 (50.0) NS
Absent 24 (36.4) 1 (4.2) 2 (8.3) 9 (37.5) 12 (50.0)
Tumour extent
T1 2 (3.1) 0 (0) 0 (0) 2 (100.0) 0 (0) NS
T2 32 (48.5) 1 (3.1) 4 (12.5) 11 (34.4) 16 (50.0)
T3 23 (34.8) 2 (8.7) 3 (13.0) 4 (17.4) 14 (60.9)
T4 9 (13.6) 1 (11.1) 1 (11.1) 3 (33.3) 4 (44.4)
Lymph node invasion
N0 8 (12.1) 0 (0) 0 (0) 5 (62.5) 3 (37.5) NS
N1 23 (34.8) 2 (8.7) 1 (4.3) 7 (30.4) 13 (56.5)
N2 21 (31.8) 2 (9.5) 4 (19.0) 5 (23.8) 10 (47.6)
N3 14 (21.2) 0 (0) 3 (21.4) 4 (28.6) 7 (50.0)
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CREB expression was also significantly associated
with the expression of C/EBPb in GC. The observation
that in normal gastric mucosa CREB and C/EBPb are
expressed in a cellular compartment that includes pro-
genitor cells suggests that CREB and C/EBPb may be
involved in maintaining a proliferative phenotype in
gastric epithelial cells. This would be in accordance with
the observed pattern of overexpression of both proteins in
the majority of the GC cases included in the present
study. These results are also in keeping with our previous
demonstration that C/EBPb is overexpressed in pre-ma-
lignant lesions and in GC, suggesting that this protein
might facilitate the transformation of gastric epithelial
cells by inducing the expression of COX-2 [23] and by
inhibiting the expression of the putative gastric tumor
suppressor gene TFF1 [24, 25].
In order to complement the aforementioned observations
with a biological readout, we evaluated the role of CREB
in mediating IL1B-induced changes in cell proliferation
and apoptosis. Although no significant effect was observed
in relation to apoptosis, our results show that CREB is an
effector of IL1B-induced cell proliferation, since down-
regulation of CREB impairs the pro-mitogenic action of
IL1B on GC cells in vitro. These results were further
supported by the CAM assays showing that inhibition of
CREB reduces the ability of GC cells to survive in this
in vivo model.
Infection with H. pylori leads to chronic inflammation
and an increased risk of developing GC. Our results sup-
port the hypothesis that the effect of chronic inflammation
on tumourigenesis includes modulation of critical sig-
nalling pathways that regulate survival in epithelial cells.
Fig. 5a–h CREB modulates both IL1B-induced and basal cell
proliferation. a Downregulation of CREB expression using shRNA.
b AGS cells expressing normal levels of CREB (transfected with
scrambled shRNA) showed an increase in cell proliferation after 24 h
of treatment with 10 ng/mL IL1B, while CREB downregulation
(transfected with anti-CREB shRNA) was responsible for a significant
decrease in IL1B-induced cell proliferation. sc shRNA control
scrambled shRNA, shRNA CREB anti-CREB shRNA. c AGS,
d GP202, and e MKN28 cells were treated for 24 and 48 h to assess
the time-dependent impact of treatment on GC cell proliferation; the
protein levels of cyclin D1 were checked in f AGS, g GP202 and
h MKN28 cells after 24 and 48 h of CBP–CREB interaction inhibitor
treatment. BrdU results represent the mean ± S.D. of three indepen-
dent experiments. Significance: *P \ 0.05, **P \ 0.01 and
***P \ 0.001
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In this scenario, H. pylori infection leads to overexpression
of IL1B which, in turn, activates CREB and C/EBPb. This
effect may be more pronounced in individuals that carry
genetic susceptibility polymorphisms that have been
demonstrated to be associated with enhanced chronic in-
flammation, such as those in the IL1B gene promoter.
Coupling cell survival with an increased likelihood of ac-
cumulating genetic mutations may help explain why indi-
viduals with pro-inflammatory genetic polymorphisms
have an increased risk of developing GC.
Materials and methods
Tissue material
Surgical specimens from 66 GCs were resected and diag-
nosed at Hospital S. Joa˜o, Porto, Portugal. Tissue frag-
ments were fixed in 10 % formaldehyde followed by
paraffin embedding. Tumour-representative areas of each
GC were selected to create a tissue microarray (TMA)
block. Serial sections of 3 lm were obtained from the
TMA block and used for routine staining with haema-
toxylin and eosin and immunohistochemistry. This study
was performed in accordance with institutional ethical
standards. All of the samples enrolled in this study were
unidentified.
Immunohistochemistry and immunofluorescence
Tissue sections from formalin-fixed paraffin-embedded
(FFPE) tissues were first deparaffinised, hydrated, and then
treated with 19 citrate buffer (pH 6.0) (Thermo Scientific,
Waltham, MA, USA) for 45 min at 100 C. All of the
following steps were performed at room temperature (RT).
Unspecific endogenous peroxidase activity was eliminated
with 3 % hydrogen peroxidase in methanol for 15 min. To
reduce nonspecific background staining, slides were
blocked with Ultra V Block (Thermo Scientific) for
10 min. Slides were rinsed in PBS–0.1 % Tween20 and
incubated for 1 h with the antibody anti-CREB [E306]
(Abcam, Cambridge, UK) diluted 1:1000 and then over-
night (ON) with anti-C/EBPb (Abcam) diluted 1:1000 in
UltraAB Diluent (Thermo Scientific). Slides were then
incubated with Dako Real EnVision HRP Rabbit/Mouse
solution (Dako, Glostrup, Denmark) for 30 min. Slides
were washed, developed for 1–3 min with 2 % Dako
REALTM DAB? Chromogen solution (Dako), counter-
stained with haematoxylin, dehydrated, and mounted with
mounting medium (Thermo Scientific). All washing steps
were performed in PBS–0.1 % Tween20 buffer. Normal
gastric mucosa was used as a control, and negative controls
were obtained by substituting the primary antibody with
immunoglobulins of the same class and concentration.
Slides were reviewed by a pathologist, and the percentage
Fig. 6a–c CREB inhibition
reduces in vivo cell growth.
a Before inoculating AGS cells
in the chorioallantoic membrane
(CAM), CREB protein
knockdown was checked by
western blotting. b AGS cells
transfected with shRNA against
CREB give rise to small-sized
tumours compared with
scramble-transfected cells;
c Images representing the
different sizes (delimited by red
dashed lines) of scramble and
shRNA CREB tumours in two
paired CAM experiments (#1
and #2). Values of P \ 0.05
were considered to be
statistically significant
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of positive cells was semiquantitatively scored as either 0
(corresponding to positivity in\5 % of the tumour cells), 1
(corresponding to positivity in [5 % and \50 % of the
tumour cells), 2 (corresponding to positivity in [50 %
and \75 % of the tumour cells), or 4 (corresponding to
positivity in [75 % of the tumour cells).
For immunofluorescence, antigen retrieval was per-
formed with 19 citrate buffer (pH 6,0). After unspecific
protein blocking with Ultra V Block (Thermo Scientific)
for 10 min, slides were incubated with the antibody anti-
CREB [E306] diluted 1:1000 for 1 h, followed by the an-
tibody anti-C/EBPb diluted 1:1000 ON. After washing
twice with PBS–Tween 0.021 % for 10 min, the slides
were incubated with a mixture of two secondary antibodies
raised in different species (with Texas Red conjugated
against rabbit and FITC conjugated against mouse) for
45 min at room temperature and protected from light. To
counterstain cell nuclei, slides were mounted with Vec-
tashield Mounting Medium with DAPI (Vector Laborato-
ries, Burlingame, CA, USA). Finally, slides were
visualised and images were captured (via ApoTome) under
a fluorescence microscope (Zeiss, Oberkochen, Germany).
Cell culture, chemical treatments and transfections
AGS, MKN28 and GP202 cell lines were maintained in
RPMI medium (Gibco, Waltham, MA, USA), supple-
mented with 10 % foetal bovine serum (FBS) (PAA,
Pasching, Austria), and 100 IU/mL penicillin and 100 lg/
mL streptomycin (Gibco), in a humidified incubator under
an atmosphere of 5 % CO2 at 37 C. Cells were grown
until 60–80 % confluence and treated with 10 ng/mL of
IL1B (Sigma, St. Louis, MO, USA) and incubated for 24 h.
For ERK1/2 inhibition, cells were treated with 25 lM
U0126 (Cayman, Ann Arbor, MI, USA) together with IL1B
for 24 h. As U0126 was diluted in DMSO, an appropriate
volume of DMSO was added to the cells as the control
condition. For CBP–CREB interaction inhibition, cells
were treated with 25 lM of the specific inhibitor (Merck–
Millipore, Darmstadt, Germany) or DMSO vehicle (Sigma)
for 24 and 48 h.
For silencing experiments, AGS cells grown until
60–80 % confluence were transfected with 1.0 lg of anti-
CREB shRNA expression vector or 1.0 lg scrambled
shRNA (Origene, Rockville, MD, USA) using Lipofec-
tamine 2000 (Invitrogen, Waltham, MA, USA), according
to the manufacturer’s specifications. At 48 h post-trans-
fection, cells were selected by adding 1.0 lg/mL of pur-
omycin (Sigma) to the culture medium. Individual
puromycin-resistant colonies were isolated after 2 weeks of
selection and expanded in the presence of puromycin
(1.0 lg/mL). For the transient silencing of CREB, AGS
cells were transfected either with 100 nM of siRNA against
CREB (Qiagen, Hilden, Germany) or with 100 nM of
siRNA control (Qiagen), using Lipofectamine 2000 (In-
vitrogen) as a vehicle. In parallel, C/EBPb silencing was
performed by transfecting AGS cells with 150nM of
siRNA against CEBPB or siRNA control (Qiagen). Protein
downregulation after gene silencing was evaluated by
western blotting following 72 h of culture.
Western blotting (immunoblotting)
Cells were washed with 19 PBS (pH 7.4) and lysed in
NP-40 buffer supplemented with phosphatase (Sigma) and
protease inhibitors (Roche, Penzberg, Germany). After
Bradford protein quantification, 40 lg of total protein
were loaded into 12.5 % acrylamide gels, separated by
SDS-PAGE under denaturing conditions and electro-
transferred to a Hybond ECL Nitrocellulose Membrane
(GE Healthcare, Little Chalfont, UK). After blocking,
membranes were incubated for 1.5 h with the primary
antibodies anti-ERK1/2 #9102 (Cell Signaling Tech-
nology, Danvers, MA, USA) diluted 1:1000, anti-pERK1/
2 #9106 (Cell Signaling Technology) diluted 1:1000, anti-
CREB [E306] diluted 1:500, anti-pCREB [E113] (Abcam)
diluted 1:1000, anti-C/EBPb [H-7] (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) diluted 1:500, anti-cyclin
D1 (Santa Cruz Biotechnology) diluted 1:500, and anti-a-
tubulin (Sigma) diluted 1:10000 in PBS-0.5 % Tween20
plus 5 % non-fat dried milk or 4 % BSA (bovine serum
albumin). The blots were then washed with PBS–0.5 %
Tween20 and incubated with horseradish peroxidase-
conjugated secondary antibodies diluted 1:10000 in PBS–
0.5 % Tween20 plus 0.5 % non-fat dried milk. Chemi-
luminescent bands were visualised using Western Blot
ECL (GE Healthcare).
BrdU incorporation assay
Cells were allowed to reach 60–80 % confluence and 19
BrdU was added to the culture medium for 1 h. Cells were
then washed with 19 PBS and fixed in freshly prepared
4 % (v/v) paraformaldehyde at RT for 30 min. The glass
slides were removed from the 6-well plate, transferred to
individual wells in a 12-well plate, and washed with
1xPBS. In order to denature the DNA and permeabilize
cells, hydrochloric acid (HCl) 2 M was added to each slide
for 20 min, followed by washing steps with PBS–0.5 %
Tween20 plus 0.05 % BSA. Cells in glass slides were in-
cubated for 1 h with mouse primary antibody against BrdU
(Dako) diluted 1:10, washed twice with PBS–0.5 %
Tween20 plus 0.05 % BSA, and incubated for 30 min with
anti-mouse secondary antibody marked with Alexa Fluor
594 (Invitrogen) diluted 1:100. Glass slides were rinsed in
PBS–0.5 % Tween20 plus 0.05 % BSA twice, mounted
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with Vectashield Mounting Medium with DAPI (Vector
Laboratories), and finally visualised under fluorescent mi-
croscopy. For each experiment, the BrdU technique was
performed in triplicate. In each assay, at least 1000 cells
were counted and BrdU incorporation was expressed as the
ratio of DAPI to BrdU-positive cells.
Promoter analysis and chromatin immunoprecipitation
(ChIP)
The nucleotide sequence of human CEBPB promoter was
obtained from the UCSC Genome Browser (http://genome.
ucsc.edu/). The putative CRE-binding sites present on
CEBPB promoter were identified using the Genomatix
MatInspector software (http://www.genomatix.de/solutions/
genomatix-genome-analyzer.html).
ChIP assay was performed using a Magna ChIP G Kit
(Millipore, Billerica, MA, USA), according to the manufac-
turer’s protocol instructions. Briefly, 1 9 107 of AGS cells
were crosslinked with 1 % formaldehyde for 10 min at RT,
and the reaction was stopped by 19 glycine solution for
5 min. Cells were rinsed with 19 PBS, lysed in order to isolate
nuclei, and then sonicated in Nuclear Lysis to shear the
chromatin to sizes of 200–500 bp. Then, 50 ll of the super-
natant were immunoprecipitated by adding 2 lg of rabbit
antibody anti-CREB (Abcam) or 2 lg of control rabbit
polyclonal anti-IgG antibody (Abcam), and the mixture was
placed on a rotator at 4 C ON in the presence of magnetic G
beads. DNA–protein crosslinks were reversed by heating
samples at 62 C for 2 h on a shaking platform. To elute DNA,
a series of wash steps followed by elution (50 ll) were per-
formed in spin columns. PCR conditions: 95 C for 15 min,
35 times (95 C for 1 min, 58–60 C for 1 min, 72 C for
1 min). The reactions were carried out with HotStarTaq DNA
Polymerase (Qiagen) as described by the manufacturer, using
2 ll of DNA template. The PCR products were analysed by
electrophoresis on a 2 % agarose gel. PCR primer pairs
flanking CREB-binding sites and for the control region (CR)
were designed using the Primer 3 software.
RNA isolation, cDNA synthesis and quantification
of CEBPB mRNA transcript
Total RNA was isolated from AGS cells grown in 6-well
culture plates using the RNeasy Mini Kit (Qiagen). Reverse
transcription was performed using a SuperScript II Reverse
Transcriptase Kit (Invitrogen) with 1000 lg of total RNA
in a 20-ll volume reaction, after treatment with DNase I
(Invitrogen).
To determine the relative amount of CEBPB transcript,
we performed quantitative target amplification, using
cDNA as the template, with the SYBR Green PCR Kit
(Qiagen), according to the manufacturer’s protocol. As an
internal control, we quantified the expression levels of
beta-actin transcript.
Analysis of in vivo tumour growth
The chicken embryo CAM model was used to evaluate the
growth capability of AGS cells transfected with scramble or
shCREB RNA (n = 16). Briefly, fertilised chick (Gallus
gallus) eggs were incubated horizontally at 37.8 C in a
humidified atmosphere. On embryonic day 3 (E3), a square
window was opened on the shell after removing 1.5–2 mL
of albumin to allow detachment of the developing CAM.
The window was sealed with a transparent adhesive tape and
the eggs returned to the incubator. Cells, re-suspended in
10 ll of complete medium, were placed on top of E10
growing CAM, and 2 9 106 cells per embryo from each cell
line (scrambled shRNA vs CREB shRNA) were placed into
a 3-mm nylon ring under sterile conditions. The eggs were
re-sealed and returned to the incubator for an additional
5 days. After removing the ring, the CAM was excised from
the embryos, photographed ex ovo under a stereoscope at
209 magnification (SZX16 coupled with a DP71 camera,
Olympus, Tokyo, Japan). The area of CAM tumour was
determined using the Cell A program (Olympus).
Statistical analysis
The clinicopathological features of GC cases were com-
pared using the v2 test. When two conditions were com-
pared, Student’s t test was used, whereas ANOVA was
employed when the comparison involved more than two
conditions. The paired t test was used for tumour area
comparisons. In order to accurately access putative dif-
ferences in tumour areas between the two cell lines, only
eggs bearing two tumours with areas C1 mm2 (n = 16)
were considered, independently of the cell group. Values of
P \ 0.05 were considered to be statistically significant.
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Gastric cancer (GC) is an important cause of morbidity
and mortality worldwide [1]. The etiology of GC has a
significant environmental component characteristic of
the geographically varied incidence in the disease distri-
bution [1–4]. Several environmental factors, including
Helicobacter pylori infection, consumption of salted and
nitrated foods, and cigarette smoking, have been found
to be associated with the risk of developing GC [2–5].
In addition to environmental factors, genetic factors
also play an important role in GC etiology, as demon-
strated by the fact that only a small proportion of indi-
viduals exposed to the known environmental risk
factors develop GC [4,6–8].
Molecular studies have provided evidence that GC
arises not only from the combined effects of environ-
mental factors and susceptible genetic variants but also
from the accumulation of genetic and epigenetic altera-
tions that play crucial roles in the process of cellular
immortalization and tumorigenesis [2,3,9].
This review is intended to focus on the recently
described basic aspects that play key roles in the process
of gastric carcinogenesis. New advances in the fields of
the individual’s genetic susceptibility for gastric carcino-
genesis, deregulation of gene expression, genetic profile
present in tumors with microsatellite instability (MSI),
and new options for treatment of GC will be discussed.
Genetic Susceptibility
In recent years, molecular epidemiological studies have
described some relatively common genetic variants as
biomarkers for genetic susceptibility to GC develop-
ment, namely single-nucleotide polymorphisms (SNPs)
[4–7,10]. These genetic variants may modulate the
effects of environmental factors by regulating multiple
biologic pathways in response to the exposure during
gastric carcinogenesis, thus exerting an effect on popu-
lation attributable risks. One major advantage of SNPs
as prognostic markers is that they can be determined
independently from the availability and quality of
tumor material as they can be easily evaluated from a
blood sample from individual patients. For example,
Fan et al. [11] described that the DNMT3A-448A>G
polymorphism is involved in the genetic susceptibility
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Abstract
Gastric cancer (GC) is an important cause of morbidity and mortality world-
wide. In addition to environmental factors, genetic factors also play an
important role in GC etiology, as demonstrated by the fact that only a small
proportion of individuals exposed to the known environmental risk factors
develop GC. Molecular studies have provided evidence that GC arises not
only from the combined effects of environmental factors and susceptible
genetic variants but also from the accumulation of genetic and epigenetic
alterations that play crucial roles in the process of cellular immortalization
and tumorigenesis. This review is intended to focus on the recently
described basic aspects that play key roles in the process of gastric carcino-
genesis. Genetic variation in the genes DNMT3A, PSCA, VEGF, and XRCC1
has been reported to modify the risk of developing gastric carcinoma. Sev-
eral genes have been newly associated with gastric carcinogenesis, both
through oncogenic activation (MYC, SEMA5A, BCL2L12, RBP2 and BUBR1)
and tumor suppressor gene inactivation mechanisms (KLF6, RELN, PTCH1A,
CLDN11, and SFRP5). At the level of gastric carcinoma treatment, the HER-2
tyrosine kinase receptor has been demonstrated to be a molecular target of
therapy.
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to GC. DNA methyltransferase-3A (DNMT3A) is essen-
tial for mammalian development and is responsible for
the generation of genomic methylation patterns [12].
De novo DNMT3A expression was reported as playing a
role in gastric carcinogenesis [13]. In another study, Ju
et al. [14] reported that the PTPRCAP )309G>T poly-
morphism is associated with increased susceptibility to
diffuse-type GC by increasing PTPRCAP expression. The
protein tyrosine phosphatase receptor type C-associated
protein (PTPRCAP) is involved in the activation of the
Src family kinases (SFKs) [15], and it is known that
overexpression of SFK is involved in the disruption of
the epithelial cell–cell adhesion by inducing impairment
in the membrane localization of E-cadherin [16].
Another gene that has been reported as having a role
in gastric carcinogenesis is the PSCA [17]. Interestingly,
PSCA was found to be expressed in differentiating gas-
tric epithelial cells, where it exerts a cell-proliferation
inhibitory activity in vitro, and it is frequently found
silenced in GC cells. Lu et al. [18] reported that two
polymorphisms (rs 2976392 and rs 2294008) in PSCA
gene may contribute to the etiology of gastric carcino-
genesis, at least in a Chinese population.
Also, vascular endothelial growth factor (VEGF) gene
has been the focus of many associative studies. VEGF,
the key mediator of angiogenesis, plays an important
role in the development of different tumors, including
GC [19], where it plays a critical role in the invasive
process of cancer cells [20]. Guan et al. [21] described
that the VEGF )634G>C polymorphism is associated
with the risk to develop GC. They showed that the het-
erozygous )634CG and the combined )634CG+CC car-
riers had an increased risk of developing GC when
compared with the )634GG genotype. In another
study, Tahara et al. [22] reported that the polymor-
phism 1612G>A in the 3¢-UTR of VEGF was associated
with an increased risk of GC. They suggest that the
nucleotide polymorphism in the 3¢-UTR, such as SNPs
and triplet nucleotide repeat, are associated with the
deregulation of affected genes.
The integrity and maintenance of the DNA nucleotide
composition are vital for cell’s normal function. X-ray
repair cross-complementing group 1 (XRCC1) is one of
the proteins involved in the base excision repair path-
way, which functions in the repair of single-strand
breaks caused by exposure to ionizing radiation, alky-
lating agents, and metabolic toxins [4,23]. It is known
that the presence of the XRCC1-77T>C promoter poly-
morphism is associated with human cancer, namely,
with non-small cell lung cancer [24]. Corso et al. [25]
reported an association between the presence of the
XRCC1-77T>C polymorphism and the increased risk of
gastric cardia carcinoma, so the referred polymorphism
was considered by the authors as a relevant host sus-
ceptibility factor for GC.
Various other articles were published last year estab-
lishing an association between genetic polymorphisms
and the risk of GC. Host genetic factors are emerging as
key elements in the risk for the development of cancer,
and the interaction of numerous polymorphisms on a
countless genes products, combined with environmen-
tal triggers may provide crucial clues explaining diverse
risks in various populations.
Molecular Alterations in Gastric Cancer
Understanding the molecular mechanisms and altera-
tions behind the initiation and progression of gastric
tumorigenesis is crucial for the early detection of the
disease and to identify novel therapeutic and clinical
targets for GC. A number of molecular abnormalities
have been identified in GC, namely gene overexpres-
sion and gene silencing, and MSI-associated gene muta-
tions. Nevertheless, the molecular pathogenesis of GC is
still incompletely understood.
Gene Overexpression
Over the last decade, a vast amount of articles referring
to the overexpression of various genes in GC was pub-
lished. Some of those genes were classified as activated
oncogenes, like Her-2 ⁄neu [26] and c-Myc [27], playing
roles in the induction of cell proliferation. Following
the search for other deregulated genes that are involved
in cell proliferation, Pan et al. reported the overexpres-
sion of SEMA5A (Semaphorin 5A) in GC [28]. With in
vitro models, and using siRNA-mediated semaphorin
5A knockdown, those authors concluded that semapho-
rin 5A may be involved in gastric carcinogenesis by
promoting cell proliferation and inhibiting apoptosis. In
another study, Florou et al. [29] described how
BCL2L12, a member of the BCL2 family that could func-
tion as an anti-apoptotic factor, was overexpressed in
early stages of GC compared to normal mucosa.
The histone-modifying enzymes are responsible for
acetylation, phosphorylation, and methylation of his-
tone proteins, playing a key role in the regulation of
gene transcription by mediating chromatin reconfigura-
tion [30]. Zeng et al. [31] described the overexpression
of histone demethylase RBP2 in GC, and they observed
that RBP2 depletion triggers the senescence of malig-
nant cells at least partially by derepressing CDKIs.
It is known that GC shows a high frequency of DNA
aneuploidy [32], and it was recently described that
knockdown or overexpression of spindle assembly
checkpoint molecules resulted in ploidy errors and
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carcinogenesis in mice [33]. Knowing that, Ando et al.
[34] assessed the expression of BUBR1 kinase, one of
the key molecules in the spindle assembly checkpoint,
in GC samples. These authors observed a high expres-
sion of BUBR1 in GCs that were aneuploid, establishing
a relation between BUBR1 expression and induction of
aneuploidy. To confirm that association, they enforced
expression of BUBR1 in cell lines and, as a result, they
observed changes in the ploidy of the cells.
Gene Silencing
Gene silencing in GC can occur mainly because of the
point mutations, loss of heterozygosity, and promoter
hypermethylation [2,3]. Genetic alterations were
reported by Sangodkar et al. [35] as the cause of KLF6
downregulation in GC, being this gene-silencing critical
to abrogate the repressive effect on proliferation of
wild-type KLF6.
Transcriptional inactivation of specific genes via aber-
rant promoter hypermethylation of CpG islands, caus-
ing permanent gene silencing, is a major epigenetic
event in carcinogenesis. Reported genes whose expres-
sion was downregulated in GC by promoter hyperme-
thylation are CDH1 [9], RELN [36], PTCH1a [37], HLA
class I [38], CLDN11 [39], SFRP5 [40], and probably CE-
BPA, because it does not harbor gene mutations that
could explain its downregulation in about 30% of GCs
[41].
Microsatellite Instability
MSI is defined as the presence of replication errors in
simple repetitive microsatellite sequences because of
the defects in mismatch repair genes [10,42]. Many
cancer-associated genes have been found to harbor
mutations at mono- or dinucleotide repeats in the cod-
ing sequences in cancers with MSI [42], and GC is no
exception [43]. Recently, Velho et al. [44] reported that
in MSI gastric tumors, MLK3, a gene that codifies a
kinase involved in MAP kinase pathway, is frequently
found mutated. Noteworthy, they found that the mis-
sense mutations found in MLK3 harbor transforming
and tumorigenic potential, in vitro and in vivo.
Autophagy-related genes ATG2B, ATG5, ATG9B, and
ATG12 were also reported as harboring mutations in
MSI tumors, contributing to cancer development by
deregulation of the autophagy process [45].
Gastric Cancer Treatment
Despite recent advances in perioperative and adjuvant
chemotherapy, most patients with advanced disease
have a median survival of less than a year. The best
prognostic parameters of the disease are TNM-staging
(invasion depth and metastasis to lymph nodes or to
distant sites) and complete surgical removal of the neo-
plastic tissue. However, these traditional prognostic
clinicopathological characteristics provide limited infor-
mation about predictive measures of the disease. So far,
genome-wide screens have provided no clinically appli-
cable predictive value in GC, and partly owing to this,
it has been more promising to focus on specific targeted
cancer treatment modalities and methods to identify
their molecular targets. Several of these novel treat-
ment options and their putative predictive markers
have not yet been proven to show clinical value in GC
(for example cyclooxygenase-2 and nonsteroidal anti-
inflammatory drugs or antibodies and small molecular
inhibitors of epidermal growth factor receptor and
amplification or mutations of the receptor). However,
HER-2 has been recently demonstrated to be a molecu-
lar target in GC.
HER-2 and Carcinogenesis
Cell proliferation is tightly regulated through cellular
signal transduction pathways, and growth factors and
their receptors play an important role in regulation of
these intracellular responses. One central family of
growth factor receptors are the four related proteins
named HER ⁄ErbB receptors [46,47]. Each of these
receptors are transmembrane proteins, and HER-1,
HER-2, and HER-4 have an intracellular domain with
tyrosine kinase activity. HER-1 (also called epidermal
growth factor receptor), HER-3, and HER-4 can bind
ligands with their extracellular domain, and the bound
ligand induces either homo- or heterodimerization of
the receptors and generates autophosphorylation,
which can lead to multiple intracellular signals. HER-2
does not bind to any known ligand, but it can heterodi-
merize with other members of the family. This is espe-
cially evident, when HER-2 is overexpressed or
activated through either amplification or mutation of
the gene. HER receptors have been shown to activate
Ras-Raf-MAPK, PI3K-AKT, and STAT pathways that
can inhibit apoptosis and promote proliferation, migra-
tion, angiogenesis, invasion, and metastasis. Thus, HER
receptors are a rational target for cancer treatment.
Indeed, work using in vitro and in vivo models of carci-
nogenesis have shown that inhibition of HER-1 and
HER-2 suppresses cancer cell growth and survival.
Finally, both monoclonal antibodies against HER-1
(cetuximab, panitumab) and HER-2 (trastuzumab) are
currently used to treat patients with metastasized colo-
rectal cancer and breast cancer, respectively. Predictive
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marker for anti-HER-1 treatment is wild-type KRAS
oncogene and for anti-HER-2 amplification of the HER-
2 gene. In addition, small molecular tyrosine kinase
inhibitors against HER-1 receptor (gefitinib, erlotinib)
and a dual HER-1 ⁄2 inhibitor (lapatinib) have been
approved for certain carcinoma treatments.
HER-2 in Experimental Gastric Cancer Models
Growth of human GC cells in vitro and in xenograft
models in vivo has been shown to be inhibited by the
anti-HER-2 monoclonal antibody tratuzumab. This
effect, which seems to require HER-2 overexpression,
and combination of trastuzumab with chemotherapy
were more effective than either treatment alone
[48,49]. More recently it was shown that both HER-2-
targeted transient transfection of siRNA molecules and
stable lentiviral-mediated shRNA expression decreased
GC cell viability, and the latter treatment was also
shown to suppress xenograft tumor growth of upper
gastrointestinal adenocarcinoma cell lines [50,51].
Combination of 5-fluorouracil and HER-2-targeting
agents, trastuzumab or lapatinib (the dual HER-1 ⁄HER-
2 tyrosine kinase inhibitor), synergistically inhibited the
proliferation and enhanced the apoptosis in GC cells
with HER-2 amplification (but not in those without it),
which may depend on downregulation of thymidylate
synthase expression, which is the target of 5-fluoroura-
cil [52]. In addition, lapatinib sensitized GC cells to
SN-38, the active metabolite of irinotecan [53]. Finally,
lapatinib acted in a synergistic manner with trastuzu-
mad as an anticancer agent both in in vitro and in vivo
conditions [54]. These data support the hypothesis that
anti-HER-2 treatment could be effective in patients
with GC at least in HER-2 amplified tumors and in
combination with cytostatic drugs.
HER-2 in Clinical Gastric Cancer Trials
Overexpression of membranous HER-2 protein positiv-
ity has been detected by immunohistochemistry in 8–
53% of gastric adenocarcinomas [48,49]. This relatively
wide range of positivity most likely is dependent on dif-
ferences in study materials (distribution of different his-
tologic types and location of the tumor) and
attributable to variable staining protocols and scoring
criteria. When Hofmann et al. [55] pooled data from 16
different studies (3264 tumor samples), a mean value of
18% of HER-2 immunopositivity was obtained, and
nine studies (from 1232 tumors) showed a mean value
of 19% of HER-2 amplified cases using either fluores-
cence or chromogen in situ hybridization (HER-2 ⁄CEN-
17‡2). These values are well in the range reported for
HER-2 amplification in breast cancer (15–25%). In sev-
eral studies, intestinal-type GCs were shown to express
HER-2 more frequently (16–34%) than the diffuse-type
tumors (2–7%). Probably because of this association
with intestinal type histology, HER-2 expression is
higher in gastroesophageal junction carcinomas when
compared to conventional (corpus and antrum) GC
(24–32% vs 10–18%), because the intestinal type is
more frequent in the proximal location. The role of
HER-2 as a prognostic factor in GC is somewhat contro-
versial, because several studies have failed to show any
role in prognosis, while others have indicated that
HER-2 is an independent prognostic factor in GC
[48,49,56–59].
A randomized multicenter phase III trial (ToGa study)
has shown that first-line treatment with trastuzumab in
combination with either cisplatin and 5-fluorouracil or
cabecitapin is effective against metastatic gastric adeno-
carcinoma [60]. Median survival was improved (from
11.1 to 13.8 months; n = 584) in patients receiving
trastuzumab in combination with cytostatic drugs,
which was even more impressive in the subgroup of
the HER-2 immunohistochemistry 3+ and 2+ with
amplification positivity (median survival 11.8 vs.
16.0 months; n = 446). No major safety issues were
reported between the two treatment arms. Consistent
with earlier data, HER-2 was more frequently positive
in intestinal (32%) than in diffuse-type tumors (6%),
and in gastroesophageal junctional cancers (33%) when
compared to those in the stomach (21%). Overall rate
of HER-2 positivity was 22% (immunohistochemistry
3+ or amplification positive) [61]. Based on these data,
trastuzumab has been approved by the EMEA for meta-
static GC and adenocarcinoma of the gastroesophageal
junction.
Assessment of HER-2 positivity in GC has become
increasingly important because of the results of the
ToGa study. Earlier studies have shown only modest
concordance between HER-2 immunopositivity and
amplification rates [48], but more recent studies have
indicated that a much higher (over 90%) concordance
between immunohistochemistry positivity and amplifi-
cation can be obtained [55]. In the ToGa trial, a
87.5% concordance was reported [61]. This suggests
that similarly to breast cancer also in GC the major
mechanism for overexpression of the protein is the
amplification of the gene. The major difference
between breast cancer and GC, based on the ToGa
trial, was the relatively high frequency of immunohis-
tochemistry 0 or 1+ that were amplification positive.
A modified scoring system of immunohistochemistry
for GC has been proposed [55]. These modifications
acknowledge incomplete basolateral (U-shaped)
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membrane staining pattern of glandular cells as posi-
tive. Also, relatively high frequency of tumor hetero-
geneity (5%) was found in GC, and the 10% cutoff of
area of positivity is restricted to surgical specimens,
but no such cutoff was recommended to the biopsy
samples.
In conclusion, the best way to help the patients with
GC would obviously be to prevent the disease alto-
gether. However, especially in the Western world we
are faced with the fact that most patients are diagnosed
in advanced stage of the disease. Although combination
chemotherapies have shown to be effective, new thera-
peutic strategies are clearly needed because of the rela-
tively rapid progression of the disease despite the
treatment. To this end, new molecular targets should
be identified and personalized treatment offered. Mech-
anisms of resistance against trastuzumab treatment
include mutation of the HER-2 receptor, masking of the
receptor, activation of insulin-like growth factor-1
receptor or PTEN deficiency. These alterations may be
overcome by novel antibodies against HER-2 or by
small molecular inhibitors of the receptor or its down-
stream targets. Indeed, ongoing phase II and III trials
test the use of lapatinib in patients with GC.
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Gastric cancer (GC) is the fourth most common cancer
and the second cause of cancer mortality worldwide
[1]. The etiology of GC has a significant environmental
component characteristic of the geographically varied
incidence in the disease distribution [1–3]. Several
environmental factors, including Helicobacter pylori infec-
tion, consumption of salted and nitrated foods, and cig-
arette smoking, have been found to be associated with
the risk of developing GC [2–4]. In addition to environ-
mental factors, genetic factors also play an important
role in GC etiology, as demonstrated by the fact that
only a small proportion of individuals exposed to the
known environmental risk factors develop GC [3,5–8].
Molecular studies have provided evidence that GC
arises not only from the combined effects of environ-
mental factors and susceptible genetic variants but also
from the accumulation of genetic and epigenetic altera-
tions that play crucial roles in the process of cellular
immortalization and tumorigenesis [2,4].
The present review is intended to focus on the
recently described basic aspects that play key roles in
the process of gastric carcinogenesis. New advances in
the fields of the individual’s genetic susceptibility for
gastric carcinogenesis and molecular alterations in GC
will be discussed.
Genetic Susceptibility
Molecular epidemiological studies have described some
relatively common genetic variants as biomarkers for
genetic susceptibility to GC development, namely single
nucleotide polymorphisms (SNPs) [3–7,9]. These
genetic variants may modulate the effects of exposure
to environmental factors by regulating multiple biologi-
cal pathways during gastric carcinogenesis.
Genetic variants in inflammation-related genes, espe-
cially cytokines and their receptors, are thought to play
a role in tumor initiation and promotion [5,6,8]. In this
perspective, the role of genetic polymorphisms in GC
risk has motivated increasing interest in recent years.
For example, a meta-analysis performed by Zhuang
et al. [10] suggests that the interleukin 10 (IL-10) -
592C>A promoter polymorphism may be associated
with GC among Asians. Even regarding IL-10 polymor-
phisms, Won et al. [11] reported that the IL-10-
1082A>G polymorphism influences the risk of GC in
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Abstract
Gastric cancer (GC) is a world health burden, ranging as the second cause of
cancer death worldwide. Etiologically, GC arises not only from the combined
effects of environmental factors and susceptible genetic variants but also
from the accumulation of genetic and epigenetic alterations. In the last
years, molecular oncobiology studies brought to light a number of genes
that are implicated in gastric carcinogenesis. This review is intended to focus
on the recently described basic aspects that play key roles in the process of
gastric carcinogenesis. Genetic variants of the genes IL-10, IL-17, MUC1,
MUC6, DNMT3B, SMAD4, and SERPINE1 have been reported to modify the
risk of developing GC. Several genes have been newly associated with gas-
tric carcinogenesis, both through oncogenic activation (GSK3b, CD133, DSC2,
P-Cadherin, CDH17, CD168, CD44, metalloproteinases MMP7 and MMP11, and
a subset of miRNAs) and through tumor suppressor gene inactivation mech-
anisms (TFF1, PDX1, BCL2L10, XRCC, psiTPTE-HERV, HAI-2, GRIK2, and
RUNX3). It also addressed the role of the inflammatory mediator cyclooxy-
genase-2 (COX-2) in the process of gastric carcinogenesis and its importance
as a potential molecular target for therapy.
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populations from East Asia but not in Caucasians, sup-
porting the idea that different mechanisms of selection
may be operating on this gene region in Caucasians
and East Asian populations. In another study, Wu et al.
[12] found an association between the interleukin IL-
17F A7488G coding variant and GC, especially with the
intestinal-type GC. This association is interesting and
relevant, because it was previously shown that IL-17F
7488 polymorphism is associated with increased inflam-
mation in H. pylori infection context [13]. Recently,
Persson et al. [14] performed a series of meta-analyses
for a group of inflammation-related gene polymor-
phisms. The clearest results were found for the associa-
tion between the IL-1RN2 polymorphism and the risk
for GC in non-Asian populations. In Asian populations,
the C carriers for the IL-1B-31 polymorphism had a
reduced overall risk of GC. According to Persson et al.,
the simultaneous analysis for multiple polymorphisms
within genes with related functions results in a broader
overview and allows for more detailed comparisons.
Genetic variants in noninflammation-related genes
and their association with GC have also been described.
For example, Saeki et al. [15] described that the A car-
riers for the mucin 1 (MUC1) rs4072037 polymorphism
are at increased risk of developing GC, especially the
diffuse type. These authors showed that rs4072037 has
a role in transcriptional regulation and also in splicing
site selection of MUC1. In another study, Kwon et al.
[16] reported the association between a new minisatel-
lite located in intron 26 of MUC6 (MUC6-MS5) and the
susceptibility to develop GC. It is noteworthy to refer
that mucins are glycosylated proteins that play impor-
tant roles in the protection of epithelial cells from
pathogens and have been implicated in the process of
epithelial renewal and differentiation, and that both
MUC1 and MUC6 are well-known stomach-secreted
mucins that may have a role in GC development [17].
The DNA methylation process is a major epigenetic
modification that involves the addition of a methyl
group to specific dinucleotide sequences [18], and it is
accepted that aberrant DNA methylation is one of the
most relevant epigenetic changes observed in cancer
[19]. In this matter, Hu et al. [20] studied the promoter
of the enzyme DNA methyltransferase 3B (DNMT3B)
gene, and they found that individuals with at least one
)579G allele were at decreased risk of developing GC
compared with those having a )599TT genotype.
According to the authors, the results are significant at
least in Chinese populations.
Transforming growth factor (TGF)-b signaling is one
of the most important tumor suppressor pathways [21].
SMAD proteins are crucial components of TGF-b signal-
ing, which negatively regulates cell growth and
promotes apoptosis of epithelial cells [21]. Recently, loss
of SMAD4, especially loss of nuclear SMAD4 expres-
sion, was described in GC progression [22]. Given the
role of SMAD4 in gastric tumor suppression, Wu et al.
[23] searched for genetic variants in the SMAD4 gene
that could be associated with the risk of GC. Of the five
SNPs studied, the authors found an association between
the allele C at position rs17663887 and the allele G at
position rs12456284 with increased expression of
SMAD4 protein and decreased risk of GC.
Proteolytic breakdown of the extracellular matrix is
an essential event involved in tumor invasion, metasta-
sis, and angiogenesis [24]. Serpin peptidase inhibitor,
clade E, member 1 (SERPINE1), plays a key role in
tumorigenesis, because it prevents excessive proteolysis,
which is necessary for capillary morphogenesis, cell
migration, and invasion [25]. According to Ju et al.
[26] a polymorphism in intron 7 (c.1162 + 162C>T) of
SERPINE1 is strongly associated with susceptibility to
diffuse-type GC. Using luciferase reporter assays, the
authors detected an increase in gene expression associ-
ated with the risk haplotype when compared with non-
risk haplotype. The results obtained are interesting,
because expression levels of SERPINE1 are elevated in
GC tissues compared with normal stomach tissue [27].
In the last year, numerous articles were published
establishing an association between genetic polymor-
phisms and the risk of GC. It is becoming evident that
host genetic factors are key agents in the risk for the
development of cancer and that the interaction of dif-
ferent polymorphisms combined with environmental
triggers may provide crucial clues to explain diverse
risks in various populations.
Molecular Alterations in Gastric Cancer
Understanding the molecular mechanisms and altera-
tions behind the initiation and progression of gastric
tumorigenesis is crucial for the early detection of the
disease and to identify novel therapeutic and clinical
targets for GC. A number of molecular abnormalities
have been identified in GC, namely gene overexpres-
sion and gene silencing. Nevertheless, it is of vital
importance to decipher the mechanisms of gastric carci-
nogenesis, because the molecular pathogenesis of GC is
still incompletely understood.
Gene Overexpression
In the last years, a vast amount of articles reporting the
overexpression and ⁄or amplification of various genes in
GC were published. Recently, Zheng et al. [28] reported
the overexpression of the inactive form of glycogen
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synthase kinase (GSK)-3b and p-GSK3b-ser9 in GC
when compared with normal mucosa. Noteworthy, the
authors addressed that the overexpression of p-GSK3b-
ser9 was positively correlated with a poor prognosis.
Interestingly, Mishra et al. [29] described that p-
GSK3b-ser9 is gastrin induced and that inhibition of
GSK3b leads to an increase in expression of Snail,
nuclear translocation of b-catenin, and an increase in
GC cell migration.
Many transmembrane proteins are described as play-
ing a role in cancer [30], and they constitute an active
target of research in the identification of novel biomar-
kers for cancer diagnosis and novel targets for treat-
ment [31]. Zhao et al. [32] analyzed the expression of
the transmembrane protein CD133 in GC, because it
was described that CD133 is overexpressed in various
solid tumors [33]. They found that CD133 was overex-
pressed in more than 55% of GC and has a positive cor-
relation with the expression of Ki-67. In another study,
Anami et al. [34] found an overexpression of the mem-
brane protein desmocollin-2 (DSC2) in intestinal-type
GC. Interestingly, they showed that expression of DSC2
was induced by CDX2, suggesting that expression of
desmocollin-2 could be a key regulator for GC with
intestinal phenotype. One transmembrane protein for
which a new targeted compound is being studied in
clinical trials on solid tumors is P-cadherin. Kim et al.
[35] reported recently that P-cadherin is not expressed
in normal gastric mucosa but is overexpressed in GC,
especially in tumors of the intestinal type. The authors
reported that the increased expression of P-cadherin in
GC was found to be significantly correlated with pro-
moter hypomethylation. Another member of the cadh-
erin superfamily, CDH17, was also reported by Lee
et al. [36] as a promising marker for early-stage gastric
cancer. Also according to Lee et al., CDH17 expression
was positively associated with a good prognosis.
Hyaluronic acid (HA) is a component of the extracel-
lular matrix. In cancerous tissue, HA is greatly secreted
from stromal fibroblasts in response to factors derived
from tumor cells [37]. The two most well-known cell
receptors for HA are CD168 and CD44 [38]. In a recent
study, Ishigami et al. [39] reported the overexpression
of CD168 in a panel of GC cases. According to these
authors, CD168 positivity was significantly associated
with the depth of invasion and metastasis of GC, an
association that was previously reported for other types
of cancer [40]. In a different study, da Cunha et al.
[41] described the de novo expression of a CD44 variant
(CD44v6) in GC. Noteworthy, they observed that
CD44v6 was rarely expressed in normal gastric mucosa
but was increasingly expressed in premalignant and
malignant lesions. A recent study by Ishimoto et al.
[42] sheds light about some roles of CD44 variants
(CD44v) expression in gastrointestinal tumors. Ishimoto
et al. found that CD44v controls the intracellular level
of reduced glutathione (GSH), and cancer cells that
express more CD44v showed an enhanced capacity for
GSH synthesis and defence against reactive oxygen spe-
cies, promoting tumor growth.
Matrix metalloproteinases (MMP), a family of zinc-
dependent endopeptidases, are involved in various
physiological and pathological processes, such as extra-
cellular matrix degradation, tissue remodeling, inflam-
mation, and tumor invasion and metastasis [43]. Owing
to the roles of MMPs in disease, two independent
reports arouse establishing a relation between the
expression of MMPs and GC. Koskensalo et al. [44]
analyzed the expression of MMP-7 , and Zhao et al.
[45] described the expression of MMP-11. In both
reports, the results were equivalent: overexpression of
MMPs in a panel of GC cases, when compared with
normal gastric mucosa, and a significant shorter sur-
vival for patients that overexpressed MMPs.
MicroRNAs (miRNAs) are a subset of noncoding RNA
molecules (21–23 nucleotides in length) that are
believed to regulate gene expression [46]. Altered
expression of miRNAs has been associated with several
diseases, particularly cancer [47]. Recently, Liu et al.
[48] performed a genome-wide serum miRNA expres-
sion profile in patients with GC and controls, and they
identified a set of five miRNAs (miR-1, miR-20a, miR-
27a, miR-34, and miR-423-5p) whose overexpression
was positively correlated with tumor stage. In a different
study, Li et al. [49] identified a seven-miRNA signature
(miR-10b, miR-21, miR-223, miR-338, let-7a, miR-30a-5p,
and miR-126) that associates with an increased risk of
recurrence and decreased overall survival, even stratify-
ing patients by stage or histology. These results indicate
that miRNAs may play an important role in the carci-
nogenesis and prognosis of GC.
Gene Silencing
Gene silencing in GC can occur mainly because of point
mutations, loss of heterozygosity, and promoter hyper-
methylation [2,3]. A putative gastric tumor suppressor
gene whose expression is frequently downregulated in
GC is trefoil factor 1 (TFF1) [50], especially by promoter
hypermethylation [51]. Tomita et al. [52] reported
recently that the peptide hormone gastrin exerts a sup-
pressive effect in gastric carcinogenesis by suppressing
TFF1 promoter hypermethylation. Pancreatic duodenal
homeobox-1 (PDX1) is another putative tumor suppres-
sor gene whose expression is frequently downregulated
in GC [53]. Ma et al. [54] described the mechanism
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responsible for PDX1 loss of expression in GC as
promoter hypermethylation. Many more articles were
published last year reporting gene promoter hyperme-
thylation as a cause of loss of protein expression in GC.
As examples, loss of expression by promoter methyla-
tion was described for BCL2L10 [55], XRCC1 [56], the
endogenous retrovirus-related gene psiTPTE-HERV [57],
HAI-2 [58], and GRIK2 [59].
Nevertheless, it is crucial to understand that the loss
of expression of one gene can occur by different mech-
anisms acting in that particular gene. As an example,
Runx3 is considered a gastric tumor-suppressor gene
whose expression is frequently downregulated in GC by
promoter hypermethylation [60]. However, Lai et al.
[61] described recently that Runx3 expression can be
negatively regulated at transcriptional level by the micr-
oRNA-130b. In another study, Tsang et al. [62]
reported that H. pylori virulence factor CagA is able to
bind to Runx3, inducing the ubiquitination and degra-
dation of Runx3 by the proteasome machinery.
The Role of Cyclooxigenase-2 (COX-2)
on GC
Cyclooxygenase-2 (COX-2) is the key regulatory enzyme
in prostanoid synthesis and the primary target of nonste-
roidal anti-inflammatory drugs (NSAIDs) in inflamma-
tory and neoplastic conditions [63]. Activation of COX-2
has been shown to be involved in many processes lead-
ing to tumor progression such as angiogenesis, survival,
proliferation, invasion, and immunosuppression [63]. An
epidemiologic cohort and case–control studies have sug-
gested that use of aspirin and other NSAIDs reduces mor-
tality from GC [64,65]. As a result, COX-2 enzyme is
considered a potential therapeutic target in cancer pre-
vention and treatment. Further support for the role of
COX-2 in gastric carcinogenesis is provided by data
which suggest that certain variants of the gene make
individuals susceptible to GC, especially in relation to
H. pylori infection [66–69]. Furthermore, H. pylori infec-
tion associates with COX-2 expression in gastric mucosa
with intestinal metaplasia and dysplasia [70], which are
precursor lesions of GC. As H. pylori infection also associ-
ates with VEGF expression [71], and manipulation of
COX-2 expression in GC cell lines leads to altered VEGF
expression [70], it is possible that H. pylori-induced VEGF
expression is at least partially regulated by COX-2-
derived prostanoids.
In humans, COX-2 expression, but not that of COX-
1, is elevated in GC tissues, and elevated level of COX-
2 expression is an independent prognostic factor in
patients with gastric cancer [72–74]. Furthermore, in
an extended multivariate model with eight prognostic
markers and clinicopathological factors, COX-2 expres-
sion is an independent prognostic factor alongside with
p53, stage, and intent of surgery [74]. It is important to
note that chemoprevention of GC is not recommended
in general population by using NSAIDs or COX-2-selec-
tive drugs, because they increase the risk for cardiovas-
cular events [75]. However, it may be possible to
recognize high-risk patients by screening for genetic
polymorphisms, and use these drugs to treat patients
with cancer [75]. Thus, these data should encourage
further prospective clinical trials aiming at clinical use
of COX-2 inhibitors as a part of combination
chemotherapy.
The mechanism of COX-2 overexpression in GC cells
has been widely studied, and signal transduction path-
ways that induce COX-2 expression include
PI3K ⁄Akt ⁄GSK-3b pathway, mitogen-activated protein
kinases (MEK 1 ⁄2, p38, and JNK), Notch1 signal path-
way, and nuclear factor-jB. Recently, microRNAs (miR-
NAs) were shown to regulat COX-2 expression. When
miRNA-101 was overexpressed in GC cells lines, the
mRNA level of COX-2 was decreased [76]. Further-
more, miRNA-101 overexpression resulted in inhibition
of proliferation, migration, and invasion in these cells,
and overexpression of miRNA-101 in GC cells leads to
reduced tumor growth in nude mice [76]. In other
mouse models, COX-2 has been shown to be involved
with tumor growth, which has been demonstrated by
genetic manipulation. Recently, it was shown that in
mice, where transgenic overexpression of Cox-2 and
mPGES-1 is combined with activation of Wnt pathway
(K19-Wnt1 ⁄C2mE) to drive adenocarcinoma develop-
ment, a COX-2-selective drug celecoxib and ZD1839, an
EGFR inhibitor, decreased the tumor volume by 90%
and 76%, respectively, and combination of both drugs
led to a complete regression of the tumors [77]. Addi-
tionally, ligands for EGFR and metalloproteinases (that
shed the ectodomains of EGFR ligands and thus activate
them) were upregulated directly and indirectly by the
COX-2-derived PGE2 [77]. The activation of the EGFR
pathway by PGE2 signaling might be responsible for
tumor cell proliferation in this model, as both Cox-2
and EGFR inhibition decreased the number of Ki-67-
positive cells.
Concluding Remarks
Gastric cancer is a complex disease that arises by the
combined interaction of different major players. The
lifestyle and alimentary habits of individuals, combined
with genetic susceptible variants and molecular altera-
tions acquired during lifetime, are at the base of the
carcinogenic process of GC. Much work has been
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carried out to find molecular markers for GC. However,
the true mechanisms are barely known and much more
work is needed to understand the causes of GC and the
best clinical approaches to assure a correct diagnosis
and efficient treatment.
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